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ABREVIATIONS
16a-DHEAS 16a-hydroxy-dehydroepiandrosterone sulphate
AFP Alphafetoprotein
BSA Bovine seum albumin
Cl Confidence in terval
cpm Counts per minute
CV C o eff ic ien t of var ia t ion
DHEAS Dehydroepiandrosterone sulphate
Fr3-hCG Free 3 subunit of human chorionic gonadotrophin
g Grams
hCG Human chorionic gonadotrophin
IU In te rnationa l units
IRMA Immunoradiometric assay
IEP Immunoelectrophoreis
IRP In te rnationa l reference preparation
K-S Kolmogorov-Smirnov tes t
KU Kilo units
1 L it re
mg Milligrams
ml M i l l i l i t r e
nmol Nanomole
MOM M ultip le  of the median
mlU Mi 11i - in te rn a t io n a l  unit
n Number
nmol Nanomole
p P robab ility
PBS Phosphate buffered saline
r Correlation co e ff ic ie n t
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RIA Radioimmunoassay
SD Standard deviation
SPi Pregnancy-specific 3-1 glycoprotein
UE3 Unconjugated e s tr io l
v /v Volume to volume
w/v Weight to volume
x Mean
M9 Microgram
Ml M ic ro l i t re
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SUMMARY
The aim of th is  project was to explore ways of using biochemical 
screening to improve the prenatal detection rate  fo r  Down’ s 
syndrome and other chromosome abnormalities over that being 
achieved using maternal age alone. I t  is  well established tha t the 
r isk  of a pregnancy being affected by Down’ s syndrome or one of
the other autosomal trisomies increases with advancing maternal
age, and since the ear ly  1970s th is  has been the c r i te r io n  used to  
select women for diagnostic fe ta l  chromosome analysis. However, 
the m ajority of a ffected pregnancies (70%) are born to women under 
35 years of age and the uptake of diagnostic tes ting  amongst women 
aged 35 years and over has been r e la t iv e ly  low (<40%) leading to  
only around 12% of the affected pregnancies being detected in
practice.
The f i r s t  phase of th is  study was a retrospective analysis of
maternal serum alphafetoprotein (AFP) results  from the west of 
Scotland prenatal screening programme for neural tube defects. 
This was carried out on 142 pregnancies with autosomal trisomy 
(114 Down’ s syndrome, 19 trisomy 18 and 9 trisomy 13) and 113,000 
unaffected pregnancies screened at 16-20 weeks gestation between 
April 1982 and May 1987. Maternal serum AFP levels  in the affected  
pregnancies were s ig n i f ic a n t ly  reduced (p<0.001) to  0.72 multiples  
of the median (MOM) of the unaffected pregnancies. Risks 
( l ike liho od  ra t io s )  were derived from the overlapping log Gaussian 
d is tr ib u tio n s  of the abnormal and unaffected pregnancies and 
combined with maternal age risks to give the overa ll odds of an 
affected pregnancy. Using a m id-trim ester threshold r isk  of 1:280,
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which approximates to  the maternal age r isk  at age 35, an overa ll  
detection rate of 37% was predicted fo r  a fa lse  positive  rate of 
6 . 6%.
Using data from the above study, the west of Scotland AFP
screening programme fo r  neural tube defects was adapted in 1987 to  
include reporting o f the r isk  of an autosomal trisomy in
individual pregnancies. Analysis of th is  routine screening in over
100,000 pregnancies has shown an improved detection of autosomal 
trisomies (43%) at a fa ls e  positive rate of 6.1%. The uptake of
diagnostic testing  amongst the high risk  group of women was
re la t iv e ly  low (42%) especia lly  amongst the women under 35 years
(32%). However, the uptake of diagnostic tes t in g  in the women over
35 years assigned to the high r isk  group increased to  56% compared 
with that from maternal age alone of less than 40%. O vera ll,  the
prenatal diagnosis rate fo r  autosomal trisomies was 25% in the 
screened population.
Although screening based on a combination of AFP levels and 
maternal age is more e f fe c t iv e  than tha t achievable with maternal 
age alone, around 60% of affected pregnancies are s t i l l  not 
detected, mainly in women under 35 years. Greater s e n s it iv i ty  is  
p o te n t ia l ly  possible using additional information obtainable from 
the analysis of other pregnancy markers in maternal serum.
The second phase of th is  study was the retrospective analysis of 
four other pregnancy markers, human chorionic gonadotrophin (hCG), 
unconjugated e s tr io l  (UE3), pregnancy spec if ic  3 i-g lycoprotein  
(SP i) and the free 3 subunit of hCG (Fr3-hCG), by immunoassay, in
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stored maternal serum samples from d i f fe re n t  types of 
chromosomally abnormal pregnancies. The objective was to  define  
the level of var ia t ion  associated with these analytes, to  find  the 
best combination of markers fo r  routine c l in ic a l  use, and to  
compare d i f fe re n t  approaches fo r combining risks from these 
markers.
S ix ty - f iv e  thousand serum samples, collected prospectively in the 
west of Scotland between January 1987 and March 1989 at 15-20 
weeks gestation fo r  routine AFP estimation provided the source 
material fo r  th is  study. A fte r  AFP estimation the samples were 
stored at -20°C u n t i l  the outcome of the pregnancy was known. 
Subsequently 78 chromosomally abnormal pregnancies were id e n t if ie d  
fo r  which stored serum was ava ilab le . The abnormal cases consisted 
of 49 Down’ s syndrome, four trisomy 18, four trisomy 13, eight  
unbalanced translocations, four balanced translocations and nine 
sex chromosome abnormalities. Five control sera were selected fo r  
each case, matched fo r  maternal age, gestation and time in frozen 
storage. Additional cases o f Down’ s syndrome and trisomy 18 were 
added as they became ava ilab le .
In ta c t  molecule hCG levels  were found to be s ig n if ic a n t ly  
increased (p<0.001) in Down’ s syndrome pregnancies, with a median 
value of 2.18 MOM of the unaffected pregnancies, and s ig n if ic a n t ly  
reduced in trisomy 18 pregnancies (0.21 MOM, p<0.001). UE3 levels  
were found to  be s ig n if ic a n t ly  decreased with a median of 0.79 MOM 
of the controls in Down’ s syndrome (p<0.02) and 0.38 MOM in 
trisomy 18 ( p<0 .01 ) .  SPi levels were s ig n if ic a n t ly  increased
(p<0.01) in Down’ s syndrome, with a median value of 1.17 MOM of
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the controls, unchanged in trisomy 18 and s ig n if ic a n t ly  reduced in 
unbalanced translocations (0.52 MOM, p<0.01). Free |3 subunit hCG 
levels were s ig n if ic a n t ly  increased in Down’ s syndrome with a 
median of 2.30 MOM of the controls (p<0.001) and reduced in 
trisomy 18 (0.23 MOM, p<0.01).
From the data derived from th is  retrospective study, the most 
e f fe c t iv e  combination of analytes fo r  screening fo r  Down’ s 
syndrome was found to  be AFP and hCG, combined with maternal age. 
This combination gave a predicted 57% detection rate  fo r  Down’ s 
syndrome at a 5% fa lse  positive  rate . UE3 was found to  be less 
useful due to  the high level of corre la t ion  found between i t  and 
AFP and using UE3 in addition to AFP and hCG reduced the predicted  
detection rate fo r Down’ s syndrome to 53% at a 5% fa ls e  positive  
rate . SPi levels in Down’ s pregnancies showed only a small s h i f t  
in mean value from that of the controls and did not improve the 
detection rate fo r  Down’ s syndrome when added to the AFP/hCG/age 
combination. Median Fr|3-hCG levels in Down’ s syndrome were 
s l ig h t ly  higher than in tac t  hCG levels , but replacing hCG with 
Frl3-hCG reduced the predicted detection rate fo r  Down’ s syndrome 
to 51% at a 5% fa lse  positive  ra te , due to  the increased spread of 
values in the d is tr ib u tio n s  of FrB-hCG, with th is  assay
method, in unaffected and Down’ s syndrome pregnancies.
The th ird  phase of th is  study was a te s t  of the performance of the 
hCG/AFP/age combination in c l in ic a l  practice . A prospective t r i a l  
was carried out between July 1989 and June 1990, assaying hCG in 
addition to AFP in a l l  serum samples routine ly  received from three  
Glasgow maternity hospitals. The hCG results  fo r  each pregnancy
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were stored on a database and only analysed a f te r  de live ry . A 
to ta l  of 7,830 pregnancies was tested and, using a threshold r isk  
of 1:220, 53% of the Down’ s pregnancies were assigned to the high
risk  group and 6.2% of a l l  pregnancies c la s s if ie d  as 'screen 
p o s it iv e ’ . This confirmed that enhanced detection o f Down’ s 
syndrome pregnancies could be achieved in routine practice using 
hCG and AFP in combination with maternal age. AFP and hCG levels  
were shown to vary with maternal weight, with l ig h te r  women having 
increased levels and reduced levels being found in heavier women. 
Cases of threatened abortion, which are known in some cases to  
have elevated AFP leve ls , had unchanged levels of hCG. Levels of  
AFP in 81 twin pregnancies were approximately double those found 
in singleton pregnancies, with a median AFP level o f 1.91 MOM and 
a median hCG level of 1.85 MOM. In 56 pregnancies affected by 
insulin  dependent diabetes, the median value of both AFP and hCG 
was s l ig h t ly  reduced, at 0.94 MOM and 0.90 MOM respective ly .
On the basis of th is  study hCG estimation was introduced in the 
west of Scotland prenatal screening programme in September 1991. 
Analysis of the f i r s t  30,084 pregnancies screened has shown th a t ,  
using a threshold r isk  of 1:220, 1,523 women (5.1%) have been
c lass if ied  as 'sc reen -pos it ive ’ and 26 Down’ s syndrome pregnancies 
id e n t if ie d  in th is  high r isk  group. There were 37 Down’ s syndrome 
pregnancies in the whole screened population, giving a detection  
rate of 70%. The uptake of diagnostic tes ting  by women in the high 
r isk  group has also increased, with 70% of women, regardless of  
age, opting fo r  tes t ing . Overall 21 of the 37 Down’ s syndrome 
pregnancies (56%) were prenata lly  diagnosed. In addition 2 out of 
7 (29%) trisomy 18 pregnancies were id e n t if ie d  in a second high
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r isk group of 87 women (0.3%) defined on the basis of low hCG.
Introduction of biochemical screening has lead to a fourfo ld  
improvement in the prenatal diagnosis rate fo r Down’ s syndrome in 
the whole west of Scotland pregnant population from 13% in 1986 to  
48% in the year September 1991 -  September 1992. Prenatal
screening fo r  chromosome abnormalities by biochemical methods in 
the second tr im ester is  therefore more e f fe c t iv e  in practice than 
using maternal age alone as the c r i te r io n  fo r  selecting women fo r  
diagnostic tes ting .
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SECTION 1
INTRODUCTION
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1.1 PRENATAL SCREENING
Prenatal screening is a way of selecting from the pregnant 
population a group of women who are at the highest r isk  of having 
a child with a p a r t ic u la r  abnormality. A positive  screening result  
does not indicate with certa in ty  the presence of an abnormality, 
but c la s s if ie s  an expectant mother as having a r isk  of an abnormal
fetus high enough to ju s t i f y  the use of diagnostic procedures to
d e f in i te ly  confirm or exclude the presence of an abnormality. 
Negative screening results reduce, but do not exclude, the r isk  of 
an abnormality.
Various parameters define the effectiveness of a screening te s t  
(Cuckle and Wald, 1984, Connor, 1989). These are s e n s it iv i ty ,  
s p e c if ic i ty ,  pos itive pred ictive  value and negative predictive  
value. The s e n s it iv i ty ,  or detection rate , is the correc tly  
predicted proportion of the actual to ta l  who are affected. The 
s p e c if ic i ty  is the correc tly  predicted proportion of the actual 
to ta l  who are unaffected (The fa lse  pos itive  rate is 1 -
s p e c if ic i ty ) .  The positive predicted value is the proportion with 
a positive te s t  resu lt  who are affected and the negative predicted  
value is the proportion with a negative te s t  resu lt  who are
unaffected.
For screening to be appropriate i t  must be fo r  a c le a r ly  defined 
disorder of known prevalence. The screening te s t  must be eas ily  
and re l ia b ly  carried out on a sample that can be obtained without 
risk to the pat ien t ,  such as maternal venous blood. There must be 
an advantage to ear ly  diagnosis and the te s t  must have good
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s e n s it iv ity  and s p e c if ic i ty .  Screening should be both cost and 
benefit e f fe c t iv e ,  both in a f inanc ia l sense and also in re la tion  
to the benefits and disadvantages fo r  the patients being offered  
screening. The performance of the screening te s t  should be 
monitored by follow-up studies to see tha t i t  is e f fe c t iv e .
Public opinion in both the UK and the USA would appear to favour 
screening during pregnancy (King’ s Fund Forum Consensus Statement, 
1987, Faden et  a l . , 1987). The King’ s Fund Forum concluded that
screening should be seen as a means of acquiring information that  
increases the scope of choice by the part ic ipan ts . However 
screening is only one possible approach to  reducing d is a b i l i t y .  
Primary prevention of environmentally determined conditions and 
improving the f a c i l i t i e s  and a ttitudes  of society to physically  
and mentally impaired people must be part of a comprehensive 
approach. P a rt ic ip a tio n  in a screening programme should be an 
informed and considered decision and a woman’ s access to screening 
or diagnostic tes ting  should be independent of any decision she 
nay make about the continuation of the pregnancy.
1.1.1 SCREENING FOR NEURAL TUBE DEFECTS
The best example of a screening programme fo r  fe ta l  abnormality is  
the measurement of maternal serum alphafetoprotein (AFP) fo r  the 
detection of neural tube defects. By 1974 i t  had been demonstrated 
that pregnancies affected by an open neural tube defect had 
elevated levels of maternal serum AFP (Brock et  a l . ,  1973, Leek et  
a l . , 1973, Brock et  a l . , 1974, Wald et  a l . ,  1974). The UK
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Collaborative Study on Alphafetoprotein in Relation to Neural Tube 
Defects (1977) determined that 84% of pregnancies where the fetus  
had an open neural tube defect were associated with maternal serum 
AFP levels >2.5 m ultip les of the median (MOM), and that 3% of 
unaffected pregnancies also had AFP levels >2.5 MOM. Maternal
venous blood samples should be collected between 16-20 weeks
gestation, the AFP level measured and the 3% of women with the 
highest AFP results  selected fo r  diagnostic tes t in g , e ith e r  
amniocentesis to measure amniotic f lu id  AFP levels  and te s t  fo r  
specific  acetyl cholinesterase (Brock, 1983), or deta iled  
ultrasonography (Morrow et  a l . ,  1991).
Maternal serum alphafetoprotein (AFP) screening in the second 
tr im ester of pregnancy has contributed to a substantial decline in 
the b ir th  incidence of neural tube defects in the west of 
Scotland, since i t  was introduced in 1976 (Ferguson-Smith, 1983) 
and in other parts of the UK (Cuckle and Wald, 1987).
1.2 CHROMOSOME ABNORMALITIES
The report by Hook and Hamerton (1977), who combined data from six  
published studies from a to ta l  of 56,952 babies, showed that
chromosome abnormalities occur in newborns at a rate of 6/1000. Of
these 2/1000 are sex chromosome abnormalities, 2/1000 are balanced 
chromosome rearrangements and the other 2/1000 involve unbalanced 
rearrangements of the autosomes. Of these unbalanced 
rearrangements, 1.4/1000 have excess chromosome material in the 
form of an additional autosome (autosomal trisom ies) and the
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remaining 0.6/1000 are unbalanced s tructura l rearrangements of the 
autosomes.
The most common autosomal abnormality is Down’ s syndrome (trisomy 
21) which has a b ir th  frequency of 1:800 (Hook and Hamerton, 
1977). The other autosomal trisomies which are re la t iv e ly  common 
are Edwards’ syndrome (trisomy 18) which has a b ir th  frequency of 
1:8000 (Hook and Hamerton, 1977) and Patau’ s syndrome (trisomy 13) 
which has a b ir th  frequency of 1:20000 (Hook and Hamerton, 1977).
Of the autosomal trisomies, Down’ s syndrome is the most important 
both from the prenatal diagnosis point of view and also with  
regard to the health care and social needs of affected  
ind iv iduals . This is due to the greater frequency of Down’ s 
syndrome b irths  and the increased l i f e  expectancy of Down’ s 
syndrome patients , which now has a median of 56 years (Dupont et  
a l . ,  1986). The median survival time fo r trisomy 18 and trisomy 13 
in an unselected population has been shown to be 6.0 days and 2.5  
days respectively (Goldstein and Nielsen, 1988). However around 
20% of affected indiv iduals survive longer than one month, and 
since the m ajority are hospitalised fo r  most of th e ir  survival  
period, these other autosomal trisomies should also be considered 
during prenatal screening and diagnosis.
I t  has been demonstrated by Hook (1978), in a study of 101 
pregnancies in which a fe ta l  chromosome abnormality was id e n t if ie d  
prenata lly  by amniocentesis but e le c t iv e  abortion did not occur, 
tha t the rate of spontaneous fe ta l  death is  six fo ld  higher in 
pregnancies with a chromosome abnormality than in those with a
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normal karyotype. The rates of chromosome abnormalities found i f  
prenatal diagnosis is carried out at m id-trim ester w i l l  therefore  
be higher than those seen at b ir th .  Cuckle et  al .  (1987) have 
estimated that the risks of a Down’ s syndrome fetus are 25% higher 
at m id-trim ester than at b ir th .  This was done by comparing the 
age-specific  r isk  of Down’ s syndrome in the second tr im ester of 
pregnancy, derived from the European co llaborative  study of 52,965 
amniocenteses in women aged 35-44 (Ferguson-Smith and Yates, 1984) 
with the corresponding age-specific  r isk  at b ir th .
Hook et  al .  (1988), in a study of 4,481 chorionic v i l lu s  samples 
(CVS), estimated that 21% of Down’ s syndrome pregnancies diagnosed 
at CVS at around 10 weeks gestation would be lost before the time 
when amniocentesis would be carried out at around 16 weeks 
gestation i . e .  tha t the rate of Down’ s syndrome at 10 weeks is  
approximately 25% higher than at 16 weeks. Thus only around 63% 
of Down’ s syndrome fetuses present at 10 weeks gestation w i l l  
therefore survive to term.
1.3 MATERNAL AGE RISKS
1.3.1 DOWN’ S SYNDROME
The l ink  between advancing maternal age and increasing risk  of 
having a Down’ s syndrome ch ild  was f i r s t  demonstrated by Penrose 
in 1933, who also showed that paternal age was an in s ig n if ic a n t  
fac tor.  With the development of chromosome banding techniques i t  
was estimated by Juberg and Mowrey (1983), in a review of 30
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previously published studies, that maternal o r ig in  accounted fo r  
80% and paternal o rig in  20% of cases. However more recent 
investigations, using DNA polymorphisms, have shown that in only 
about 5% of cases was the extra  chromosome 21 of paternal o rig in  
(Sherman et  a l . ,  1991, Antonarakis et  a l . ,  1991). This much lower 
rate of extra  chromosomes of paternal o r ig in  provides fu rther  
evidence tha t paternal age has l i t t l e  or no e f fe c t  on the rate of 
Down’ s syndrome.
There have been eight large published surveys of Down’ s syndrome 
in l ive  b irths  which specify the r isk  fo r  single age years (Hook 
and Chalmers, 1977, Hook and Fabia, 1978, Hook and Lindsjo, 1978, 
Trimble and Baird, 1978, Sutherland et  a l . ,  1979, Young et  a l . ,  
1980, Koulischer and G i l le r o t ,  1980, Huether et  a l . ,  1981). Hook 
and Chalmers (1977) ascertained 933 Down’ s syndrome cases from 
1,729,909 l iv e  b irths  from b ir th  c e r t i f ic a te s  between 1963 and 
1974 in New York State. To allow fo r  under-ascertainment the 
observed number of cases was m ultip lied  by 2.66 to estimate the 
true age-specific  r is k .  This fac to r  was derived from a sub-set of 
301 cases of Down’ s syndrome id e n t if ie d  from cytogenetic records. 
113 of these had Down’ s syndrome mentioned on the b ir th  
c e r t i f ic a te .
Hook and Fabia (1978) id e n t if ie d  1,250 Down’ s syndrome cases in 
832,531 l iv e  b irths in the white population between 1958 and 1965 
in Massachusetts. The cases of Down’ s syndrome were ascertained  
from surveys of hospitals and in s t itu t io n s  and from cytogenetic  
records. Unaffected maternal age data was only ava ilab le  in f iv e  
year in te rva ls , and rates from individual maternal age years were
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estimated by comparison with the rates in New York.
A study in Sweden by Hook and Lindsjo (1979) analysed 438 Down’ s 
syndrome b irths in 330,859 l iv e  b irths between 1968 and 1970. The 
Down’ s syndrome cases were id e n t if ie d  from a v a r ie ty  of community 
sources and population demographic information on single-year
maternal l iv e  b irths  was ava ilab le .
Trimble and Baird (1978), using B r it ish  Columbia data from 1961 to  
1970, ascertained 519 Down’ s syndrome births out of a to ta l  of 
354,880 l iv e  b ir th s . The data were obtained by l ink ing  records of  
children with Down’ s syndrome at the B r it ish  Columbia Health 
Surveillance Registry (BCHSR) to the appropriate b ir th  
reg is tra tions  to derive maternal ages. The BCHSR uses numerous 
sources of ascertainment and completeness of reporting of Down’ s 
syndrome cases is thought to be very high. Single year maternal 
age rates of l iv e  b ir th  were ava ilab le .
In a survey of Down’ s syndrome in South A ustra lia  between 1960 and 
1977 Sutherland et  al .  (1979) id e n t if ie d  447 Down’ s syndrome 
births . There were 375,488 l iv e  b irths  during th is  period with  
single-year maternal ages ava ilab le . Ascertainment of Down’ s 
syndrome cases was from the records of public in s t itu t io n s .
Seventy cases of Down’ s syndrome were id e n t if ie d  in South Wales 
between 1968 and 1976 by Young et  al .  (1980). Cases were 
ascertained from the C ard if f  B irth  Survey and from cytogenetic  
records. The number of l iv e  b irths during the study period was
46,048. Maternal age in the general population was recorded only
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in f ive -ye ar  in te rva ls  and s ingle-year rates were derived by 
comparison with the Swedish study (Hook and Lindsjo, 1978).
The report by Koulischer and G i l le r o t  (1980) concerns a group of
268 Down’ s syndrome patients born in South Belgium between 1971
and 1978. The to ta l  number of l iv e  b irths  during th is  time was
102,863. Down’ s syndrome cases were id e n t if ie d  by cytogenetic  
examination of a l l  newborns thought to be affected on examination 
by an obstetr ic ian  and a paed ia tr ic ian . A s ingle-year age 
d is tr ib u t io n  was ava ilab le .
The study by Huether et  al .  (1981) was carried out on b irths in 
the white population between 1970 and 1979 in Ohio. I t  was
conducted in a s im ila r  way to tha t of Hook and Chalmers (1977) by 
comparing data on Down’ s syndrome with tha t  ava ilab le  from 
cytogenetics laboratories and using th is  information to estimate 
the level of under-reporting on b ir th  c e r t i f ic a te s .  Single-year  
maternal age rates were ava ilab le . 851 Down’ s syndrome b irths  were 
id e n t if ie d  from b ir th  c e r t i f ic a te s  and the true level of Down’ s 
syndrome was estimated to be 2.74 times th is .  There were 1,460,449 
l iv e  b irths during th is  time. A regression equation fo r  Down’ s 
syndrome r isk  was calculated using the model o f Lamson and Hook
(1980) and the regression equation corrected fo r  
under-ascertainment to  derive risks fo r  individual maternal ages.
Cuckle et  al .  (1987) compiled risks from these eight surveys of  
Down’ s syndrome in l iv e  b ir th s , and applied the 
constant-plus-exponential (CPE) model proposed by Lamson and Hook
(1980) to derive a regression equation fo r  maternal age r isk . The
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equation is in the form
y = a + exp (b + cx) 
where y is the rate in l iv e  b ir th s ,  x is maternal age and a, b and 
c are constants. Lamson and Hook (1980) proposed that th is  model 
is consistent with a continuously accumulating b io logical process 
resulting in Down’ s syndrome, in which the rate of increase is  
proportional to the level already reached, analogous to the type 
of curve produced by an infectious process.
A weighted average of the separate r isk  estimates, on a log scale, 
from each of these studies was produced. To reduce random error a 
regression analysis was performed. The regression equation was
were MA is maternal age in years. The r isk  of having a Down’ s 
syndrome b ir th  is
Since these risks are derived from 4528 Down’ s syndrome 
pregnancies and over 5,000,000 l iv e  b irths they are the best 
estimates of r isk  of a Down’ s syndrome b ir th  ava ilab le .
A ll these data have been gathered in Caucasian populations. 
Several studies have been carried  out to investigate whether there  
are any rac ia l d ifferences in Down’ s syndrome rates in other 
ethnic populations. The evidence fo r  th is  is c o n f l ic t in g ,  with  
d if fe re n t  studies reporting d i f fe re n t  resu lts . In the black 
population the Down’ s syndrome rate has been shown to be higher 
(Hook and Harlap, 1 9 7 9 ) ,  unchanged (Marmol et  a h ,  1969)  and lower 
(Stark and White, 1977)  than in Caucasian populations. S im ila r ly  
co n flic t in g  evidence has been shown fo r  Asian populations, with
p = 0 . 0 0 0 6 2 7  + e ( " 16- 2395 + 0 . 2 8 6 MA)
1:(1 -  P)/P
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reports showing higher rates (Hook and Harlap, 1979), unchanged 
rates (Verma and Singh, 1975) and lower rates (Rogers, 1986) when 
compared with the white population. In the Japanese population 
Matsunaga (1967) found rates of Down’ s syndrome in d i f fe re n t  
maternal age groups not s ig n if ic a n t ly  d i f fe re n t  from that found in 
Caucasian populations. In the Chinese population rates of Down’ s 
syndrome lower than those in the Caucasian population have been 
reported (Emanuel et  a l . ,  1972). In the l ig h t  of any d e f in ite
evidence to the contrary a reasonable assumption at th is  stage is 
that Down’ s syndrome risks derived from the Caucasian population 
can be applied to other ethnic groups. Further studies, ca re fu l ly  
controlled fo r  maternal age, would be necessary to te s t  whether 
there is any d ifference in Down’ s syndrome risks between d i f fe re n t  
ethnic groups.
1.3.2 OTHER AUTOSOMAL TRISOMIES
The risk  of having a pregnancy associated with trisomy 18 or 
trisomy 13 also increases with maternal age. In a review of the 
l i t e r a tu r e  Taylor (1968) found a mean maternal age at b ir th  of  
31.7 years in 153 cases o f Edwards’ syndrome, and 31.6 years in 74 
cases of Patau’ s syndrome, compared with around 25 years in the 
unaffected pregnancies. Hook et  al .  (1979) compared rates of  
Down’ s syndrome and trisomy 18 in s ingle-year maternal ages in 
l iv e b ir th s  in the same population and found s im ila r  rates of 
change re la t iv e  to maternal age, with a ra t io  of trisomy 18 to  
Down’ s syndrome of 0.135 (Cl 0.052 -  0 .297). From these data Hook
(1981) produced estimated rates per thousand l iv e  b ir ths  in single
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year in te rva ls  from 15-49 years fo r  Down’ s syndrome, trisomy 18 
and trisomy 13. The data fo r trisomy 13 assumed the same rate of 
change with age as tha t  found fo r  Down’ s syndrome and trisomy 18. 
Ferguson-Smith and Yates (1984) reported on the European 
collaborative  study of chromosome abnormalities in 52,965 
amniocenteses carried out fo r  maternal age 35 years and over. The 
rates found in th is  study show the same rate of change as those 
predicted by Hook (1981) but are higher due to  the known fe ta l  
loss of autosomal trisomies between m id-trim ester prenatal 
diagnosis and b ir th  (Hook, 1978).
1.4 MATERNAL AGE IN SCREENING FOR CHROMOSOME ABNORMALITIES
The association between r isk  and maternal age has been the basis 
of a widely used method to screen pregnant women fo r  chromosome 
abnormalities. Since the early  1970s i t  has been established  
practice to o f fe r  diagnostic amniocentesis, and more recently CVS, 
to women at or above a certa in  age, commonly 35-37 years. As a 
screening te s t  maternal age meets the c r i t e r ia  of s im p lic ity  and 
accep tab ili ty  to the patient as i t  depends on recognition of an 
age threshold rather than knowledge or in te rp re ta t io n  of a 
specific  r isk  f ig u re . However i t  is an in e f fe c t iv e  method of 
screening. For example, in the west of Scotland using age 35 as a 
c u t -o ff ,  6.7% of the pregnant population require diagnostic  
tes ting , but the s e n s it iv i ty  is only 30%, which represents the 
proportion of autosomal trisomy pregnancies w ith in  th is  age group 
(Figure 1 -1 ) .  The positive pred ic tive  value of the te s t  is also 
poor since only one abnormality w i l l  be found fo r every 125
diagnostic tests  performed. This screening method has made l i t t l e  
impact on the number of children born with Down’ s syndrome in the 
west of Scotland (Stone et  a h ,  1989) since the poor s e n s it iv i ty  
of the te s t  has been compounded by the low uptake of diagnostic  
testing  (less than 40%) in women aged 35 years and over. However 
even i f  a l l  e l ig ib le  women of 35 years and over had had prenatal 
diagnosis th is  screening method would s t i l l  f a i l  to access the 70% 
of affected pregnancies which occur in women under 35 years.
1.5 BIOCHEMICAL MARKERS FOR CHROMOSOME ABNORMALITIES
1.5.1 ALPHAFETOPROTEIN
The association between low maternal serum alphafetoprotein (AFP) 
and fe ta l  aneuploidy was f i r s t  reported by Merkatz et  al .  (1984), 
who f i r s t  observed levels 'below s e n s i t iv i t y ’ of the assay in two 
patients with trisomy 18. Following th is  with a study of maternal 
serum AFP in 52 chromosomally abnormal pregnancies, 21 out of 25 
Down’ s syndrome (84%), 11 out of 12 trisomy 18 (92%), 3 out of 3
trisomy 13 and 7 out of 12 (58%) sex chromosome abnormalities were 
found to have AFP values below the median of unaffected  
pregnancies. This resu lt  was confirmed fo r  Down’ s syndrome by 
Cuckle et  al .  (1984), S e lle r  (1984), Guibaud et  al .  (1984), Tabor 
et  al .  (1984), Trigg et  al .  (1984), Fuhrmann et  al .  (1984) and 
Voigtlander and Vogel (1985), who reported levels  with median 
values ranging from 0.72 -  0.80 MOM fo r  Down’ s syndrome cases, 
with 80 -  88% of values below the median of control cases. However
8
%
6 
4 
2 
0
Figure 1 -1
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Hershey et  al .  (1985) found, in a series of 32 cases of autosomal 
trisomy, (28 Down’ s syndrome and 4 Trisomy 18) only s l ig h t ly  
lowered maternal serum AFP levels  (0.87 MOM) and Cowchock and Ruch
(1984) found no d ifference between Down’ s syndrome and control 
cases in a study of 40 cases of trisomy 21.
Cuckle et  al .  (1984) calculated a re la t iv e  r isk  of Down’ s syndrome 
at each d i f fe re n t  level of AFP in MOM and proposed using a s lid ing  
scale of MOM as a c u t -o f f  fo r  d i f fe re n t  maternal ages. Using th is  
method a 40% detection rate fo r  Down’ s syndrome was predicted, at 
a 6.8% fa lse  positive rate .
Baumgarten (1985) proposed an algorithm fo r  ca lcu lating  a woman’ s 
Down’ s syndrome r isk  based on her age and AFP leve l,  and reported 
a prospective t r i a l  of th is  type of screening in women aged under 
35 years (Baumgarten et  a l . ,  1985). The algorithm was based on a 
Gaussian rather than log Gaussian d is tr ib u t io n  fo r AFP levels in 
MOM, However, in p ractice , screening 9059 women aged less than 35 
years, 444 (4.9%) had a r isk  greater than 1:250. Of these, 6 women 
had a Down’ s pregnancy and one a trisomy 18 pregnancy, giving  
overall odds of find ing an affected pregnancy of 1:63. The number 
of autosomal pregnancies in women in the low r isk  group was not 
reported.
Spencer and Carpenter (1985) reviewed a four year period when 
27,064 pregnancies were screened fo r neural tube defects using 
AFP. Twenty seven Down’ s syndrome cases were id e n t if ie d  in the 
screened population and these had a median value of 0.82 MOM of 
unaffected pregnancies. Using the strategy suggested by Cuckle et
al .  (1984) in th is  population the detection rate was only 14.8% 
and the fa lse  positive  rate 8.6%, and the authors suggested that  
the fe ta l  loss rate would be higher than the detection rate and 
therefore suggesting caution in the introduction of th is  type of 
screening.
Murday and Slack (1985) reported on a 12 month retrospective study 
of maternal age/AFP screening in the North East Thames region of 
London. There were 78 Down’ s syndrome pregnancies id e n t if ie d  and 
AFP measurements were ava ilab le  fo r  45 of these. Fourteen of the 
Down’ s syndrome pregnancies were prenata lly  diagnosed. The 
affected pregnancies had reduced levels  of maternal serum AFP at 
0.63 MOM of unaffected pregnancies. The authors proposed a method 
of r isk ca lcu lation  from the overlapping log Gaussian 
d is tr ib u tio n s , based on the Bayes calcu lation  method of Dennis and 
Carter (1978). They estimated that by o ffe r in g  amniocentesis to  
women aged 32 or greater who had a r isk  based on age and AFP level 
of 1:200 or greater, an extra  12 Down’ s syndrome cases would have 
been detected, i f  a l l  of the women in the high r isk  group had had 
a diagnostic te s t .  The authors suggested th a t  th e i r  be tte r  
detection ra te , compared with that of Spencer and Carpenter (1985) 
may in part be a ttr ib u ted  to more older mothers in th e ir  
population. The lower levels of AFP in the Down’ s cases (Median of 
0.63 MOM versus 0.83 MOM) may also have been a contributory  
factor.
Another retrospective analysis of results from a screening 
programme in Canada was reported by Doran et  al .  (1986), who 
considered results not only from mothers with Down’ s syndrome
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pregnancies but also with trisomies 18 and 13. They reviewed 6851 
maternal serum AFP results from samples taken p r io r  to
amniocentesis, and a fu rthe r  6505 results  from women having AFP 
screening. There were 61 autosomal trisomy pregnancies, consisting  
of 46 Down’ s syndrome, 10 trisomy 18 and 5 trisomy 13. The levels  
in the Down’ s and trisomy 18 pregnancies were reduced, at 0.79 MOM 
and 0.64 MOM respective ly. The levels in the trisomy 13
pregnancies was not s ig n if ic a n t ly  d i f fe re n t  from the controls, at 
1.19 MOM. Reviewing th e ir  results the authors suggested that  
offering  amniocentesis to women under 35 who had AFP levels of 
less than 0.5 MOM would detect 20% of fe ta l  autosomal trisomies
and put 5% of women in the high risk group, with overa ll odds of
finding an affected pregnancy of 1:180.
Martin and Liu (1986) produced risk  tables fo r  both b ir th  and 
mid-trimester which included p rio r r is k ,  r isk  i f  AFP <0.4 MOM and 
r isk  i f  AFP >0.4 MOM from the results of two other published 
studies. Hershey et  al .  (1986) also published risk  tables based on 
results from 28 Down’ s cases from th e i r  own centre, combined with 
137 other previously published results from other centres. These 
risks were based on maternal age and a s l id in g  scale of AFP 
values. Risks were calculated by Bayes theorem.
Results of a prospective t r i a l  of age/AFP screening in 51,141 
women under 35 years from eight centres were reported by Palomaki
(1986), on behalf o f the New England Collaborative Down Syndrome 
Prenatal Screening Study. Of the 1050 women (2.1%) assigned to the 
high risk group (2.1%), 807 (77%) opted fo r  amniocentesis. Amongst 
these women 12 autosomal trisomy pregnancies (8 Down’ s syndrome
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and 4 trisomy 18) were id e n t i f ie d ,  giving overa ll odds of an 
affected pregnancy of 1:58. No b ir th  outcome information on the 
women who did not have a diagnostic te s t ,  from e ith e r  the high or 
low risk group was ava ilab le  at the time of pub lication . The study 
concluded that th is  method of screening appeared feas ib le  in 
practice.
Ashwood et  al .  (1987) carried  out a retrospective study on
maternal serum samples taken fo r  AFP analysis p r io r  to
amniocentesis from 3,411 women. There were 71 fe ta l  chromosome 
abnormalities in these patients , including 26 Down’ s syndrome and 
10 trisomy 18. Risks of Down’ s syndrome were calculated from the 
cumulative proportions of unaffected and Down’ s syndrome samples 
and compiled Down’ s syndrome maternal age risks produced by Hook
(1981) a f te r  adjusting these to m id-trim ester. The calcu lation  of 
r isk  was by Bayes theorem. Due to the r e la t iv e ly  small numbers of 
Down’ s syndrome samples i t  was not possible to derive a smooth 
cumulative proportion curve and the assumption was made that the 
affected d is tr ib u t io n  was sh ifted  0.3 MOM from the control 
d is tr ib u t io n  and tha t any point on the Down’ s d is tr ib u t io n  was 
equivalent to the same point on the curve -  0 .3 .  Since AFP f i t s  a 
log Gaussian rather than a Gaussian d is tr ib u t io n  (Cuckle et  a l . ,  
1987) th is  is not a va lid  assumption.
Palomaki and Haddow (1987) were the f i r s t  to  suggest the 
l ike lihood ra t io  method of ca lcu lating  Down’ s syndrome r isks. This
method derives risks from the overlapping log Gaussian
d is tr ibu tio ns  of control and Down’ s syndrome samples. The 
l ike lihood ra t io  a t  any given AFP resu lt  in MOM is the distance
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from a point on the base l in e  to the curve representing the 
affected population divided by the distance to the unaffected 
curve. The height to a Gaussian d is tr ib u t io n  can be calculated by 
a formula which uses the mean and standard deviation of the 
d is tr ib u t io n  (Cuckle and Wald, 1984).
Cuckle et  ah  (1987) extended th is  method of r isk  ca lcu lation  
suggested by Palomaki and Haddow to include maternal age risks  
from a compilation of eight other studies (see Section 1 .3 ) .  These 
were combined with risks derived from AFP results from th e ir  own 
series of 68 Down’ s syndrome samples and 36,645 unaffected  
pregnancies. They described how to calculate a like lihood ra t io  
fo r  any given AFP value in MOM using a formula which u t i l i z e s  the 
means and standard deviations of the Down’ s syndrome and 
unaffected d is tr ib u t io n s . The authors compiled r isk  tables giving  
an individual woman’ s r isk of having a Down’ s b i r th ,  based on her 
age and AFP le v e l,  fo r  gestations based on las t  menstrual period 
or ultrasound, and fo r  AFP values which included or excluded a 
correction fo r  maternal weight. This study also derived fa lse  
positive  rates and detection rates fo r  screening po lic ies  using 
d if fe r in g  r isk  thresholds as a c u t -o f f ,  predicting, fo r  example, a 
36% detection rate fo r  Down’ s syndrome at a 5.4% fa lse  positive  
rate using a 1:300 r isk  threshold. I t  concluded th a t  screening 
using AFP/age was more e f f ic ie n t  than using maternal age alone and 
that where prenatal screening fo r  neural tube defects was in 
progress i t  was also ju s t i f ia b le  to use the results fo r  screening 
fo r Down’ s syndrome.
Tabor et  ah  (1987), using data derived from 86 Down’ s syndrome
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pregnancies and 2018 unaffected singleton controls, used Bayes 
theorem to  derive risks from the log Gaussian d is tr ib u tio n s  of 
affected and unaffected pregnancies. From these they constructed 
an iso -r isk  curve equal to a r isk  of 1:400 to se lect women fo r  
amniocentesis. Women whose AFP/age combination f e l l  below the 
iso -r isk  l in e  were in the high r isk  group and would be offered  
amniocentesis. Using th e ir  data, where the Down’ s cases had a 
median of 0.64 MOM, they predicted, in th e i r  population, a 
detection rate of 53% for Down’ s syndrome with a fa lse  positive  
rate of 9.4%. This compares with a detection rate of 28% at a 
fa lse  positive  rate of 6.9% using maternal age >35 years in the 
same population.
Lindenbaum et  ah  (1987) reported on maternal serum levels of AFP 
in 50 cases of trisomy 18. Of these 38 (76%) had neither
exomphalos nor neural tube defect and for these cases the median 
level of AFP was 0.60 MOM with 30 of the cases having values below 
the median. Screening programmes fo r  Down’ s syndrome using low AFP 
levels w i l l  therefore also detect trisomy 18 pregnancies.
Di Maio et  al .  (1987) reported on prospective screening with  
AFP/age in 35,797 women of whom 34,354 (96%) were aged less than 
35 years. Risks were calculated by the method of Baumgarten et  al .
(1985) which assumes a Gaussian rather than log Gaussian 
d is tr ib u t io n  fo r  AFP. Using a r isk  threshold of 1:270 1814 (5.3%) 
were assigned to the high r isk  group. Of these 18% were found to  
have overestimated gestation. Of the 1451 with a confirmed r isk  of  
>1:270, 1102 (76%) elected to have amniocentesis. Of the women in
the confirmed high r isk  group 9 had a fetus with Down’ s syndrome
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and 8 of these were p renata lly  diagnosed. In addition 3 cases of 
trisomy 18 and one of trisomy 13 were assigned to the high risk  
group. Screening id e n t if ie d  9 out of 27 Down’ s cases (33%), 3 out 
of 6 trisomy 18 cases (50%) and 1 out of 3 trisomy 13 cases (33%).
Another prospective series , with incomplete ascertainment of 
Down’ s cases, was reported by Lustig et  al .  (1988). They reported 
on 174,784 women screened in C a li fo rn ia .  3,939 women (2.25%) were 
assigned to the high r isk  group ( r is k  >1:365) on the basis of 
risks derived from th e i r  AFP level and maternal age, using the 
r isk  ca lculation method of Cuckle et  al .  (1987) and the Down’ s 
syndrome incidence figures of Hook and Chalmers (1977). 2,552 of
these women remained in the high r isk  group a f te r  ultrasound 
assessment of th e i r  gestation and 1940 (76%) had amniocentesis. 
There were 23 Down’ s syndrome pregnancies amongst these women of 
which 17 were diagnosed by amniocentesis. Five of the remaining 
cases were missed due to an i n i t i a l  policy of requesting a repeat 
sample and assigning women to the low r isk  group i f  th is  second 
sample gave a r isk  less than the threshold. This repeat policy was 
changed in the la t t e r  h a lf  of the period reviewed on recognition  
of the issue of regression to the mean (Haddow et  a l . ,  1986). 
Amongst the women in the high r isk  group there were also 4 cases 
of trisomy 18, 1 trisomy 13, 2 Turner’ s syndrome, 4 Turner
mosaics, 1 K 1 in e fe lte r ’ s syndrome, 1 K l in e fe lte r  mosaic and 1 
t r ip lo id y .  No data were ava ilab le  on chromosome abnormalities in 
women assigned to the low r isk  group.
Hook (1988) discussed the v a l id i t y  of using AFP/age to reassure 
older women (age >35 years), who have re la t iv e ly  high AFP resu lt
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which gave a r isk  of Down’ s syndrome lower than tha t  associated 
with th e i r  age, and who consequently might avoid the need fo r  
amniocentesis. The crit ic ism s of th is  approach were (a) that  
Down’ s syndrome risks from AFP levels were derived from a 
mathematical model of a r e la t iv e ly  small amount of data rather  
than from d irec t  observation, (b) that the assumption is made that  
AFP d is tr ibu tio ns  do not change with maternal age and (c) tha t the 
risks and re la t iv e  proportions assigned to high and low risk  
groups at the same maternal age and AFP level vary between 
d if fe re n t  studies (Ashwood et  a l . ,  1987, Cuckle et  a l . ,  1987, Di 
Maio et  a l . ,  1987, Palomaki and Haddow, 1987, Tabor et  a l . ,  1987)
Wald and Cuckle (1988) discussed th is  last point fu r th e r  and 
compared the methods used to derive risks in these f iv e  studies. 
Two were based on an inappropriate mathematical model (Ashwood et  
a l . ,  1987, Di Maio et  a l . ,  1987).  The risks of Tabor et  al .  (1987) 
are discrepant from the others due to a lower median level of AFP 
(0 .64 MOM) found compared to that found by Cuckle et  al .  (1987) 
and Palomaki and Haddow (1987) (0.72 MOM) who used the same data 
set. The small d ifferences in the risks of Cuckle et  al .  (1987) 
and Palomaki and Haddow (1987) can be a ttr ib u ted  to  the d i f fe re n t  
method used to calculated the standard deviation. Palomaki and 
Haddow (1987) used the in te rq u a r t i le  range whereas Cuckle et  al .
(1987) used the 10th -  90th c e n ti le  range. This la t t e r  method is  
thought to be more appropriate.
The economics of using AFP/age screening have been investigated by 
G il l  et al .  (1987), Swint and Greenberg (1988) and Wald and Cuckle
(1988). G i l l  et  al .  (1987) carried out a cost benefit  analysis of
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the costs of screening, diagnosis and termination of pregnancy 
compared with the l i fe t im e  costs of a Down’ s b i r th ,  taking into  
account that a termination of pregnancy w i l l  probably be replaced 
by an unaffected pregnancy. They concluded tha t  the f inanc ia l  
benefits of screening e ith e r  by age alone or by AFP/age are 
favourable and tha t  not o ffe r ing  AFP/age screening would be 
discriminating against younger women. Swint and Greenberg (1988) 
concluded that i f  screening by maternal age is economically 
ju s t i f ia b le  then o ffe r in g  amniocentesis to younger women on the 
basis of AFP/age is also economically v iab le . Wald and Cuckle
(1988) pointed out tha t since the overa ll odds of find ing an 
affected pregnancy are greater in women selected by AFP/age rather  
than by age alone the net cost of detecting a Down’ s pregnancy is  
lower when screening by AFP/age.
1 .5 .2  UNCONJUGATEP ESTRIOL
Greater s e n s it iv i ty  is  p o te n t ia l ly  possible using additional  
information from the analysis of other pregnancy markers in 
maternal serum. I t  had been observed by Jorgensen and T ro l le  
(1972) that to ta l  urinary e s t r io l  secretion in the th ird  tr im ester  
of pregnancy was lower in Down’ s syndrome pregnancies than in 
unaffected pregnancies. Canick et  al .  (1988) and Wald et  al .  
(1988a) reported lower second tr im ester levels  of unconjugated 
e s tr io l  (UE3) in Down’ s syndrome pregnancies. Canick et  a l . ,  in 22 
Down’ s syndrome pregnancies and 110 matched controls found a 
median level of 0.79 MOM in the Down’ s pregnancies. Unconjugated 
e s t r io l ,  unlike to ta l  e s t r io l ,  is almost e n t i re ly  derived from the
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fetus and placenta ( S i i t e r i  and MacDonald, 1966).
Wald e t a l .  found levels of 0.73 MOM In 77 Down’ s syndrome 
pregnancies, compared with the levels in 385 controls. S ign ifican t  
corre lation  was found between AFP and UE3. Extending the approach 
to risk calculation previously described fo r  AFP and age (Palomaki 
and Haddow, 1987, Cuckle at  a l . ,  1987) to include UE3, and
allowing fo r  the corre la t ion  between AFP and UE3, a detection rate  
fo r  Down’ s syndrome of 45% was predicted with a fa lse  positive  
rate of 5.2%, using a r isk  threshold of 1:250.
1 .5.3 HUMAN CHORIONIC GONADOTROPHIN
Bogart et  al .  (1987) found elevated levels of to ta l  human 
chorionic gonadotrophin (hCG) and free  a-subunit hCG in 17 cases 
of Down’ s syndrome compared with the levels in 74 controls. 
Samples were taken between 18 and 25 weeks a f te r  fe ta l  chromosome 
analysis had been carried out following amniocentesis. Screening 
using elevated levels of hCG would be more e f fe c t iv e  than using 
low levels of AFP.
Wald et  al .  (1988b), in a study of hCG levels  in 77 Down’ s 
syndrome pregnancies and 385 controls, found a median hCG level in 
the Down’ s syndrome pregnancies of 2.04 MOM and predicted a 55% 
detection rate by combining hCG and AFP results with maternal age 
risks, as described fo r  UE3. By also including UE3 results  the 
predicted detection rate was increased to 61% fo r  a 5% follow up 
rate . This combination of analytes (AFP/hCG/UE3) has become known
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as 'The T r ip le  Tes t’ .
Arab et  al .  (1988) suggested an a lte rn a t ive  approach fo r  the use 
of hCG in screening fo r  Down’ s syndrome by combining hCG and AFP 
results as a ra t io ,  and from a study of 29 Down’ s syndrome 
pregnancies predicted a 60% detection rate fo r  a 10% amniocentesis 
rate , but the data were not combined with maternal age risks.
1 .5 .4  PREGNANCY-SPECIFIC Bi-GLYCOPROTEIN
Bartels and Lindemann (1988) found elevated levels  of maternal 
serum pregnancy-specific 3i-g lycoprotein  (S P i) ,  s im ila r  in 
magnitude to that reported fo r  hCG. In 24 pregnancies with Down’ s 
syndrome a median level of SPi of 2.1 MOM was found compared with  
the levels in 34 unaffected controls, with 18 out of 24 values 
being above the 90th c e n t i le .  Samples were taken between 16 and 19 
weeks of gestation a f te r  patients had undergone amniocentesis and 
fe ta l  chromosome analysis carried out.
1.6 DEVELOPING SCREENING
At the commencement of th is  project in 1988 the p o s s ib i l i ty  
therefore existed to increase the detection rate  fo r  Down’ s 
syndrome in the second tr im ester of pregnancy to around 60% using 
a combination of maternal serum markers and maternal age r isks.  
However the e f fe c t  of th is  type of screening on the detection of  
other types of chromosome abnormalities, especia lly  other
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autosomal trisom ies, 
questions regarding 
routine practice.
was not known and there were many unanswered 
the e ff icacy  of multimarker screening in
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SECTION 2
AIMS
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The study can be divided into three main parts:
2.1 PHASE 1
Retrospective data analysis of maternal serum AFP results  in 142 
autosomal trisomy pregnancies to establish the parameters of the 
d is tr ibu tio ns  in abnormal and unaffected pregnancies and derive  
risk tables applicable to routine AFP screening.
2.2 PHASE 2
Retrospective analysis of four other pregnancy markers 
(a lphafetoprote in , human chorionic gonadotrophin, unconjugated 
e s tr io l  and the free  3 subunit of hCG) in stored maternal serum 
samples from pregnancies with Down’ s syndrome and other chromosome 
abnormalities to establish the va r ia t io n  in levels between 
unaffected and abnormal pregnancies, and to look at ways tha t  
these variations might be exploited to provide r isk  estimation fo r  
population screening
2.3 PHASE 3
To establish the impact of biochemical screening fo r  chromosome 
abnormalities in a large unselected population, by determining 
detection rates, fa lse  positive  rates and the impact on prenatal 
diagnosis rates and b ir th  incidence.
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3.1 PATIENT SAMPLES
The Duncan Guthrie In s t i tu te  of Medical Genetics, Y o rk h il l ,  
Glasgow provides a comprehensive Medical Genetics Service to 3.0  
m ill ion  people in the west of Scotland. One aspect of th is  service  
is prenatal screening fo r  women in 8 Area Health boards (Argyll 
and Clyde, Ayrshire and Arran, Dumfries and Galloway, Forth 
Valley, Greater Glasgow, Highland, Lanarkshire and Western Is le s ) .  
Screening fo r  neural tube defects started in 1976 and was extended 
in 1987 to include chromosome disorders, mainly Down’ s syndrome. 
In th is  region there are around 37,500 b irths per year and 80% of 
pregnant women (30,000 per year) choose to have a prenatal 
screening te s t .
The m ajority of venous blood samples (5-10 mis) are collected at
15-20 weeks gestation from women attending one of the 18 maternity  
units in the west of Scotland. A few samples are taken d ire c t ly  by 
GPs. Samples are sent to the Biochemical Genetics Division of the 
In s t i tu te  of Medical Genetics where they are given a laboratory  
accession number, separated, an a liquot of serum used fo r  assay 
and the remainder (1-3  mis) stored at - 2 0 °C. A standard request 
form accompanies the sample, giving d e ta i ls  of the patient and her 
pregnancy: Name, date of b ir th ,  weight, gestation (derived from
menstrual dates, by c l in ic a l  examination and ultrasound
estimation, usually derived e ith e r  from b i -p a r ie ta l  diameter or 
crown-rump length), h istory of previous neural tube defect or 
chromosome abnormalities, and d e ta i ls  of pregnancy complications 
(threatened abortion, twins, insulin  dependant diabetes,
anticonvulsant therapy, invasive diagnostic procedures). Patient
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and sample d e ta i ls  are entered into a computerised database which 
is used to generate assay w ork lis ts . Following analysis of  
samples, results are merged with patient information, reports are 
generated and completed records archived as prin tout or on disc.
The Medical Genetics department also provides a cytogenetic  
service fo r  a l l  of the previously above Health Boards apart from 
Highland region which has i ts  own cytogenetics laboratory. 
Chromosomally abnormal pregnancies, id e n t if ie d  e i th e r  pre- or 
po s t-n a ta l ly ,  can be ascertained from inspection of departmental 
cytogenetic records. Information on patients from Highland region 
was obtained from the Cytogenetics Department in Raigmore 
Hospital, Inverness.
3 .1 .1  RETROSPECTIVE AFP STUDY
Pregnancies affected by Down’ s syndrome or other autosomal 
trisomies, diagnosed e ith e r  at b ir th  or p renata lly  between April  
1982 and May 1987 in the west of Scotland, were id e n t if ie d  from 
departmental cytogenetic records. A fte r  exclusion o f twin 
pregnancies and cases complicated by ventral wall or neural tube 
defects or other s tructura l abnormalities, maternal serum AFP 
results were ava ilab le  from the screening archive fo r  142 affected  
pregnancies screened between 16 and 20 weeks gestation (32 
terminations and 110 l iv e  b ir th s ) .  The study group consisted of 
114 Down’ s syndrome, 19 with trisomy 18 and 9 with trisomy 13. 
Maternal serum AFP results at 16-20 weeks gestation from 113,045 
unaffected pregnancies (without autosomal trisomy or neural tube
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defect) tested during the same period were used fo r  comparison as 
a control group. I f  more than one AFP resu lt was obtained in any 
pregnancy, only the f i r s t  was used.
Estimates of gestation were based mainly on the time since the 
f i r s t  day of the las t  menstrual period (LMP), modified by 
ultrasound as suggested by Rossavik and Fishburn (1989). 
Ultrasound measurement was used only were the date o f the LMP was 
not ava ilab le  or were there was a discrepancy of ±2 weeks in the 
estimated gestation by ultrasound. A ll gestations were established  
by th is  method using the information obtained at the time of 
sampling. This therefore re f lec ts  the q u a lity  of information 
l ik e ly  to be ava ilab le  in routine screening programmes and avoids 
dependence on a single dating method which was not ava ilab le  fo r  
a l l  samples.
3 .1 .2  RETROSPECTIVE STUDIES ON OTHER PREGNANCY MARKERS
In addition to AFP, retrospective analysis using stored samples 
was undertaken fo r  four other markers: hCG, SP1, UE3 and the free  
|3 subunit of hCG. S ix ty - f iv e  thousand serum samples collected  
prospectively in the west of Scotland a t 15-20 weeks gestation fo r  
routine AFP estimation between January 1987 and March 1989 
provided the basic source material fo r  these studies. A fte r  
routine AFP estimation, sera were stored at -20°C u n t i l  the 
outcome of the pregnancy was known. An i n i t i a l  pool of 78 
chromosomally abnormal pregnancies were id e n t if ie d  from which 
stored serum was ava ilab le . The chromosomally abnormal cases are
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l is ted  in Table 3-1. In any abnormal case where two consecutive 
samples were ava ilab le  only the f i r s t  sample was used. Five 
control sera were selected fo r  each case, matched fo r  maternal age 
(w ith in  12 months), completed weeks of gestation and time in 
frozen storage (w ith in  6 months). A ll control specimens were 
selected without reference to th e ir  AFP le v e l.  Additional cases of 
Down’ s syndrome and trisomy 18 were added to the study group as 
they were id e n t if ie d  within the samples stored following routine 
screening. In a l l ,  a panel of 120 serum samples from chromosomally 
abnormal pregnancies were accumulated fo r  use in the retrospective  
analyses of pregnancy markers (81 Down’ s syndrome, 12 trisomy 18, 
4 trisomy 13, 10 unbalanced translocations, 4 balanced
translocations and 9 sex chromosome abnorm alities). To avoid 
repeated thawing and freezing, samples were recovered from
storage, thawed once, divided into small a liquots and refrozen
pending fu rth e r  analyses.
Gestational age (completed weeks) fo r  both affected and unaffected  
pregnancies was based mainly on the time since the f i r s t  day of 
the last menstrual period (LMP i . e .  by dates). Ultrasound 
estimates of gestation were used only fo r  those patients in whom 
e ith er  the LMP was not ava ilab le  or there was a discrepancy of at  
least ±2 weeks in gestational age calculated using dates and 
ultrasound.
3 .1 .3  PROSPECTIVE hCG TRIAL
Between July 1989 and June 1990 a l l  samples sent fo r  routine AFP
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Table 3 - 1
Chromosomally abnormal pregnancies used in retrospective studies  
of pregnancy markers.
Abnormality n Karyotype
Down’ s syndrome 49
Trisomy 18 4
Trisomy 13 4
Unbalanced 
T ranslocations 8 46,XY 2p+
46,XY ,del(21)(q22qter)
4 6 ,Y , -X ,+ d e r (X ) ( t ;1 1 ) (p22p15)mat 
46,X X ,-11,+ d e r (11) t (4 ;11)
(q31.1q25) pat 
46,XY,del( 4 ) ( q12q21.3)  
46,XX ,del(11)(q24qter)
4 5 ,X Y 10,—1 4 ,+ t (10;14 )(p13q11-2)
46,XY/47,XY+m
Balanced 
T ranslocations 4 46,XY,inv(2)(p11q13)
4 6 ,X X ,t (9 ;1 0 ) (q32p13)pat
45,XX,t(13q;15q)
4 6 ,XX, t (1 2 ;1 6 ) (q13p11.2)
Sex Chromosome 
Abnormalities 9 3 4 5 ,X 
4 9 ,XXXXX 
47,XXY 
3 47 ,XYY 
45,X/46,XY
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estimation from three Glasgow maternity hospitals (Glasgow Royal 
Maternity Hospital, The Queen Mothers Hospital and Rutherglen 
Maternity Hospital) also had hCG estimation carried  out. The hCG 
results were stored and only analysed a f te r  de live ry .  7,830 
pregnancies were tested and 16 Down’ s syndrome and 2 trisomy 18 
pregnancies id e n t if ie d  amongst the women screened.
3 .1 .4  CLINICAL PRACTICE
In July 1987,The west of Scotland maternal serum screening service  
fo r  neural tube defects was adapted to include the reporting of  
risks of an autosomal trisomy in individual pregnancies, using the 
risks derived from maternal age and AFP resu lt .  From September 
1991 hCG estimation, in addition to AFP, was carried out routinely  
on a l l  samples received by to the west of Scotland prenatal 
screening service. Table 3-2 gives a summary of the number of 
women screened and uptake of screening from July 1987 to September 
1992.
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Table 3 - 2
Births, pregnancies screened and uptake of screening in the west 
of Scotland.
T ime No.births No.women 
screened
Uptake of 
screening
Gestation 
range (weeks)
July 87- 
Dec 90
128,824 100,481 78% 16-20
Sept 91- 
Sept 92
37,500* 30,084 80% 15-20
* Estimate
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4.1 ASSAY METHODS
4.1.1  IMMUNOASSAYS
Immunoassays u t i l i z e  the spec if ic  binding between an antibody and 
an anti gentic substance to quantify the levels o f the antigen in 
biological f lu id s .  A prepared antibody may be polyclonal i . e .  
containing many d i f fe re n t  antibodies with d i f fe r in g  s p e c if ic i t ie s  
to m ultip le  epitopes (binding s ite s )  on the antigen molecule, or 
monoclonal i . e .  homogeneous in s p e c if ic i ty  and recognising only 
one epitope on the antigen. Polyclonal antibodies are the 
conventional serum product of an immunised animal. Monoclonal 
antibodies are prepared from a c e l l  l in e  derived from a single  
antibody-producing c e l l  immortalised by fusion to a B lymphocyte 
tumour c e l l  l in e  to form a 'hybridoma’ clone.
Three types of immunoassay were used in th is  pro ject,  
radioimmunoassay (RIA), immunoradiometric assay (IRMA) and rocket 
immunoelectrophoresis (IEP).
4 .1 .1 .1  RADIOIMMUNOASSAY
In th is  technique labelled antigen competes with te s t  antigen to  
complex with l im ited antibody in l iq u id  phase. E ither polyclonal 
or monoclonal antibody can be used but the antibody must have a 
high a f f in i t y  fo r  the antigen and also stringent s p e c if ic i ty .  The 
antibody-antigen complex is prec ip ita ted  and the ra d io a c t iv ity  in 
the bound (p rec ip ita ted ) f ra c tio n  counted. The radioactive counts
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obtained are inversely proportional to the amount of antigen in 
the sample (Catty and Murphy, 1989).
4 .1 .1 .2  IMMUNORADIOMETRIC ASSAY
This technique uses radio labelled monoclonal antibody to  measure 
the amount of antigen in a sample. In a 'sandwich* ( tw o -s ite )  
assay, so lid  phase antibody (polyclonal or monoclonal antibody 
bound to beads or p la s t ic  tubes) binds antigen and the presence of  
bound antigen is detected by the use of a second rad io labelled  
antibody (monoclonal). Antibody is present in excess. Free and 
bound labelled antibody are separated by one or more wash steps. 
The ra d io a c t iv ity  in the bound frac tio n  is counted. The counts 
obtained are proportional to  the amount of antigen present in the 
sample (Catty and Murphy, 1989).
4 .1 .1 .3  ROCKET IMMUNOELECTROPHORESIS
This method combines the e lectrophoretic  migration o f antigens in 
agarose with immunoprecipitation in the gel. Test samples are 
loaded into wells in an agarose p late  containing antibody. 
E lec tr ic  current is applied to move the antigen in to  the gel. Gels 
are prepared and run at a pH at or close to the is o e le c tr ic  point 
of the antibody to prevent i t s  migration from the gel. Sharply 
pointed p rec ip ita t io n  peaks ( 'ro c k e ts ’ ) form as the antigen 
accumulates bound antibody during migration. The area of the 
rockets is proportional to the antigen concentration (Catty and 
Raykundalia, 1988).
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4 .1 .2  ALPHAFETOPROTEIN
AFP was f i r s t  id e n t if ie d  in 1956 (Bergstand and Czar, 1956), but 
i t s  function is s t i l l  unknown. I t  is a glycoprotein, with a 
molecular weight o f 69,000. D if fe ren t molecular forms of AFP have 
been id e n t if ie d ,  which have differences 1n the amount and 
structure of carbohydrate residues of the molecule. AFP is  
synthesised by the yolk-sac and the fe ta l  l iv e r .  The yolk-sac  
atrophies towards the end of the f i r s t  tr im ester and a f te r  th is  
synthesis is by the fe ta l  l iv e r .  The two sources produce d i f fe re n t  
forms of AFP (Ruoslahti et  a / . , 1978) which can be d i f fe re n t ia te d
by th e ir  binding to concavalin A, fe ta l  l iv e r  AFP having much 
greater a f f in i t y .  At 17 weeks of pregnancy the concentration of 
AFP in fe ta l  serum is 50,000 times greater than 1n maternal serum 
(Wald and Cuckle, 1984)^AFP is the fe ta l  equivalent of serum albumin.
AFP levels , measured prospectively at the time of sample 
co llec tion  as part of routine screening, were ava ilab le  fo r  a l l  
cases. AFP levels were determined using a radioimmunoassay u n t i l  
June 1985. Thereafter, the method was changed to  an 
immunoradiometric assay (Stevenson et  a l . ,1987).
4 .1 .2 .1  RADIOIMMUNOASSAY FOR ALPHAFETOPROTEIN
A semi-automated protocol using a Micromedic APS-2 sample 
processor to dispense assay buffer and serum was employed. 40 pi 
of sample or standard serum were incubated with 800pl assay 
diluent (0.05 mol/1 barbitone, pH 8 .6 ,  with 0.1% w/v sodium azide)
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containing 10% w/v polyethylene glycol 6000 (BDH), 1.1 pg/1 
125I-AFP 310 pg/1, bovine gamma globulin (Sigma) and sheep
anti-human AFP antiserum ( f in a l  d i lu t io n  1:52,000) fo r  16 hours at  
ambient temperature. A ll samples were assayed in duplicate. Bound 
and free  frac tions  were separated by centr ifugation  at 1,500g fo r  
30 minutes at 4°C. The supernatant was then aspirated. The bound 
frac tio n  was counted on an LKB Rackgamma counter. Data processing 
used the programme developed by McKenzie and Thomson (1983), which 
uses 5 parameter lo g is tics  fo r  curve f i t t i n g ,  in a PDP11/24 
minicomputer (DEC).
4 .1 .2 .2  IMMUNORADIOMETRIC ASSAY FOR ALPHAFETOPROTEIN
This is a tw o-s ite  IRMA. Samples and assay buffer were dispensed 
using a Micromedic APS-2 or Kemble 1000 automatic sample 
processor. 25pl of serum sample or standard were d ilu ted  with  
200pl assay buffer (0.1 mol/1 EPPS (Sigma), pH 8 .0 ,  0.1% v/v Tween 
20 (Sigma), and 0.1% w/v sodium azide (Sigma)). To th is  was added 
200 pi assay buffer containing 2.2% v/v  sheep serum (SAPU), 25 
|ig /l 125I  monoclonal anti-AFP (AF5/A2; Radioimmunoassay Section, 
Department of Obstetrics and Gynaecology, Ninewells Hospital 
Dundee) and 5 g/1 polyclonal sheep anti-human AFP linked to
Sepharose CL-4B (SAPU). A ll samples were assayed in duplicate. The 
assay was incubated at ambient temperature fo r  2£ hours on an 
o rb ita l  shaker at 400 rpm. Separation of bound and free  fractions  
was by two cycles of sucrose density sedimentation. F i rs t  1 ml of  
wash reagent (9 g/1 sodium chloride (BDH) and 0.1% v/v Tween 20) 
was added to each tube. Then 3 ml of density sedimentation reagent
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(30 g/1 sucrose, 0.1% v/v Tween 20) was pumped c a re fu l ly  into  the 
bottom of each tube. A fte r  15-30 minutes the supernatant was 
aspirated and a f te r  the process had been repeated, the bound 
frac tion  counted in e i th e r  an LKB Rackgamma counter or a Packard 
Cobra 5010 gamma counter. Data reduction was e i th e r  by the method 
described fo r  the RIA AFP assay or, using an Epson PC AX 
microcomputer, by the WHO immunoassay programme developed by 
Edwards and E kins (1983) which uses a 4 parameter mass action  
model fo r  curve f i t t i n g .
4 .1 .2 .3  AFP ASSAY PARAMETERS
The RIA assay had a working range of 25-400 KU/1 and ty p ic a l ly  
had an inter-assay c o e ff ic ie n t  of va r ia t io n  (CV) o f 11% and an 
intra-assay CV of 5% between 40-400 KU/1. The IRMA assay has a 
working range of 1.5-500 KU/1 and ty p ic a l ly  has an inter-assay CV 
of 6.0% and intra-assay CV of 2.5% between 5 and 500 KU/1. The AFP 
results fo r  both RIA and IRMA methods were expressed as KU/1 (IRP 
72/227) and converted to m ultiples of the median (MOM) by using 
the appropriate median fo r  unaffected pregnancies fo r  the 
gestation and assay method.
4 .1 .3  HUMAN CHORIONIC GONADOTROPHIN
HCG is a sialoglycoprotein with a molecular weight of 40,000, 
produced in the syncytiotrophoblast of the placenta (Dreskin et  
a l . , 1970). I t  is composed of two non-covalently bound subunits
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o f unequal s ize , a and 13 (Bahl et  a l . ,  1972). The a subunit is  
v i r tu a l ly  identica l to  that of the p i tu i ta r y  hormones lu te in is in g  
hormone (LH), fo l l ic le -s t im u la t in g  hormone (FSH), and thyroid  
stimulating hormone (TSH) (Bahl et  a l . ,  1972). The |3 subunit 
shares a high degree of homology with LH, but possesses an extra  
24 afmino acid carboxy-terminal extension. The I3LH and |3hCG 
subunits can be distinguished immunologically (V a itu ka is is  et  a l . ,
1972). The major physiological role o f hCG appears to be support 
of corpus luteum progesterone production, a function essential fo r  
pregnancy maintenance in the f i r s t  seven weeks (Csapo et  a l . ,
1973). The concentration of hCG in the maternal c irc u la t io n  fa r  
exceeds that found in the fe ta l  c ircu la tio n  (V a itu ka is is ,  1977).
4 .1 .3 .1  IMMUNORADIOMETRIC ASSAY FOR HUMAN CHORIONIC GONADOTROPHIN
For both retrospective and prospective studies hCG was estimated 
using a commercially ava ilab le  immunoradiometric assay (Serono 
MAIA-clone k i t )  which measures predominantly in ta c t  molecule hCG 
but does have some c ro s s -re a c tiv ity  with free  0 subunit of hCG. 
This assay u t i l i z e s  three monoclonal antibodies to hCG, two of  
which are labelled with 125I .  The th ird  monoclonal, recognising a 
d if fe re n t  epitope on the hCG molecule, is  labelled  with  
fluorescein. A fte r  incubation, sheep antiserum to fluorescein  
coupled to a magnetic so lid  phase is added in excess. This rapidly  
and s p e c if ic a l ly  binds to the hCG-monoclonal antibody complex and 
is sedimented in a magnetic f ie ld .
For retrospective studies abnormal cases and th e i r  matched
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controls were randomised and assayed in the same batch. To bring 
second tr im ester serum samples into the range of the assay a l l  
samples were d ilu ted  1 in 500 in a two-step d i lu t io n  (1/20 then 
1/25) using the horse serum supplied with the k i t .  For reasons of 
economy a l l  sample, standard and reagent volumes, apart from the 
f in a l  wash step, were halved from th a t  given in the supplied 
protocol. This change did not appear to  a l te r  the performance of 
the assay. The s e n s it iv i ty  remained unchanged at 0.5 mlU/ml and 
over four assays the inter-assay CVs fo r  two q u a li ty  control 
samples with values of 78 IU/ml and 27 IU/ml were 7.8% fo r  assay 
done with f u l l  volume and 7.4% for assays at h a lf  volume.
25 pi of standard or d ilu ted  sample were pipetted into  tubes. A ll  
standards and samples were assayed in duplicate. 250 pi of 125I  
anti-hCG reagent, containing fluorescein and 125I  labelled mouse 
monoclonal antibodies to hCG in T r is  buffer with normal sheep
serum, bovine serum albumin (BSA) and 0.2% w/v sodium azide, was
\
added to each tube. The tubes were vortex mixed and incubated at  
37°C in a water bath fo r  15 minutes. 100pl of separation reagent, 
containing sheep antiserum to fluorescein covalently bound to  
magnetic p a r t ic le s  in T r is  buffer with BSA and 0.1% w/v sodium 
azide, was added to each tube and, a f te r  gentle mixing, incubated 
at room temperature fo r  5 minutes. The racks of tubes were placed 
in magnetic separators and the p a rt ic les  allowed to sediment fo r  2 
minutes. The supernatant was decanted by inversion of the rack. A 
f in a l  wash step reduces non-specific binding. 500pl of wash buffer  
(T r is  buffer with 0.2% w/v sodium azide) was added to each tube 
and a l l  tubes thoroughly mixed by vortexing. The magnetic 
sedimentation step and decanting of the supernatant were repeated.
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The bound fra c tio n  was counted using a Packard Cobra 5010 gamma 
counter. Data reduction was by e i th e r  the data reduction package 
in the gamma counter on-board microcomputer using spline curve 
f i t t i n g  on a lo g /l in e a r  scale (RIA-Smart) or by the WHO package 
described in the AFP IRMA assay method.
For routine use in the whole screening population, a 
semi-automated hCG assay protocol was used, with the assay 
d ilu t io n  step, and the dispensing of sample being carried  out by a 
Kemble 1000 automatic sample processor.
4 .1 .3 .2  hCG ASSAY PARAMETERS
The assay has a range of 0.5-500 mlU/ml (0.25-250 IU/ml fo r  1 in 
500 d ilu ted  samples). The hCG results were expressed as IU/ml 
( f i r s t  IRP 75/537) and converted to m ultip les of the median of the 
appropriate gestation. Median values fo r  each gestation fo r  the 
controls were calculated by l in e a r  in te rp o la tion . Two q u a lity  
control samples, with values of 29 and 81 IU/ml were assayed twice 
in each batch. For the retrospective manual assays the inter-assay  
CV was 8.3% and the intra-assay CV 2.6% at 29 IU/ml and 6.2% and 
2.6% at 81 IU/ml. The routine semi-automated assay ty p ic a l ly  has 
an inter-assay CV of 7.5% and an intra-assay CV of 3% between 5 
and 100 IU/ml.
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4 .1 .4  PREGNANCY SPECIFIC (3-1 GLYCOPROTEIN
SPi is a glycoprotein with a molecular weight of 90,000. I t  is  
synthesised by the syncytiotrophoblast of the placenta (Horne et  
a h ,  1976). C ircu la ting  levels of SPi r ise  s tead ily  during 
gestation and reach a plateau near term (Bohn, 1980). The maternal 
levels of SPi are higher in molar terms than any other placental 
product (Chard and Grudzinskas, 1980). Levels of SPi found in the 
maternal c ircu la t io n  greatly  exceed those found in the fe ta l  
c ircu la tion  (Gordon and Chard, 1979).
4 .1 .4 .1  PREGNANCY SPECIFIC 0-1 GLYCOPROTEIN ASSAY
SPi concentration was measured by 'Rocket* immunoelectrophoresis 
(Teisner et  ah  1978), using commercially ava ilab le  0-1 
glycoprotein anti serum (Dakopatts) and, as a standard, lyophilised  
0-1 glycoprotein (Behring). Agarose gels were prepared on 8cm x 
8cm glass plates using 10 ml of 1% w/v Agarose 15 (BDH) in 
Barbitone buffer ( 3mmol/l d iethyl b a rb itu r ic  acid (BDH), 17 
mmol/1 sodium barbitone (BDH) and 1.7mmol/l calcium lac ta te  (BDH), 
pH 8 .6 ) .  The central s t r ip  of agarose (2cm wide) was cut out and 
replaced with 2.5 ml buffered agarose containing anti-SPi 
anti serum at an antibody d i lu t io n  of 1:62.5. A l in e  of wells was 
cut in the agarose below the antibody s t r ip .  Abnormal cases and 
th e ir  matched controls were selected b lind . A lyophilised 0-1 
glycoprotein preparation (Behring), reconstituted to a 
concentration of 48.4 mg/L, was used as a standard. 2 pi of sample 
or standard was added to each w e ll .  Samples and standards were
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assayed in quadruplicate, using pairs of wells on two separate 
plates. The plates were placed in an electrophoresis tank prepared 
with Barbitone electrophoresis buffer (7 .5  mmol/1 diethyl  
barb itu r ic  acid (BDH), 42.5 mmol/1 sodium barbitone (BDH) and 1.2 
mmol/1 calcium lac ta te  (BDH), pH 8 .6 )  and electrophoresed at 
constant voltage (90 vo lts ,  6-10 mAmps) at 4°C overnight. SPi 
migrates from the cathode to the anode. The plates were rinsed 
with d is t i l le d  water, dried using f i l t e r  paper overlays in a warm 
a i r  stream and stained with Coomassie b r i l l i a n t  Blue (2 g/1
Coomassie B r i l l i a n t  Blue (BDH) in 45% v/v  methanol (BDH), 10% v/v  
g lac ia l acetic acid) and dried again. Peak heights were measured 
in m illim etres and the concentration of SPi calculated from the 
height of the standard peak by proportion.
4 .1 .4 .2  SPi ASSAY PARAMETERS
A q u a lity  control sample, prepared from pooled maternal serum at
16-21 weeks, and with value of 23.0 mg/1, was run on each p la te .  
The inter-assay CV was 15.3% and the intra-assay CV 8.8%. SPi 
results were expressed as mg/L and converted to m ultip les of the 
median for the appropriate gestation. Median control values were 
calculated fo r  each gestation by weighted l in e a r  regression.
4 .1 .5  UNCONJUGATED ESTRIOL
UE3 is a steroid  hormone which is v i r tu a l ly  undetectable in 
non-pregnant women. I t  is produced p r in c ip a lly  from placental
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conversion of fe ta l  16a-hydroxy-dehydroepiandrosterone sulphate 
(16a-DHEAS) (D iczfa lusy, 1974). 16a-DHEAS is produced in the fe ta l  
l iv e r  from dehydroepiandrosterone sulphate (DHEAS). DHEAS is  
synthesised in the fe ta l  adrenal cortex from cholesterol (Buster, 
1984). Approximately 90% of UE3 produced in the fetoplacental unit  
is derived from fe ta l  DHEAS and only 10% from maternal DHEAS 
( S i i t e r i  and MacDonald, 1963). In the maternal c irc u la t io n  5-10% 
of e s t r io l  is present in the unconjugated form and the rest as 
conjugates o f sulphate and glucuronide, the most abundant form 
being e s tr io l-3 -s u lp h a te ,  -16-glucuronide (Lev itz  et  a l . , 1975).
Concentrations of c irc u la t in g  unconjugated e s tr io l  are 4-8 times 
higher in the fetus than in the maternal c irc u la t io n  (Pasqualini 
and K in d ,  1985).
4 .1 .5 .1  UNCONJUGATED ESTRIOL ASSAY
UE3 was measured using a commercially ava ilab le  radioimmunoassay 
(Amersham AMERLEX-M, IM4, 2nd t r im e s te r ) .  This assay k i t  is  
optimised fo r  use at the concentration levels  of UE3 p reva iling  in 
the second tr im ester ,  with a range of 1-50 nmol/1, and replaces 
the Amersham IM2 assay designed fo r  use at the higher th ird  
tr im ester concentrations. Unlike the previous th ird  tr im ester UE3 
assay the optimised 2nd tr im ester assay requires no modification  
to  increase i ts  s e n s it iv i ty  and has a zero standard which is  
charcoal stripped human serum and should contain no UE3. The 
anti-UE3 antibody is bound to magnetic polymer p a r t ic le s  and 
separation of the antibody bound f ra c tio n  is by magnetic 
separation.
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For economy of sample volume the assay method was modified to  use 
ha lf  the stated volume of reagents, standards and samples. This 
change in protocol did not a l t e r  the s e n s it iv i ty  of the assay from 
0.2 nmol/1. The intra-assay CVs also remained s im ila r ,  with CVs 
fo r  four samples with values of 1.9, 4 .0 ,  8.2 and 30.8 nmol/1 of
7.6%, 6.0%, 7.2% and 6.2% in 10 duplicates in a f u l l  volume assay, 
and 7.5%, 6.2%, 4.8% and 7.3% in a h a lf  volume assay. Abnormal
cases and th e i r  matched controls were randomised and assayed in 
the same batch. 40 pi of sample or standard were pipetted into  
tubes. A ll standards and samples were assayed in duplicate . 40 pi 
of 125I  labelled e s t r io l  solution and 400 pi of AMERLEX-M e s tr io l  
antibody suspension (containing anti-UE3 bound to magnetic 
p a rt ic le s )  were added to each tube and incubated at 37°C in a 
water bath fo r  1 hour. The racks of tubes were then attached to  
the magnetic separator at room temperature and the magnetic 
p art ic les  allowed to sediment fo r  15 minutes. The supernatant was 
discarded by inversion of the tubes. The bound f ra c tio n  was 
counted using a Packard Cobra 5010 gamma counter. Data reduction 
was performed by the gamma counter on-board microcomputer, using 
spline curve f i t t i n g  on a lo g /l in e a r  scale (RIA-Smart).
4 .1 .5 .2  UE3 ASSAY PARAMETERS
The UE3 results  were expressed as nmol/1 and converted to  
multiples of the median fo r  the appropriate gestation. Median 
values for each gestation fo r  the controls were calculated by
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l inear  in te rpo la tion . Four q u a lity  control samples, with values of 
1.9, 3 .9 , 8 .0 , 27.6 nmol/1 were assayed twice in each batch. The
inter-assay CVs were 6.8%, 5.6%, 5.6% and 7.2% respective ly  and
the intra-assay CVs, 5.8%, 4.9%, 3.5% and 5.4% respective ly .
4 .1 .6  FREE 0 SUBUNIT OF hCG
In the second tr im ester of pregnancy, maternal serum levels  of 
unbound 0 subunit hCG are around 0.5% of the levels  of the in tac t  
(a + B) molecule (Osturk et  a h ,  1988). The use of monoclonal 
antibodies has led to the a b i l i t y  to  construct assays of greater  
s p e c if ic ity .  Knowledge of the stereo structure of the hCG molecule 
and advances in ra is ing ep itope-spec if ic  assays have resulted in
the production of antibodies capable of recognising free  a
subunit, free  0 subunit, C-terminal region and in ta c t  hCG (Norman 
et  a h ,  1990). Assays fo r  Fr0-hCG recognise an epitope on the 0 
subunit which is on the binding s i te  o f the a and 0 subunits and 
which is therefore not exposed in the in ta c t  molecule (Macri et  
a h ,  1990, Macri et  a h ,  1993).
4 .1 .6 .1  FREE 0 SUBUNIT OF hCG ASSAY
The free 0-subunit of hCG (FrB-hCG) was measured using a
commercially ava ilab le  immunoradiometric assay (Bioclone Free 0 
hCG k i t )  which measures predominantly free  0 hCG but has a small 
amount of c ro s s -re a c tiv ity  with in tac t hCG (up to 0.4%). The free  
0 subunit to in ta c t  molecule ra t io  in the maternal c ircu la t io n  in
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the second tr im ester of pregnancy is around 1:200. The assay 
u t i l i z e s  two monoclonal antibodies, one labelled with 125I  and the 
other bound to magnetised polystyrene p a r t ic le s ,  d irected against 
d i f fe re n t  free  3 subunit epitopes.
For economy of sample the assay method was modified to use h a lf  
the volume of samples, standards and reagents. This did not appear 
to change the performance of the assay. The s e n s it iv i ty  remained 
unchanged at 0.3 IU /1 . Two samples, run in f iv e  d i f fe re n t  assays, 
had inter-assay CVs of 14.3% fo r  the f u l l  volume assay and 13.8% 
fo r  the h a lf  volume assay at 6.4 IU/1 and 7.3% fo r  the f u l l  volume 
assay and 6.9% fo r  the h a lf  volume assay at 88 IU /1 . Abnormal
cases and th e i r  matched controls were randomised and assayed in 
the same batch. 40 pi of sample or standard were pipetted into  
tubes. A ll  standards and samples were assayed in duplicate. 200 pi 
of the solution containing 125I  a n t i - f r e e  0 hCG ( in  BSA PBS buffer  
with 0.1% w/v sodium azide) and 200 pi of the suspension of  
a n t i - f re e  0 hCG bound to magnetic p a rt ic les  ( in  BSA PBS buffer  
with 0.1% w/v sodium azide) were added to  each tube. The tubes 
were vortexed gently then incubated at 37°C in a water bath fo r  1 
hour. The racks of tubes were then placed in magnetic separators 
and the p a rt ic les  allowed to sediment fo r  15 minutes. The
supernatant was decanted by inversion of the rack. A f in a l  wash
step reduces non-specific binding. 200pl of wash buffer (BSA PBS 
buffer with 0.1% w/v sodium azide) was added to each tube and a l l  
tubes thoroughly mixed by vortexing. The magnetic sedimentation 
and decanting of the supernatant steps were repeated. The bound 
frac tion  was counted using a Packard Cobra 5010 gamma counter. The
average CPM for each pa ir  of duplicates was determined. The
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standard curve was plotted on log-log graph paper and the results  
fo r  the samples read from the graph.
4 .1 .6 .2  FREE 0 SUBUNIT ASSAY PARAMETERS
The assay has a range of 0.5-500 IU /1 . The hCG results  were 
expressed as IU/1 (IRP 75/551) and converted to m ultip les of the 
median of the appropriate gestation. Median values fo r  each 
gestation fo r  the controls were calculated by linear  
in te rpo la tion . Two q u a lity  control samples, with values of 3.9  
IU/1 and 20.5 IU/1 were assayed twice in each batch. The 
inter-assay CV was 22.8% and the intra-assay CV was 16.7% at 3.9  
IU/1 and 7.0% and 4.1% at 20.5 IU /1 .
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4.2 STATISTICAL METHODS
4.2 .1  MEDIAN AND CENTILES
The median is defined as the middle value of the var iab le , when 
the data are arranged in order of increasing magnitude. I t  can be 
calculated from a frequency d is tr ib u t io n ,  where the values have 
been divided into classes of even width, using the formula below 
and is the ( ( n + l ) / 2 ) t h  value.
Median = (P -  f )  x (X -  x)
(F -  f )
Where X = upper boundary o f median class 
x = lower boundary of median class 
F = upper frequency of median class  
f  = lower frequency of median class  
P = median frequency i . e .  (n + 1 ) /2  
Medians can also be generated from a frequency d is tr ib u t io n  
derived using a s ta t is t ic a l  ca lcu lation  programme in a
microcomputer. SPSS/PC+ was used fo r  many o f the calcu lations.
S im ila r ly ,  p a r t ic u la r  cen ti les  can be derived from a set of data. 
The pth c e n ti le  is the value of the variab le  such tha t  p percent 
of the measurements are less than tha t value and (100 -  p) are 
greater. Centiles were calculated e ith e r  by using the same method 
as fo r the median, working out the pth c e n ti le  as the (n -p )/100 th  
value, or using the SPSS/PS+ s ta t is t ic a l  package.
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4 .2 .1 .1  MEDIANS BY WEIGHTED LOG-LINEAR REGRESSION
This is  a method of smoothing the median values obtained from the 
raw data, where less than an optimum number o f values are 
availab le  fo r  each gestational week, and where the medians 
obtained d ire c t ly  from the raw data are e r r a t ic .
Medians were f i r s t  calculated fo r  each week of gestation from the 
raw data and then lo g - l in e a r  regression analysis, weighted 
according to the number of data points at each gestational age,
was carried out to obtain the equation of the regression l in e .
Smoothed medians were then calculated from the equation and used
to work out m ultip les of the median. The ca lcu la tion  was as
follows:
Regressed median = 10<MG + B>
M = slope = N/D 
B = intercept = Y -  MG
N = IW(G -  G)( logY -  Y)
D = IW(G -  G)2
Y = K logY  . W)
IW
G = KG . W)
IW
where G = gestation (weeks)
Y = raw median
logY = logio(raw median)
W = number of samples at week of gestation.
Substituting the required median into the derived formula fo r  the
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regressed median gives the value of the regressed median.
4 .2 .2  GAUSSIAN DISTRIBUTIONS
A Gaussian or normal d is tr ib u t io n  is a symmetrical bell-shaped  
curve with the formula:
2
- i  (x -x)/SD  
y = 1 . e L
SD Vr(2n)
where x = mean
SD = standard deviation  
The curve is symmetrical about the mean.
4 .2 .3  MEAN AND STANDARD DEVIATION
The mean (x) is  a measure of central tendency, th a t  is ,  a measure 
of the central point of the d is tr ib u t io n  of data. I t  was 
calculated by:
n
I  X 
X = n = 1
n
where n = number of measurements
The standard deviation (SD) is  a measure of the v a r ia b i l i t y  or 
dispersion of the data. I t  was calculated by:
I  (X -  X)2
SD = HiJ_________
n-1
-85 -
The standard deviation represents the horizontal distance on 
e ith e r  side of the mean which reaches out to the points of 
in f le c t io n  i . e .  the points on the Gaussian curve where the slope 
changes from getting steeper to getting f l a t t e r .  Means and 
standard deviations were calculated using a pocket ca lcu la tor with  
s ta t is t ic a l  functions or using the SPSS/PC+ s t a t is t ic a l  package in 
a microcomputer.
4 .2 .3 .1  ESTIMATION OF THE MEAN AND STANDARD DEVIATION FROM A 
FREQUENCY DISTRIBUTION
Means and standard deviations were also estimated from a frequency 
d is tr ib u tio n  as described by Cuckle et  a h  (1987). For a Gaussian 
d is tr ib u tio n  the median was taken as an estimate of the mean and 
the standard deviation estimated from the d ifference between the 
90th and 10th c en ti le s ,  divided by 2.56. For a log Gaussian 
d is tr ib u tio n  logio(Median) was taken as an estimate of the mean 
and the d ifference between logio(90th c e n t i le )  and logio(10th  
c e n t i le ) ,  divided by 2.56, taken as an estimate o f the standard 
deviation. This method avoids undue influence of outly ing values
when re la t iv e ly  small numbers of values are being used.
\
4 .2 .4  PROBABILITY PLOTS
Before using many s ta t is t ic a l  tests  and also when using data fo r  
deriving risks (see Section 4 .2 .8 )  i t  is  important to  know whether 
data can reasonably be regarded as sampled from an underlying
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Gaussian d is tr ib u t io n  or can be transformed i . e .  by taking logio, 
to f i t  a Gaussian d is tr ib u t io n .  One way of proving th is
graphically is by a p ro b a b il ity  p lo t.
For a given set of data, a l l  values were ranked in ascending 
order. Each value was assigned i ts  c e n t i le  value and from these, 
using the known area under a Gaussian d is tr ib u t io n  (ava ilab le  in 
s ta t is t ic a l  tab les ) the standard deviation of each value derived. 
A graph was p lotted  with the standard deviations on a l in e a r  scale 
on the x-axis  and the values on e ith e r  a l in e a r  scale ( fo r  a 
Gaussian d is tr ib u t io n )  or a logio scale ( fo r  a log Gaussian
d is tr ib u t io n )  on the y -ax is . A continuous l in e  of the appropriate  
Gaussian or log Gaussian d is tr ib u t io n  derived from the mean and
standard deviation of the data was also p lotted and the graph
inspected fo r  deviation from the expected d is tr ib u t io n .
4 .2 .5  STUDENT’ S t-TEST
This is used to compare two d i f fe re n t  groups, each with known mean 
and standard dev iation , to te s t  whether they should be regarded as 
(a) samples from two d i f fe re n t  underlying populations, or (b) 
samples from one underlying population, the d ifference between 
means having arisen by chance. The t - t e s t  should only be used on 
data shown to  be normally d is tr ib u ted .
The s t a t is t ic  t  can be calculated by varying formulae, depending 
on whether the data are paired or unpaired and whether the two 
samples have the same or d i f fe r in g  standard deviations. The
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formula below, which is fo r  unpaired variables and two samples 
with d i f fe r in g  standard deviations was used.
| X1 -  X2 |
t  = _______________________________________________________________
V (( (m  x SDi) + (n2 x SD2 ) ) / ( m  + n2 -  2 ) )  x VXl/m  + 1/n2)
Degrees of freedom = m + n2 -  2
The null hypothesis fo r  the t - t e s t  is th a t  there is  no d ifference  
in the underlying populations from which the two samples were 
drawn, and tha t the differences in mean are due to chance. 
S ta t is t ic a l  tab les, at the appropriate degrees o f freedom, were 
consulted fo r  the calculated t  values and the p ro b a b il ity  value 
associated with the found value of t  derived. I f  the p robab il ity  
(p) is <0.05 or <0.01 the d ifference between the two means is said 
to be s ig n if ic a n t  and the null hypothesis rejected.
4 .2 .6  KOLMOGOROV-SMIRNOV TEST
The Kolmogorov-Smirnov (K-S) te s t  is used to te s t  the deviations  
of observed frequency d is tr ibu tio ns  from expected ones. The K-S 
s t a t is t i c ,  D, is defined as the absolute value of the largest  
d ifference between two cumulative frequency d is tr ib u t io n s , one 
expected and the other observed. Each value in the d is tr ib u t io n  
being tested is converted to a standard dev iation . From these, 
using s ta t is t ic a l  tab les, the cumulative area under the curve to  
each value is  derived. These are compared with the predicted  
cumulative frequency d is tr ib u t io n  and the d ifference between these 
at each individual value calculated. The value of D is the largest
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absolute d ifference found. The found value of D can be looked up 
in s ta t is t ic a l  tables at the appropriate sample s ize and the 
probab il ity  (p) derived. The null hypothesis is  tha t  there is no 
difference between the expected and observed d is tr ib u t io n s . I f  the 
probab ility  (p) is less than 0.05 or 0.01 the d ifference between 
the observed and expected d is tr ib u tio n s  is said to  be s ig n if ic a n t  
and the null hypothesis rejected. The SPSS/PC+ s t a t is t ic a l  package 
was used for the m ajority of the calculations o f the K-S s t a t is t ic  
(D) and the associated p ro b ab il ity .
4 .2 .7  CORRELATION
For two sets of normally d is tr ibu ted  data the product-moment 
correlation co e ff ic ie n t  ( r )  can be calculated to give a measure of 
the level of association between the variab les. For two variab les,  
x and y, the formula fo r  r is
K x  -  x ) (y  -y )  
r= _ _
K x  -  x)2 . I ( y  -  y)2)
The corre lation  c o e ff ic ie n t  , r ,  has values from 0 to ±1. A 
positive value of r s ig n if ie s  positive  corre la t ion  and a negative 
value negative corre la t ion . Values of r close to 0 indicate  
v i r tu a l ly  no association between variables and the closer the 
value of r gets to 1 the greater the level of association.
To determine s ta t is t ic a l  s ign ificance, the calculated value of r 
was looked up in s ta t is t ic a l  tables at the appropriate degrees of 
freedom (n -  2) and the p ro b ab il ity  (p) derived from the tab le .
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The null hypothesis is that there is no association between the 
variables.
Values of r and the appropriate s ignificance were mainly 
calculated using the SPSS/PC+ s ta t is t ic a l  package.
4 . 2 . 8  DERIVING RISKS (LIKELIHOOD RATIOS) FROM GAUSSIAN 
DISTRIBUTIONS
The risk ( l ike l ih o o d  ra t io )  tha t a spec if ic  resu lt  of a p a r t ic u la r  
analyte is associated with an abnormality, such as Down’ s 
syndrome, is the proportion of affected pregnancies with the given 
analyte le v e l,  divided by the proportion of unaffected pregnancies 
with the same leve l.  I t  is  estimated as the height to the Gaussian 
or log Gaussian d is tr ib u t io n  of affected pregnancies divided by 
the height to  the d is tr ib u t io n  of unaffected pregnancies and can 
be calculated by the formula
LR = (SDc/SDd ) e *
r 2 r
l o q io ( x )  -  Md - lOQio(x) -  Me
SDd SDc
where Md and SDd are the mean and standard deviation of the 
affected d is tr ib u t io n  and Me and SDc the mean and standard 
deviation of the control d is tr ib u t io n  (Palomaki and Haddow, 1987, 
Cuckle et  a h ,  1987). Likelihood ra t io s ,  and hence the r isk  of an 
affected pregnancy, increase moving towards the affected curve and 
decrease moving towards the unaffected curve. At the point of
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intersection of the two curves the l ike lihood ra t io  is  equal to
one.
Likelihood ra tios  can also be calculated for two variables by a 
combined formula which allows fo r  corre la t ion  between the two 
(Wald et a h ,  1988a). In th is  case the formula fo r  ca lcu la ting  the 
combined like lihood ra t io  at a given level (x) fo r  analyte (1) and 
(y) fo r analyte (2) is
Vc -  Vd
LR = 1 SDc 2 SDc . ( E M  •
V ( 1  -1 SDd 2 SDd ( R d ) 2 )
Vc = ( P Z c ) 2 ~ 2 R c 1 Z c 2 Zc +  ( 2 Zc  ) 2 ) 
(1  -  ( R c ) 2 )
Vd = ( P Z d ) 2 -  2R d 1 Z d 2 Z d +  ( 2 Z d ) 2 ) 
(1  -  ( R d ) 2 )
1Zc = log io (x ) -  1 Me 
1 SDc
1 Zd = log io (x) -  1Md 
1 SDd
2Zc = log io (y) -  2Me 
2 SDc
2 Zd = log io (y ) -  2 Md 
2 SDd
where, fo r  analyte (1 ) ,  1Mc and 1SDc are the mean and standard 
deviation of the control d is tr ib u t io n  and 1Md and 1 SDd those of 
the affected d is tr ib u t io n ,  and, for analyte (2 ) ,  2Mc and 2SDc are 
the mean and standard deviation of the control d is tr ib u t io n  and 
2 Md and 2 SDd those of the affected d is tr ib u t io n .  Rc is the
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corre la tion  co e ff ic ien t  between analyte (1 ) and analyte (2) fo r  
the controls and Rd tha t  fo r  the affected samples.
4 .2 .9  CALCULATION OF DETECTION AND FALSE POSITIVE RATES
The proportion of women at each individual maternal age in the 
west of Scotland screened population was derived from the ages of 
women having an AFP screening te s t  during 1986 and 1987, adjusted 
fo r  the number of women aged 35 years and over proceeding d ire c t ly  
to amniocentesis without having a screening te s t .
The proportion of Down’ s syndrome or autosomal trisomy pregnancies 
at each individual maternal age was derived by ca lcu la t in g , from 
the number of women and the maternal age r is k ,  the number of 
affected pregnancies per year at each maternal age 1n the west of 
Scotland population. These were then converted to  percentages.
Likelihood ratios fo r  each analyte or combination of analytes were 
calculated fo r a l l  of the affected and control samples. The 
d is tr ibu tio ns  of these like lihood ra tios  were then used to  
estimate detection and fa ls e  positive rates. The detection rate at  
a specific  r isk  threshold fo r  a p a r t ic u la r  combination of analytes  
was calculated at each individual maternal age from the proportion  
of the d is tr ib u tio n  o f the like lihood ra tios  fo r  the affected  
samples which would give a r isk  equal to or greater than the 
specified r isk . This was then m ultip lied  by the predicted  
percentage of affected pregnancies at each maternal age and an 
overall detection rate obtained by summation. S im ila r ly ,  the
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corresponding fa lse  positive rate was obtained using the
d is tr ib u t io n  of like lihood ra tios  fo r the control samples and the
percentage of pregnancies at individual maternal ages in the west 
of Scotland pregnant population.
4 .2 .10 CONFIDENCE LIMITS
4.2.10.1 95% CONFIDENCE LIMITS OF THE MEAN
The mean obtained from a series of measurements is a point 
estimate of the mean of the underlying population. To obtain an 
in te rva l estimate of the underlying mean lower and upper boundary 
values can be calculated w ithin which the population mean has a 
95% probab il ity  of f a l l in g .  These are 95% confidence l im its  (CL).
The formula fo r  ca lcu la ting  these is
95% CL = x ± t(SEM)
where t  = Students t  s t a t is t ic  at the appropriate degrees of
freedom ( n—1)
SEM = standard e rro r  of the mean
SEM = SD 
Vn
Where medians were used as estimates of the mean, a 95% confidence 
in terva l was calculated fo r  the mean and used as a confidence
in terva l fo r  the median, taking 10x i f  from a log Gaussiasn
d is tr ib u t io n .
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4 .2 .1 0 .2  95% CONFIDENCE INTERVALS FOR SINGLE OBSERVED VALUES
The Poisson d is tr ib u t io n  is a discrete frequency d is tr ib u t io n  of 
the number of times a rare event occurs. The events must be random 
and occur independently of each other. For observed values which 
f u l f i l  these c r i t e r i a ,  the range which represents 95% confidence 
l im its  was obtained from the appropriate s t a t is t ic a l  tab les.
4 .2 .1 0 .3  95% CONFIDENCE INTERVALS FOR PROPORTIONS AND PERCENTAGES
Confidence in te rva ls  fo r  proportions or percentages were derived 
from s ta t is t ic a l  tables based on the binomial d is tr ib u t io n ,  which 
is the p robab il ity  d is tr ib u t io n  of random d iscrete  variables with  
two possible outcomes. For sample numbers greater than 100, the 
binomial d is tr ib u t io n  approaches the normal d is tr ib u t io n  and the 
95% confidence in te rva l was calculated from the formula: 
p ± V(p(p -  1) /n )  
where p is the proportion.
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SECTION 5
RESULTS
PHASE 1
5.1 MATERNAL SERUM ALPHAFETOPROTEIN AND CHROMOSOME ABNORMALITIES
5.1 .1  RETROSPECTIVE ANALYSIS OF AFP LEVELS
5 .1 .1 .1  AFP LEVELS IN UNAFFECTED PREGNANCIES
Maternal serum AFP resu lts , stored on a database between April  
1982 and May 1987, from 113,045 singleton pregnancies unaffected  
by neural tube defect or chromosome abnormality were analysed to  
provide normal population parameters. Median AFP values increase 
with advancing gestation between 16 and 20 weeks. For the RIA 
assay (p r io r  to  July 1985, 69,000 samples) median values were 27
KU/1 at 16 weeks, 31 KU/1 at 17 weeks, 36 KU/1 at 18 weeks, 42 
KU/1 at 19 weeks and 49 KU/1 at 20 weeks. For the IRMA assay (July  
1985 onwards, 44,000 pregnancies) median values were 34 KU/1 at 16 
weeks, 37 KU/1 at 17 weeks, 43 KU/1 a t 18 weeks, 50 KU/1 at 19 
weeks and 58 KU/1 at 20 weeks. The appropriate method-related 
gestational median was used to convert AFP levels  in individual 
autosomal trisomy pregnancies to MOM.
5 .1 .1 .2  AFP LEVELS IN AUTOSOMAL TRISOMIES
Over the same screening period 142 autosomal trisomy pregnancies 
were also id e n t i f ie d  fo r  which maternal serum AFP results  were 
ava ilab le . Indiv idual maternal serum AFP levels ( in  MOM) fo r  each 
pregnancy with an autosomal trisomy p lotted  at the appropriate  
completed week of gestation are shown in Figure 5-1. The median 
AFP value fo r  the autosomal trisomy pregnancies was s ig n if ic a n t ly
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Figure 5 - 1
Maternal serum alphafetoprotein  (AFP) leve ls , in m ultip les  of the 
median (MOM), in 142 autosomal trisomy pregnancies (114 Down’ s, 19 
Trisomy 18, 9 Trisomy 13) compared with the leve ls  in 113,045
unaffected singleton pregnancies.
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lowered at 0.72 MOM (95% CL 0.67 -  0.77 MOM) of the unaffected  
pregnancies (p<0.001 by t - t e s t  on unpaired v a r iab les ) .  The 
proportions of control, Down’ s syndrome, trisomy 18 and 13 and a l l  
autosomal trisomy pregnancies with values less than or equal to  
selected c u t -o f f  levels  are shown in Table 5-1 w ith , fo r  example, 
117 out of 142 autosomal trisomy values (82%) equal to or below 
the median. Also 12% of pregnancies with Down’ s syndrome, 25% of 
trisomies 18 and 13 and 15% of a l l  autosomal trisomies had AFP 
levels less than 0.5 MOM compared with 4.2% of unaffected  
pregnancies. P rob ab ility  plots (Figure 5-2) show that the AFP 
levels in the unaffected pregnancies Figure 5 -2a ) ,  the Down’ s 
syndrome pregnancies ( f ig u re  5-2b), the trisomies 18 and 13 
combined (Figure 5-2c) and the e n t ire  group of autosomal trisomies  
(Figure 5-2d) f i t  log Gaussian d is tr ib u tio n s  between 0.35 and 2.0  
MOM (Figure 5 -2 ) .  The log Gaussian d is tr ib u tio n s  of the unaffected  
and autosomal trisomy d is tr ib u tio n s  are shown in Figure 5-3. The 
in tersection point o f the two curves is 0.85 MOM There was no 
s t a t is t i c a l ly  s ig n if ic a n t  d ifference between the means fo r  the 
trisomy 18 group (0 .68 MOM) and the trisomy 13 group (0 .74 MOM, 
t - t e s t ,  p>0.5) nor between the trisomies 18 and 13 combined (0.72  
MOM) and the Down’ s syndrome cases (0.72 MOM, t - t e s t ,  p>0.5). The 
means and standard deviations of the controls, Down’ s and 
autosomal trisomy d is tr ib u tio n s  were estimated as described in 
Section 4 .2 .3 .1  and are shown in Table 5-2. There was no evidence 
of corre la t ion  between AFP and age (r=0.0098, p>0.05) 1n the
Down’ s syndrome pregnancies.
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Table 5-1
Proportions of unaffected singleton pregnancies, Down’ s syndrome 
pregnancies and autosomal trisomy pregnancies with 
alphafetoprotein (AFP) levels , in m ultip les of the median (MOM) 
equal to or less than selected c u t -o ff  levels .
AFP Unaffected Down’ s T risomy T risomy
(MOM) 18+13 21+18+13
(n= 113,045) (n= 114) (n=28) (n=142)
% (n) % (n) % (n) % (n)
<1.6 89 (100,972) 96 (109) 96 (27) 96 (136)
<1.4 82 (92,622) 94 (107) 93 (26) 94 (133)
<1.2 70 (78,665) 90 (103) 89 (25) 90 (128)
<1.0 52 (58,119) 84 (96) 75 (21) 82 (117)
<0.9 39 (44.576) 74 (84) 64 (18) 72 (102)
<0.8 28 (31,276) 64 (73) 53 (15) 62 (88)
<0.7 18 (20,059) 46 (53) 50 (14) 47 (67)
<0.6 9 (10,597) 28 (32) 32 (9) 29 (41)
<0.5 4 (4,752) 12 (14) 25 (7) 15 (21)
<0.4 2 (1 ,890) 6 (7) 18 (5) 8 (12)
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(b) Down’s syndrome
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(c) trisomy 18 arid trisomy 13 
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(d) autosomal trisomy
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Figure 5 - 2
Prob ab ility  p lo t of maternal serum alphafetoprotein  (AFP) leve ls ,  
in m ultip les of the median (MOM), on a log scale, in (a ) a 
sub-group of 113,000 unaffected pregnancies, (b) 114 Down’ s
syndrome pregnancies, (c) 28 trisomy 18 and 13 pregnancies, (d) 
a l l  142 autosomal trisomies combined. The continuous lines are 
those defined by log Gaussian d is tr ib u t io n s  with means and 
standard deviations as given in Table 5-2.
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Trisomy
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AFP (MOM)
Figure 5 - 3
Log Gaussian d is tr ib u tio n s  of maternal serum alphafetoprotein  
(AFP) leve ls , in m ultip les of the median (MOM), p lotted  from the 
means and standard deviation of 113,000 unaffected and 142 
autosomal trisomy pregnancies as given in Table 5-2.
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Table 5-2
Medians, means and standard deviations of the maternal serum 
alphafetoprotein (AFP) d is tr ib u tio n s  in Down’ s syndrome, autosomal 
trisomy and unaffected pregnancies.
(n) Median
(MOM)
Mean
logio
SD
logio
Down’ s syndrome 114 0.72 -0.1427 0.1626
Trisomy 18 19 0.68 -0.1673 0.2201
Trisomy 13 9 0.74 -0.1304 0.2159
Trisomy 18+13 28 0.70 -0.1549 0.2190
Trisomy 21+18+13 142 0.72 -0.1427 0.1780
Unaffected 113,045 0.99 -0.0044 0.1668
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5.1 .2  USE OF AFP IN SCREENING FOR AUTOSOMAL TRISOMIES
Independent estimates of the r isk  of Down’ s syndrome or an 
autosomal trisomy pregnancy can be obtained from (a) the maternal 
serum AFP resu lt and (b) the a p r i o r i  maternal age r is k .  Maternal 
serum AFP screening programmes can therefore be adapted to provide 
a combined r isk  of e i th e r  Down’ s syndrome or of an autosomal 
trisomy.
5 .1 .2 .1  RISK ESTIMATIONS FROM AFP LEVELS
I t  has been shown 1n Section 5 .1 .1 .2  tha t the d is tr ib u tio n s  of  
maternal serum AFP in the control samples, the Down’ s syndrome 
samples and the e n t ire  group of autosomal trisomy pregnancies 
conform to  log Gaussian D is tr ibu tions. The r isk  ( l ike l ih o o d  ra t io )  
that a p a r t ic u la r  AFP resu lt is associated with a pregnancy with 
Down’ s syndrome or an autosomal trisomy can be estimated from the 
ra t io  of the heights of the d is tr ib u tio n s  at tha t AFP le v e l ,  as 
described in Section 4 .2 .8 . ,  using the means and standard 
deviations as given in Table 5-2.
5 .1 .2 .2  MATERNAL AGE RISKS
The maternal age-specific  risks used in th is  study (Table 5-3) are 
derived from those presented by Cuckle et  a l  (1987), who combined 
the results of eight large published surveys of Down’ s syndrome in 
l iv e  b irths which specify the r isk  fo r  single years of age. The
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Table 5 - 3
Estimated maternal age-specific  r isk estimates of a Down’ s 
syndrome pregnancy or autosomal trisomy at b ir th  and at 
mid-trimester.
Maternal
age
(years)
Risk of a Risk of an 
Down’ s autosomal 
syndrome trisomy 
b ir th  b ir th  
(Cuckle et  
a/,1987)
Risk of a 
Down’ s 
syndrome 
pregnancy 
at mid­
tr im ester
Risk of an 
autosomal 
trisomy 
pregnancy 
at mid­
tr im ester
16 1:1572 1 1388 1:1257 1 1055
17 1:1565 1 1382 1:1252 1 1050
18 1:1556 1 1374 1:1245 1 1044
19 1:1544 1 1364 1:1235 1 1036
20 1:1528 1 1349 1:1222 1 1025
21 1:1507 1 1330 1:1206 1 1011
22 1:1481 1 1307 1:1185 1 993
23 1:1447 1 1277 1:1158 1 971
24 1:1404 1 1240 1:1123 1 942
25 1:1351 1 1193 1:1081 1 907
26 1:1286 1 1135 1:1029 1 863
27 1:1208 1 1066 1: 996 1 810
28 1:1119 1 988 1: 895 1 751
29 1:1018 1 899 1: 814 1 683
30 1: 909 1 803 1: 727 1 610
31 1: 796 1 703 1: 637 1 534
32 1: 683 1 603 1: 546 1 458
33 1: 574 1 507 1: 459 1 385
34 1: 474 1 418 1: 379 1 318
35 1: 384 1 339 1: 307 1 258
36 1: 307 1 271 1: 246 1 206
37 1: 242 1 214 1: 194 1 163
38 1: 189 1 167 1: 151 1 127
39 1: 146 1 129 1: 117 1 98
40 1: 112 1 99 1: 90 1 75
41 1: 85 1 75 1: 68 1 57
42 1: 65 1 57 1: 52 1 43
43 1: 49 1 43 1: 39 1 33
44 1: 37 1 33 1: 30 1 25
45 1: 28 1 25 1: 22 1 19
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odds of an individual woman having a Down’ s syndrome fetus  
id e n t if ie d  at the time of screening rather than an affected b ir th  
were calculated by m ultip ly ing the right-hand side of the odds
ra t io  by 0 .8 . This fac to r  was suggested by Cuckle et  a l  (1987) and 
derived by comparing the estimated age-specific  r isk  of Down’ s 
syndrome in the second tr im ester of pregnancy with the 
corresponding age-specific  r isk  of Down’ s syndrome at b ir th .  
Because o f the re la t iv e ly  small number of cases of trisomies 18 
and 13 recorded in the l i t e r a tu r e ,  individual age-specific  risks  
are not ava ilab le  fo r  these chromosomal abnormalities. Therefore, 
in order to obtain spec if ic  age-related risks fo r  an autosomal 
trisomy, Down’ s syndrome risks were m ultip lied  by 1.1327. This
m u lt ip lica t io n  factor was derived from the sum of known incidences 
of Down’ s syndrome per 1,000 b irths  (Hook and Lindsjo, 1978), and 
trisomies 18 and 13 (Hook and Hamerton, 1977) divided by the 
incidence fo r  Down’ s syndrome (1.324 + 0.123 + 0.0527 /  1.324 =
1.1327). The risks b ir th  risks fo r an autosomal trisomy can be
modified to re f le c t  the odds of a fetus at the time of screening
rather than at b ir th  by m ultip ly ing the right-hand side of the 
odds ra t io  by 0.76. This fac to r  was derived by comparing the 
co lle c t iv e  age-specific  r isk  of trisomies 21, 18 and 13 in the
second tr im ester of pregnancy (Ferguson Smith and Yates, 1984) 
with the corresponding age-specific  r isk  of an autosomal trisomy 
at b ir th .  In the estimation of th is  fac to r ,  the age-specific  r isk  
of an autosomal trisomy was corrected to take into account the 
expected proportion (27%) of pregnancies complicated with an ter io r  
abdominal wall defect and/or neural tube defect in the second 
tr im ester of pregnancy (Linenbaum et a 7, 1987)
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5 .1 .2 .3  CALCULATION OF A COMBINED RISK FOR AN INDIVIDUAL PREGNANCY
A combined r isk  fo r  an individual pregnancy can be obtained by 
m ultip ly ing the left-hand side of the maternal age-specific  r isk  
by the like lihood ra t io .  M id-trim ester risks were calculated fo r  
both Down’ s syndrome alone (Table 5-4) and fo r  an autosomal 
trisomy (Table 5 -5 ) ,  using, fo r  Down’ s syndrome, m id-trim ester  
risks of a Down’ s syndrome pregnancy and like lihood ra tios  from 
the Down’ s syndrome log Gaussian d is tr ib u t io n ,  and fo r  autosomal 
trisomies, m id-trim ester risks of an autosomal trisomy pregnancy 
and like lihood ra tios  from the autosomal trisomy d is tr ib u t io n .  For 
example, as shown in Figure 4a, a woman aged 31 years has an a 
p r i o r i  mid tr im ester r isk  of an autosomal trisomy of 1:534. With 
an AFP level of 0.5 MOM the derived l ike lihood ra t io  fo r  an 
autosomal trisomy 1s 3.07, which would modify her age-related r isk  
to 1:170 ( I . e .  3 .07:534). On the other hand, a woman aged 37 years 
with an AFP resu lt  of 1.5 MOM (Figure 4b) has a l ike lihood  ra t io  
of an autosomal trisomy of 0.34 and an a p r i o r i  r isk  of 1:163 from 
her age. This would give a combined mid tr im ester r isk  of an 
autosomal trisomy of 1:480 ( i . e .  0 .34:163).
Figures 5-5 and 5-6 show the change in m id-trim ester risks fo r  
Down’ s syndrome alone and autosomal trisomies at d i f fe re n t  AFP 
levels ( in  MOM) and maternal ages. At any given AFP level the 
risks are lower fo r  Down’ s syndrome alone than fo r  autosomal 
trisomies. For example, an AFP level o f 0.5 MOM generates a 
m id-trimester r isk  of an autosomal trisomy of 1:200 a t maternal 
age 30, but a m id-trim ester Down’ s syndrome r isk  of 1:230. At an 
AFP level of 1.5 MOM the m id-trim ester r isk  of an autosomal
-106-
Table 5 - 4
Risk estimates of find ing  a Down’ s syndrome fetus at
m id-trim ester, based on maternal age and maternal serum 
alphafetoprotein (AFP) at 16-20 weeks gestation (MOM = m ultiples  
of the median).
Nat.
Age
(yrs)
AFP(HQH)
0 .3 5  0 .4 0  0 .4 5  0 .5 0  0 .5 5  0 .6 0  0 .6 5  0 .7 0  0 .7 5  0 .8 0  0 .8 5
25 1 170 1 220 1 280 1 350 1 420 1 510 1 600 1 700 1 820 1 940 1 1100
26 1 160 1 210 1 270 1 330 1 400 1 480 1 570 1 670 1 780 1 890 1 1000
27 1 160 1 210 1 260 1 320 1 390 1 470 1 550 1 650 1 750 1 870 1 990
28 1 140 1 180 1 230 1 290 1 350 1 420 1 500 1 580 1 680 1 780 1 890
29 1 130 1 170 1 210 1 260 1 320 1 380 1 450 1 530 1 620 1 710 1 810
30 1 120 1 150 1 190 1 230 1 290 1 340 1 400 1 470 1 550 1 630 1 720
31 1 100 1 130 1 170 1 210 1 250 1 300 1 350 1 410 1 480 1 550 1 630
32 1 87 1 110 1 140 1 180 1 210 1 260 1 300 1 350 1 410 1 470 1 540
33 1 73 1 95 1 120 1 150 1 180 1 220 1 260 1 300 1 350 1 400 1 450
34 1 61 1 78 1 100 1 120 1 150 1 180 1 210 1 250 1 290 1 330 1 380
35 1 49 1 63 1 80 1 100 1 120 1 140 1 170 1 200 1 230 1 270 1 300
36 1 39 1 51 1 64 1 79 1 100 1 120 1 140 1 160 1 190 1 210 1 240
37 1 31 1 40 1 51 1 63 1 76 1 91 1 110 1 130 1 150 1 170 1 190
38 1 24 1 31 1 39 1 49 1 59 1 71 1 84 1 100 1 110 1 130 1 150
39 1 19 1 24 1 30 1 38 1 46 1 55 1 65 1 76 1 89 1 100 1 120
40 1 14 1 19 1 23 1 29 1 35 1 42 1 50 1 58 1 68 1 78 1 89
41 1 11 1 14 1 18 1 22 1 27 1 32 1 38 1 44 1 52 1 59 1 67
42 1 8 1 11 1 14 1 17 1 20 1 24 1 29 1 34 1 39 1 45 1 51
43 1 6 1 8 1 10 1 13 1 15 1 18 1 22 1 25 1 30 1 34 1 39
44 1 5 1 6 1 8 1 10 1 12 1 14 1 17 1 19 1 23 1 26 1 30
45 1 4 1 5 1 6 1 7 1 9 1 10 1 12 1 14 1 17 1 19 1 22
Nat.
Age
(yrs) 0 .9 0  0 .9 5
AFP(HON) 
1 .00  1 .1 0  1 .2 0  1 .30 1 .4 0  1 .5 0  1 .80  2 .0 0
25 1 1200 1 1400 1 1500 1 1800 1 2400 1 2800 1 3400 1 4000 1 6400 1 8300
26 1 1200 1 1300 1 1500 1 1800 1 2200 1 2700 1 3200 1 3800 1 6100 1 7900
27 1 1100 1 1300 1 1400 1 1800 1 2200 1 2600 1 3100 1 3700 1 5900 1 7700
28 1 1000 1 1200 1 1300 1 1600 1 2000 1 2400 1 2800 1 3300 1 5300 1 6900
29 1 910 1 1000 1 1200 1 1500 1 1800 1 2100 1 2500 1 3000 1 4800 1 6300
30 1 820 1 930 1 1000 1 1300 1 1600 1 1900 1 2300 1 2700 1 4300 1 5400
31 1 720 1 820 1 910 1 1100 1 1400 1 1700 1 2000 1 2400 1 3800 1 4900
32 1 610 1 700 1 780 1 980 1 1200 1 1400 1 1700 1 2000 1 3200 1 4200
33 1 520 1 590 1 660 1 820 1 1000 1 1200 1 1400 1 1700 1 2700 1 3600
34 1 430 1 490 1 540 1 680 1 820 1 1000 1 1200 1 1400 1 2200 1 2900
35 1 340 1 380 1 440 1 550 1 670 1 810 1 960 1 1100 1 1800 1 2400
36 1 280 1 320 1 350 1 440 1 530 1 650 1 770 1 910 1 1500 1 1900
37 1 220 1 250 1 280 1 350 1 420 1 510 1 610 1 720 1 1100 1 1500
38 1 170 1 190 1 220 1 270 1 330 1 400 1 470 1 560 1 890 1 1200
39 1 130 1 150 1 170 1 210 1 250 1 310 1 370 1 430 1 690 1 900
40 1 100 1 120 1 130 1 160 1 200 1 240 1 280 1 330 1 530 1 690
41 1 76 1 87 1 100 1 120 1 150 1 180 1 210 1 250 1 400 1 520
42 1 58 1 67 1 74 1 93 1 110 1 140 1 160 1 190 1 310 1 400
43 1 44 1 50 1 56 1 70 1 85 1 100 1 120 1 140 1 230 1 300
44 1 34 1 38 1 43 1 54 1 65 1 79 1 94 1 110 1 180 t 230
45 1 25 1 28 1 31 1 39 1 48 1 58 1 69 1 81 1 130 1 170
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Table 5 - 5
Risk estimates of f ind ing an autosomal trisomy fetus at 
m id-trim ester, based on maternal age and maternal serum 
alphafetoprotein (AFP) at 16-20 weeks gestation (MOM = m ultip les  
of the median).
Hat.
Age
(yrs) 0 .3 5 0 .4 0 0 .4 5 0 .5 0 0 .5 5
AFP(MOH) 
0 .6 0  0 .6 5 0 .7 0 0 .7 5 0 .8 0 0 .8 5
25 1 120 1 170 1 230 1 300 1 370 1 460 1 550 1 650 1 750 1 860 1 980
26 1 110 1 160 1 220 1 280 1 360 1 430 1 520 1 620 1 710 1 810 1 930
27 1 100 1 150 1 200 1 260 1 330 1 410 1 490 1 580 1 670 1 760 1 870
28 1 94 1 140 1 190 1 240 1 310 1 380 1 460 1 540 1 620 1 710 1 810
29 1 88 1 130 1 170 1 220 1 280 1 340 1 410 1 490 1 560 1 640 1 730
30 1 79 1 110 1 150 1 200 1 250 1 310 1 370 1 440 1 500 1 580 1 660
31 1 69 1 100 1 130 1 170 1 220 1 270 1 320 1 380 1 440 1 500 1 570
32 1 59 1 85 1 110 1 150 1 190 1 230 1 280 1 330 1 380 1 430 1 490
33 1 50 1 71 1 100 1 130 1 160 1 190 1 230 1 280 1 320 1 360 1 410
34 1 41 1 59 1 80 1 100 1 130 1 160 1 190 1 230 1 260 1 300 1 340
35 1 33 1 48 1 65 1 84 1 110 1 130 1 160 1 180 1 210 1 240 1 280
36 1 27 1 38 1 52 1 67 1 85 1 100 1 120 1 150 1 170 1 190 1 220
37 1 21 1 30 1 41 1 53 1 67 1 82 1 100 1 120 1 130 1 150 1 180
38 1 16 1 23 1 32 1 41 1 52 1 64 1 77 1 91 1 too 1 120 1 140
39 1 13 1 18 1 25 1 32 1 40 1 49 1 59 1 70 1 81 1 92 1 110
40 1 10 1 14 1 19 1 24 1 31 1 38 1 45 1 54 1 62 1 71 1 81
41 1 7 1 11 1 14 1 19 1 23 1 29 1 35 1 41 1 47 1 54 1 61
42 1 6 1 8 1 11 1 14 1 18 1 22 1 26 1 31 1 36 1 41 1 46
43 1 4 1 6 1 8 1 11 1 14 1 17 1 20 1 24 1 27 1 31 1 35
44 1 3 1 5 1 6 1 8 1 10 1 13 1 15 1 18 1 21 1 24 1 27
45 1 2 1 4 1 5 1 6 1 8 1 10 1 12 1 14 1 16 1 18 1 20
Mat.
Age
(yrs) 0 .9 0  0 .9 5
AFP(MOM) 
1 .0 0  1 .10  1 .20  1 .30 1 .4 0  1 .5 0  1 .8 0  2 .0 0
25 1 1100 1 1200 1 1300 1 1600 1 1900 1 2100 1 2400 1 2700 1 3500 1 4100
26 1 1000 1 1200 1 1300 1 1500 1 1800 1 2000 1 2300 1 2500 1 3300 1 3900
27 1 980 1 1100 1 1200 1 1400 1 1700 1 1900 1 2100 1 2600 1 3100 1 3700
28 1 900 1 1000 1 1100 1 1300 1 1500 1 1700 1 2000 1 2200 1 2900 1 3400
29 1 820 1 910 1 1000 1 1200 1 1400 1 1600 1 1800 1 2000 1 2600 1 3100
30 1 730 1 810 1 900 1 1100 1 1200 1 1400 1 1600 1 1800 1 2300 1 2800
31 1 640 1 710 1 790 1 940 1 1100 1 1200 1 1400 1 1600 1 2100 1 2400
32 1 550 1 610 1 670 1 800 1 930 1 1100 1 1200 1 1300 1 1800 1 2100
33 1 460 1 510 1 570 1 680 1 790 1 900 1 1000 1 1100 1 1500 1 1800
34 1 380 1 420 1 470 1 560 1 650 1 740 1 840 1 940 1 1200 1 1400
35 1 310 1 430 1 380 1 450 1 530 1 600 1 680 1 760 1 990 1 1200
36 1 250 1 270 1 300 1 360 1 420 1 480 1 540 1 610 1 790 1 940
37 1 200 1 220 1 240 1 290 1 330 1 380 1 430 1 480 1 630 1 470
38 1 150 1 170 1 190 1 220 1 260 1 300 1 330 1 370 1 490 1 580
39 1 120 1 130 1 140 1 170 1 200 1 230 1 260 1 290 1 380 1 450
40 1 90 1 100 1 110 1 130 1 150 1 170 1 200 1 220 1 290 1 340
41 1 69 1 76 1 84 1 100 1 120 1 130 1 150 1 170 1 220 1 260
42 1 52 1 57 1 63 1 75 1 88 1 100 1 110 1 130 1 170 1 200
43 1 40 1 44 1 49 1 58 1 67 1 77 1 87 1 97 1 130 1 150
44 1 30 1 33 1 37 1 44 1 51 1 58 1 66 1 74 1 96 1 110
45 1 23 1 25 1 28 1 33 1 39 1 44 1 50 1 56 1 73 1 86
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Maternal age 31 years AFP 0.5 MOM 
Maternal age risk = 1:534 
Likelihood ratio = a/b = 3.07 
Combined risk =1:170
Autosomal 
Trisomy /
Unaffected
1.0 2.00.3 0.5
AFP (MOM)
Maternal age 37 years AFP 1.5 MOM 
Maternal age risk =1:163  
Likelihood ratio = a/b =0.34 
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Figure 5 - 4
Combining (a) maternal age r is k  at age 31 with the l ike lihood  
ra t io  from AFP level of 0 .5  MOM or (b) maternal age at age 37 with  
the l ike lihood  ra t io  from AFP level of 1.5 MOM, to  give a combined 
r is k  o f an autosomal trisomy.
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Figure 5 - 5
Risk of a Down’ s syndrome pregnancy a t  m id-trim ester based on a 
combination o f maternal age and maternal serum alphafetoprotein  
(AFP) level (MOM = m ultip le  of the median).
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Figure 5 - 6
Risk o f an autosomal trisomy pregnancy a t m id-trim ester based on a 
combination o f maternal age and maternal serum alphafetoprotein  
(AFP) level (MOM = m ultip le  of the median).
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trisomy is 1:220 at age 40 but the m id-trim ester r isk  of Down’ s 
syndrome is 1:330. This is mainly due to the population maternal 
age r isk  of an autosomal trisomy being higher than th a t  fo r  Down’ s 
syndrome alone, but the larger standard deviation of the autosomal 
trisomy d is tr ib u t io n ,  causing greater l ike lihood ra t ios  (Figure  
5-7) is also a contributory fac to r .
5 . 1 . 2 . 4  PREDICTED DETECTION RATES
Detection and corresponding fa ls e  positive rates were estimated in 
the west of Scotland pregnant population as described in Section 
4 .2 .9 .  Table 5-6 shows a comparison of detection and fa lse  
posit ive  rates, at a range of mid tr im ester threshold r isks , using 
e ith e r  (a) the risks derived from the autosomal trisomy log 
Gaussian d is tr ib u t io n  and population m id-trim ester autosomal 
trisomy r isks, or (b) the risks derived from the Down’ s syndrome 
log Gaussian d is tr ib u t io n  and population m id-trim ester Down’ s 
syndrome r isks. I t  can be seen tha t at a l l  c u t -o f f  r isks shown the 
detection rate fo r  Down’ s syndrome and the corresponding fa lse  
positive  rate are lower when method (b ) ,  using risks derived fo r  
Down’ s syndrome alone, are used. However at any given detection  
rate the fa lse  pos itive  rates are equivalent. Using method (a ) ,  
the overa ll detection rate fo r  a l l  three autosomal trisomies  
combined is s l ig h t ly  higher than fo r  Down’ s syndrome alone. This 
is due to trisomy 18 pregnancies having s l ig h t ly  lower AFP values 
than Down’ s syndrome, and therefore having a s l ig h t ly  increased 
rate of detection.
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Figure 5 - 7
Likelihood ra tios  fo r  autosomal trisomies and fo r  Down’ s syndrome 
at alphafetoprotein (AFP) levels  between 0.35 and 2.00 m ultip les  
of the median (MOM) calculated from the log Gaussian d is tr ib u t io n s  
with means and standard deviations given in Table 5-2.
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Table 5 - 6
Comparison of detection and fa lse  positive rates at varying mid 
trim ester r isk  thresholds in the west of Scotland pregnant 
population using (a) m id-trim ester risks of an autosomal trisomy 
or (b) m id-trim ester risks of Down’ s syndrome.
Cut-off (a) Autosomal trisomy risks (b) Down’ s risks
risk False Detn Detn False Detn
+ve rate rate +ve rate
rate Aut.Tr. Down’ s rate Down’ s
(%) (%) (%) (%) (%)
1:100 1.9 20 18 1.2 16
1:150 3.2 26 24 2.0 20
1:200 4.4 31 29 3.3 26
1:250 5.7 34 32 4.5 30
1:280 6.6 37 35 5.4 32
1:350 8.5 41 40 8.0 39
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In  practice , screening cannot distinguish between the d i f fe re n t  
types of autosomal trisomy. Therefore the risks of an autosomal 
trisomy were considered more appropriate and have been used in the 
west of Scotland AFP/age prenatal screening programme fo r  
chromosome abnormalities. Using the above AFP and age parameters, 
an overall detection rate of 37% fo r  autosomal trisomies was 
estimated at a fa lse  pos itive  rate of 6.6%, using a threshold r isk  
of 1:280. The corresponding figures using maternal age 35 years 
and over as the ind icator fo r  amniocentesis in the west of 
Scotland population, are 30% detection with a 6.7% fa ls e  positive  
rate . The use of combined AFP/age screening extends the age range 
fo r  screening to 25 years and over, but i t  should be noted that  
there is  considerable var ia t io n  in detection and fa lse  positive  
rates between d i f fe re n t  maternal age groups (Table 5 -7 ) .  For 
example, only 12% of the autosomal trisomies in the age group 
25-29 years are id e n t if ie d  w ithin the high risk group, compared 
with 71% in the 35-37 years group and 100% in the 40 years and 
over age group.
Combined AFP/age screening improves the overa ll odds of f ind ing an 
affected pregnancy when compared with screening by maternal age 
>35 years. Using maternal age the overa ll odds are 1:125 and using 
AFP/age screening at a m id-trim ester r is k  threshold of 1:280 the 
odds are (Table 5 -8 ) .  Using AFP/age screening, fo r  women aged 35 
years and over, assigned to the high r isk  group, the overa ll odds 
of an affected pregnancy are 1:80, compared with 1:470 in the low 
r isk  (<1:280) group. For women age 25-34, the overa ll r isk  of an 
autosomal trisomy is 1:650. For the high r isk  (>1:280) group on 
AFP/age screening the overa ll odds of an affected pregnancy are
-115-
Table 5 - 7
Comparison of fa lse  positive  rates and detection rates  
autosomal trisomies w ithin d i f fe re n t  maternal age groups in 
west of Scotland.
Age group % a l l  % a l l  % in age % autosomal
(years) pregnancies autosomal group with trisomies in
trisomies r isk  >1:280 age group
detected
<25 40 23 - -
25-29 36 25 3 12
30-34 18 21 10 33
35-37 4.4 12 37 71
38-39 1.3 7 80 94
>40 1.0 12 100 100
overall 100 100 6.6 37
for
the
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Table 5 - 8
Comparison of overa ll odds of an autosomal trisomy pregnancy at 
m id-trimester
OVERALL ODDS OF AN AFFECTED 
PREGNANCY
(a) POPULATION RISKS
Overall 1:570
Age >35 years 1:125
Age 25-34 years 1:650
(b) WITH AGE/AFP RISK >1:280
Overal1 
Age >35 years 
Age 25-34 years
(c) WITH AGE /AFP RISK <1:280
Overall 1:840
Age >35 years 1:470
Age 25-34 years 1:780
1:100  
1: 80 
1:165
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1:165, compared with 1:780 i f  in the low risk  (<1:280) group. 
Screening fo r  autosomal trisomies using AFP/age therefore gives 
women aged 25 years and over who are assigned to the low risk  
group a reduced overa ll odds of having an affected pregnancy 
compared with th e ir  overa ll a p r i o r i  odds.
5 .1 .3  ROUTINE PROSPECTIVE SCREENING FOR AUTOSOMAL TRISOMIES USING 
AFP/AGE
Screening fo r  autosomal trisomies using AFP/age was added to the 
existing  west of Scotland screening programme fo r  neural tube 
defects in July 1987. AFP results were converted to MOM, using the 
appropriate gestation and an individual woman’ s combined r isk  of 
an autosomal trisomy derived from Table 5-5. Where maternal weight 
was ava ilab le  MOM values were corrected fo r  maternal weight by the 
formula
MOM* = MOM X 0.4592 X (1 .01272)WT 
where MOM* is the weight adjusted AFP value 1n MOM and WT is the 
maternal weight in kilogrammes (Wald et  a l . ,  1981). A threshold
risk  of 1:280 was used to define the high r isk  group.
During the period July 1987 to December 1990 there were 128,824 
pregnancies and 100,481 women chose to have prenatal screening, an 
uptake of 78%. The results  of screening during th is  period are 
summarised in Tables 5-9 and 5-10. The fa lse  pos it ive  ra te , a f te r  
some gestations had been reassessed, was 6.1%, with 44% of these 
women being aged 35 years and over and the remaining 56% being 
aged between 25 and 34 years. The overa ll uptake of amniocentesis
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Table 5 - 9
Prospective AFP/age screening fo r autospmal trisomies in the west 
of Scotland, July 1987 to December 1990: False pos it ive  rate and
uptake of diagnostic tes t ing .
Total no of pregnancies screened : 100,481
High risk group (Risk >1:280)
Number (%) screen pos itive  : 6,149 (6.1%)
>35 years : 2,706
<35 years : 3,443
Uptake of amniocentesis >35 years : 56%
<35 years : 32%
Overall : 42%
Low risk group (Risk <1:280. Age >35 years)
Number of women : 2,159
% of a l l  pregnancies >35 years : 44%
Proportion having diagnostic tes ting  : 23%
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Table 5 - 1 0
Prospective AFP/age screening fo r  autosomal trisomies in the 
of Scotland, July 1987 to December 1990: Detection rates.
Down’ s syndrome in screened population : 94
T risomy 18 in screened population 13
T risomy 13 in screened population : 3
Total autosomal trisomy in screened population : 110
Number (%) Down’ s syndrome with r isk  >1:280 : 39 (41%)
Number (%) trisomy 18 with r isk  >1:280 7 (54%)
Number (%) trisomy 13 with r isk  >1:280 : 1 (33%)
Number (%) a l l  autosomal trisomy with r isk  >1:280 : 47 (43%)
Number (%) Down’ s syndrome prenata lly  diagnosed : 22 (23%)
Number (%) trisomy 18 prenata lly  diagnosed : 6 (46%)
Number {%) trisomy 18 prenata lly  diagnosed : 0 ( 0%)
Number (%) a l l  autosomal trisomies prenata lly
diagnosed : 28 (25%)
west
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by women in the high r isk  group was 42%, with a marked difference  
between the women age 35 years and over, who had an uptake of 56%, 
compared with those under 35 years, with an uptake of only 32%. 
The uptake of prenatal diagnosis in the 44% of women age 35 years 
and over who where assigned to the low r is k  group was 23%.
The overall detection rate fo r  autosomal trisomies by screening 
was 43%, but the rate p renata lly  diagnosed was only 25% due mainly 
to the low uptake of amniocentesis by women aged less than 35 
years. Of the 39 Down’ s syndrome pregnancies in the high r isk  
group, 25 were in women aged 35 years and over, and of these 18 
(72%) were prenata lly  diagnosed. The remaining 14 were in women 
aged 25-34 years and only 4 of these (29%) were prenata lly  
diagnosed. The proportion of trisomy 18 pregnancies ac tua lly  
prenata lly  diagnosed (6 out of 7 assigned to  the high r isk  group) 
was greater than that fo r  Down’ s syndrome. This is due to trisomy 
18 pregnancies tending to have s l ig h t ly  lower AFP results  and 
hence higher risks than Down’ s syndrome pregnancies.
A summary of a l l  the autosomal trisomy pregnancies id e n t if ie d  
cytogenetically  re la t in g  to th is  period o f screening is given in 
Table 5-11. There were 170 autosomal trisomy pregnancies in to ta l  
(1.3/1000 pregnancies), consisting of 139 Down’ s syndrome 
(1.1/1000 pregnancies), 23 trisomy 18 and 8 trisomy 13. Of these, 
59 (35%) were p renata lly  diagnosed, fo r  a v a r ie ty  o f indications:  
Risk >1:280 from AFP/age screening, maternal age 35 years or over, 
high maternal serum AFP (>2.0 MOM) and abnormal ultrasound 
findings. The largest group (28, 47%) were those id e n t if ie d  by 
AFP/age screening.
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Table 5 - 1 1
Summary of a l l  autosomal trisomy pregnancies in the west of 
Scotland fo r  the period screened July 1987 to December 1990.
Down’ s 
syndrome
T risomy 
18
T risomy 
13
Total
autosomal
trisomy
Singleton pregnancies 
Screened-HR-PND 22 6 0 28
Screened-HR-Born 17 1 1 19
Screened-LR-PND 2 0 0 2
Screened-LR-Born 53 6 2 61
High AFP-PND 1 1 1 3
1st Tri CVS-MA-PND 8 5 0 13
Amnio-MA-PND 7 1 2 10
CVS/Amnio U/S-PND 3 0 0 3
Not screened-Born 23 3 2 28
Twin pregnancies
Screened-Born 2 0 0 2
Not screened-Born 1 0 0 1
Total 139 23 8 170
HR = High r isk  group (Risk >1:280)
LR = Low risk  group (Risk <1:280)
PND = Prenata lly  diagnosed
CVS = Chorionic v i l lu s  sampling
Amnio = Amniocentesis
MA = Maternal age >35 years
High AFP = Maternal serum AFP >2.0 MOM
U/S = Abnormal ultrasound findings
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PHASE 2
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5.2 RETROSPECTIVE ANALYSIS OF PREGNANCY MARKERS IN STORED MATERNAL
SERUM
A panel of serum samples consisting of 118 chromosomally abnormal 
pregnancies and 410 controls was used in the analysis of four 
maternal serum markers: in tac t hCG, SPi, UE3 and Fr|3-hCG.
5.2 .1  ANALYTE LEVELS
5 .2 .1 .1  HUMAN CHORIONIC GONADOTROPHIN
5 .2 .1 .1 .1  hCG LEVELS IN UNAFFECTED PREGNANCIES
Four hundred and ten control sera taken between 15-20 weeks 
gestation were analysed fo r  in tac t hCG as described in Section 
4 .1 .3 .1 .  These consisted of 11 samples at 15 weeks gestation, 184 
at 16 weeks, 145 at 17 weeks, 44 at 18 weeks, 16 at 19 weeks and 
10 at 20 weeks. Median hCG levels declined s l ig h t ly  with advancing 
gestation between 15 and 20 weeks. Medians, calculated by linear
interpolation,were 25 IU/ml at 15 weeks, 23 IU/ml at 16 and 17 
weeks, 20 IU/ml at 18 weeks and 19 IU/ml at 19 and 20 weeks.
5 .2 .1 .1 .2  hCG LEVELS IN DOWN’ S SYNDROME
The levels of in ta c t  hCG ( in  MOM) found in 49 Down’ s syndrome
pregnancies, p lotted at the appropriate completed week of
gestation, are shown on Figure 5-8. The median hCG value fo r  the 
pregnancies affected by Down’s syndrome was found to be
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Figure 5 - 8
Maternal serum in ta c t  chorionic gonadotrophin (hCG) leve ls , in 
m ultip les of the median (MOM), in 49 Down’ s syndrome pregnancies 
compared with the levels  in 410 unaffected controls.
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s ig n if ic a n t ly  elevated at 2.18 MOM (95% CL 1.77 -  2.68 MOM) of the 
unaffected pregnancies (p<0.001 by t - t e s t  on unpaired var iab les ) .  
The proportions of control and Down’ s syndrome pregnancies with 
hCG levels equal to or greater than selected c u t -o f f  levels  are 
shown in Table 5-12, w ith, fo r  example 26 of the 49 Down’ s samples 
(53%) having levels  greater than or equal to 2.0 MOM, compared 
with 35 of 410 controls (8.5%). A p ro b a b il ity  p lo t (Figure 5-9) 
shows that the d is tr ib u tio n s  of hCG values in the control samples 
up to 2.0 MOM and in the Down’ s syndrome samples between 0.6 and 
6.0 MOM f i t  log Gaussian d is tr ib u tio n s  (Figure 5 -10 ) .  The 
intersection point of the two curves is 1.59 MOM. The means and 
standard deviations of the d is tr ib u tio n s  were estimated as
described in Section 4 .2 .3 .1  and are shown in Table 5-13.
5 .2 .1 .1 .3  hCG LEVELS IN OTHER CHROMOSOME ABNORMALITIES
The levels of hCG, in MOM, in sera from the other types of 
chromosomally abnormal pregnancies are shown in Figure 5-11 and 
th e ir  median values in Table 5-14. Differences between the 
d is tr ibu tio ns  of the levels  in the control samples and the 
d if fe re n t  types of chromosome abnormality were determined by the 
Kolmorogov-Smirnov te s t  (Table 5 -14). There was no s ig n if ic a n t  
difference between the controls and the four trisomy 13
pregnancies, the four balanced translocations and the 
heterogeneous group of nine sex chromosome abnormalities. The
group of eight unbalanced translocations appear to show some 
lowering of hCG levels (0.05>p>0.01) ,  while the levels in the 12 
trisomy 18 pregnancies were a l l  below 0.6 MOM, with a median value
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Table 5 - 1 2
Proportion of contro l, Down’ s syndrome and trisomy samples with  
maternal serum chorionic gonadotrophin (hCG) leve ls , in m ultip les  
of the median (MOM), greater than or equal to selected c u t -o ff  
values.
hCG Controls Down’ s Trisomy 18
(MOM) (n= 410) (n=49) (n= 12)
% (n) % (n) % (n)
>3.0 0.7 (3) 28.6 (14) 0 (0)
>2.5 3.4 (14) 36.7 (18) 0 (0)
>2.0 8.5 (35) 53.1 (26) 0 (0)
>1.5 21.7 (89) 71.4 (35) 0 (0)
>1.0 51.0 (209) 79.6 (39) 0 (0)
>0.5 87.8 (360) 100 (49) 8. 3 (1)
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Figure 5 - 9
P ro b ab ili ty  p lot of maternal serum chorionic gonadotrophin (hCG) 
leve ls ,  in m ultip les of the median (MOM), on a log scale, in 
selected unaffected control pregnancies, Down’ s syndrome 
pregnancies and trisomy 18 pregnancies. The continuous lines are 
those defined by log Gaussian d is tr ib u tio n s  with means and 
standard deviations as given in Table 5-13.
-128 -
Unaffected
Down’s syndromeTrisomy 18
0.05 0.1 0.2 0.5 1.0 2.0 5.0 10.0
hCG (MOM)
Figure 5 - 1 0
Log Gaussian d is tr ib u t io n s  of maternal serum chorionic  
gonadotrophin (hCG) leve ls , in m ultip les of the median (MOM), in 
unaffected control pregnancies, Down’ s syndrome pregnancies and 
trisomy 18 pregnancies. These are p lotted  from the means and 
standard deviations of 410 unaffected, 49 Down’ s syndrome and 12 
Trisomy 18 pregnancies as given in Table 5-13.
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Table 5 - 1 3
Maternal serum chorionic gonadotrophin (hCG) medians, in m ultip les  
of the median (MOM), and means and standard deviations (SD) of the 
logio d is tr ib u tio n s  fo r  the controls, Down’ s syndrome pregnancies 
and trisomy 18 pregnancies.
n Median
(MOM)
Mean SD
Controls 410 1.01 0.0043 0.2499
Down’ s 49 2.18 0.3385 0.3127
Trisomy 18 12 0.21 -0.6778 0.2730
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Figure 5 - 1 1
Maternal serum chorionic gonadotrophin (hCG) leve ls , in m ultip les  
of the median (MOM), in 86 pregnancies with chromosome 
abnormalities compared with the levels  in 410 unaffected controls.
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Table 5 - 1 4
Maternal serum chorionic gonadotrophin (hCG) median values, in 
multiples of the median (MOM), and significance tes t in g  by the 
Kolmogorov-Smirnov (K-S) te s t  of the d is tr ib u tio n s  of hCG levels  
in trisomy 18, trisomy 13, unbalanced translocations, balanced 
translocations and sex chromosome abnormalities against the 
control group. (D = absolute d ifference, p = p ro b a b il i ty ) .
n hCG
median
(MOM)
K-S tes t  
D P
Trisomy 18 12 0.21 0.8757 <0.001
Trisomy 13 4 0.78 0.3749 >0.2
Unbalanced trans. 8 0.67 0.4745 0.021
Balanced trans. 4 1.39 0.3526 >0.2
Sex chrom. abn. 9 0.70 0.3367 >0.2
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of 0.21 MOM, a highly s ig n if ic a n t  d ifference (p<0.001).
Although the numbers are small, the trisomy 18 hCG values appear 
to  f i t  a log Gaussian d is tr ib u t io n  (See p ro b a b il ity  p lo t ,  Figure 
5 -9 ) .  The log Gaussian d is tr ib u t io n  of hCG in the trisomy 18 
samples, with mean and standard deviation as given in Table 5-13, 
appears to have a greater s h i f t  away from the levels  in the
controls than the Down’ s syndrome samples (Figure 5 -10 ).  The
proportions of trisomy 18 samples with levels greater than or 
equal to selected c u t -o f f  levels are shown in Table 5-12, with  
only 1 case out of 12 (8.3%) having a value greater than or equal 
to  0.5 MOM. In comparison 360 out of 410 of the controls (87.8%) 
and a l l  49 (100%) of the Down’ s syndrome samples had hCG levels  
>0.5 MOM.
5 . 2 . 1 .2  PREGNANCY SPECIFIC 0-1 GLYCOPROTEIN
5. 2 . 1 .2 .1  SPi LEVELS IN UNAFFECTED PREGNANCIES
SPi was assayed as described in Section 4 .1 .4 .1  in 377 controls at
15 to 20 weeks gestation, consisting of 11 samples a t 15 weeks 
gestation, 179 at 16 weeks, 128 at 17 weeks, 39 at 18 weeks, 10 at
19 weeks and 10 at 20 weeks. Median SPi levels increased with
advancing gestation between 15 and 20 weeks. The regressed median 
values in the controls were: 26.1 mg/L at 15 weeks, 28.2 mg/1 at
16 weeks, 30.5 mg/1 a t 17 weeks, 32.9 mg/1 at 18 weeks, 35.6 mg/1 
at 19 weeks and 38.5 mg/1 at 20 weeks.
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5 . 2 . 1 . 2 . 2  SPi LEVELS IN DOWN’ S SYNDROME
The levels of SPi, in MOM, in 48 Down’ s syndrome cases plotted at  
the appropriate completed week o f gestation, are shown in Figure 
5-12. The median SPi level in 48 Down’ s syndrome pregnancies was 
s ig n if ic a n t ly  elevated ( p<0.01 by t - t e s t  on unpaired variab les) at 
1.17 MOM (95% CL 1.04 -  1.32 MOM) of the unaffected pregnancies. 
The proportions of control and Down’ s syndrome pregnancies with  
SPi levels equal to  or greater than selected c u t -o f f  levels  are 
shown in Table 5-15, w ith, fo r  example 34 of the 48 Down’ s 
syndrome pregnancies (70.8%) having values greater than or equal 
to 1.0 MOM compared with 190 of 377 controls (50.4%). A 
probab il ity  p lo t (Figure 5-13) shows that the d is tr ib u t io n s  of SPi 
values between 0.6 and 1.8 MOM in the controls and between 0.7 and
2.4 MOM in the Down’ s syndrome samples f i t  log Gaussian 
d is tr ib u tio n s  (Figure 5-14). The intersection  point of the two 
curves is 1.23 MOM. The means and standard deviations of the 
control and Down’ s syndrome SPi d is tr ib u tio n s  were estimated as 
described in Section 4 .2 .3 .1  and are shown in Table 5-16.
5 . 2 . 1 .2 . 3  SPi LEVELS IN OTHER CHROMOSOME ABNORMALITIES
The levels of SPi, 1n MOM, in the sera from the other 
chromosomally abnormal pregnancies are shown in Figure 5-15, and 
th e i r  median values in Table 5-17. Differences between the 
d is tr ib u tio n s  of the SPi levels  in the control samples and the 
other types of chromosome abnormality were assessed by the 
Kolmorgorov-Smirnov te s t  (Table 5 -17). The eight unbalanced
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Figure 5 - 1 2
Maternal serum pregnancy sp ec if ic  3-1 glycoprotein (SPi) leve ls ,  
in m ultip les  of the median (MOM), in 48 Down’ s syndrome 
pregnancies compared with the levels  in 377 unaffected controls.
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Table 5 - 1 5
Proportion of contro l, Down’ syndrome and trisomy 18 samples with 
maternal serum pregnancy spec if ic  13-1 glycoprotein (SPi) levels ,  
in multiples of the median (MOM), greater than or equal to  
selected c u t -o f f  values.
SPi Controls Down’ s T risomy 18
(MOM) (n= 377) (n= 48) (n=9)
% (n) % (n) % (n)
>2.5 0 (0) 2.1 (1) 0 (0)
>2.0 1.1 (14) 14.6 (7) 0 (0)
>1.5 10.1 (38) 35.4 (17) 0 (0)
>1.0 50.4 (190) 70.8 (34) 44.4 (4)
>0.5 96.8 (365) 97.9 (47) 100 (9)
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Figure 5 - 1 3
P rob ab ility  p lo t of maternal serum pregnancy spec if ic  3-1 
glycoprotein (SPi) leve ls , in m ultip les of the median (MOM), on a 
log scale, in selected control pregnancies and those affected by 
Down’ s syndrome. The continuous lines are those defined by log 
Gaussian d is tr ib u t io n s  with means and standard deviations as given 
in Table 5-16.
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Figure 5 - 1 4
Log Gaussian d is tr ib u t io n s  of maternal serum pregnancy sp ec if ic  
3-1 glycoprotein (SPi) leve ls , in m ultip les of the median (MOM), 
in controls and Down’ s syndrome pregnancies. These are p lo tted  
from the means and standard deviations o f  377 unaffected and 48 
Down’ s syndrome pregnancies as given in Table 5-16.
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Table 5 - 1 6
Maternal serum pregnancy specif ic  (3-1 glycoprotein (SPi) medians, 
in multiples of the median (MOM), and means and standard 
deviations (SD) of the log-io d is tr ib u tio n s  of the controls and 
Down’ s syndrome pregnancies.
n SPi
Median
(MOM)
Mean SD
Controls 377 1.00 0.000 0.146
Down’ s 48 1.17 0.068 0.176
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Figure 5 - 1 5
Maternal serum pregnancy sp ec if ic  3-1 glycoprotein (SP i) leve ls ,  
in m ultiples of the median (MOM), in 82 pregnancies with  
chromosome abnormalities compared with the levels  in 377 controls.
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Table 5 - 1 7
Maternal serum pregnancy spec if ic  (3-1 glycoprotein (SP i) median 
values, in m ultip les of the median (MOM), and s ignificance testing  
by the Kolmogorov-Smirnov (K-S) tes t  of the d is tr ib u tio n s  fo r  
trisomy 18, trisomy 13, unbalanced translocations, balanced 
translocations and sex chromosome abnormalities, against the 
control group. (D = absolute d ifference, p = p ro b a b il i ty ) .
n SPi
Median
(MOM)
K-S
D
te s t
P
Trisomy 18 9 0.87 0.276 >0.2
Trisomy 13 4 1.01 0.258 >0.2
Unbalanced trans. 8 0.52 0.814 <0.01
Balanced trans. 4 0.79 0.413 >0.2
Sex chrom. abn. 9 0.93 0.144 >0.2
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translocations showed a s ig n if ic a n t  decrease in SPi leve ls , with  
a l l  values being below 0.74 MOM, with a median value of 0.52 MOM 
( p<0.01). There was no s ig n if ic a n t  d ifference between the controls  
and the nine trisomy 18 pregnancies, the four trisomy 13 
pregnancies, the four balanced translocations or the nine sex 
chromosome abnormalities. The proportions of trisomy 18
pregnancies with SPi levels greater than or equal to  selected
c u t-o ff  levels  are shown in Table 5-15, with, fo r  example, 4 out 
of 9 cases (44.4%) having values greater than or equal to 1.0 MOM, 
compared with 190 out of 377 controls (50.4%) and 34 out o f 48 
Down’ s syndrome pregnancies (70.8%).
5 .2 .1 .3  UNCONJUGATED ESTRIOL
5 .2 .1 .3 .1  UE3 LEVELS IN UNAFFECTED PREGNANCIES
UE3 levels were analysed as described in Section 4 .1 .5 .1  in 390 
control sera taken between 15 and 20 weeks gestation. There were
11 samples at 11 weeks gestation, 184 at 16 weeks, 136 at 17
weeks, 39 at 18 weeks, 10 at 19 weeks and 10 a t 20 weeks. Median 
UE3 values increased with advancing gestation between 15 and 20 
weeks. Medians, calculated by l in e a r  in terpo la tion  were 3.4 nmol/1 
at 15 weeks, 4.7 nmol/1 at 16 weeks, 5.5 nmol/1 at 17 weeks, 6.8  
nmol/1 at 18 weeks, 8 .5  nmol/1 at 19 weeks and 9.9 nmol/1 at 20 
weeks.
-142-
5 .2 .1 .3 .2  UE3 LEVELS IN DOWN’ S SYNDROME
The levels of UE3 ( in  MOM) found in 49 Down’ s syndrome cases, 
plotted at the appropriate completed week of gestation, are shown 
in Figure 5-16. The median value was s ig n if ic a n t ly  reduced at 0.79  
MOM (95% CL 0.71 -  0.87 MOM) of the unaffected pregnancies (p<0.02 
by t - t e s t  on unpaired var iab les ) .  The observed numbers and 
proportion of Down’ s syndrome and unaffected pregnancies with UE3 
levels less than or equal to specif ic  UE3 values are shown in 
Table 5-18, with, fo r  example, 41 out of 49 of the Down/s 
pregnancies (84%) having UE3 values less than or equal to  1.0 
MOM, compared with 202 out of 390 of the unaffected pregnancies 
(52%).
The d is tr ib u t io n  of UE3 in the Down’ s syndrome and unaffected  
pregnancies was tested fo r  f i t  to both a Gaussian and a log 
Gaussian d is tr ib u t io n .  Means and standard deviations of e i th e r  a 
Gaussian or log Gaussian d is tr ib u t io n  were estimated as described 
in Section 4 .2 .3 .1  and are shown in Table 5-19. The f i t  of the 
individual UE3 values to the d is tr ib u tio n s  predicted by these 
means and standard deviations assessed by the Kolmogorov-Smirnov 
Test (Table 5-19). Figure 5-17 shows p ro b a b il ity  plots comparing 
the observed values, both on a l inear  scale (Figure 5-17a) and on 
a log scale (Figure 5—17b) with the predicted Gaussian or log 
Gaussian d is tr ib u t io n s . The observed values, especia lly  those from 
the unaffected pregnancies, f i t  a Gaussian d is tr ib u t io n  bette r  
than a log Gaussian d is tr ib u t io n .  The Gaussian d is tr ib u tio n s  of 
UE3 in the Down’ s and control samples are shown in Figure 5-18. 
The intersection point of the two curves is 0.86 MOM.
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Figure 5 - 1 6
Maternal serum unconjugated e s t r io l  (UE3) leve ls , in m ultip les of 
the median (MOM), in 49 Down’ s syndrome pregnancies compared with 
the levels  in 390 controls.
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Table 5 - 1 8
Proportion of control and Down’ s syndrome samples with maternal 
serum unconjugated e s tr io l  (UE3) values, in m ultip les of the 
median (MOM), equal to  or less than selected c u t -o f f  levels .
UE3 Controls Down’ s
(MOM) (n=390) (n=49)
% (n) % (n)
<1.9 99 (386) 100 (49)
<1.6 96 (376) 96 (47)
<1.3 85 (332) 92 (45)
<1.0 52 (202) 84 (41)
<0.7 15 (58) 39 (19)
<0.4 1 (5) 2 (1)
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Table 5 - 1 9
Parameters of Gaussian or log Gaussian d is tr ib u tio n s  of maternal 
serum unconjugated e s tr io l  values in Down’ s syndrome and control 
samples. Kolmorogov-Smirnov (K-S) tes ting  indicates tha t the 
Gaussian d is tr ib u t io n  is the best f i t .  (D = absolute d ifference,  
p = p ro b ab il ity )
Down’ s Controls
(n=49) (n=390)
Gaussian Mean: 0.79 1.00
Standard Deviation: 0.29 0.29
K-S te s t  D: 0.124 0.036
p: 0.44 0.69
Log Gaussian Mean: -0 .102 0.0
Standard Deviation: 0.156 0.130
K-S te s t  D: 0.138 0.057
p: 0.31 0.16
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Figure 5 - 1 7
P robab ility  p lo t of maternal serum unconjugated e s t r io l  (UE3) 
levels , in m ultip les of the median (MOM), on (a) a l in e a r  scale 
and (b) a log scale in selected controls and in Down’ s syndrome 
pregnancies. The continuous lines are those defined by e ith e r  
Gaussian or log Gaussian d is tr ib u tio n s  with means and standard 
deviations as defined in Table 5-19.
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Down’s Controls
0 .5 1.0 1.5 2.0
UE3 (MOM)
Figure 5 - 1 8
Gaussian d is tr ib u t io n s  of maternal serum unconjugated e s tr io l  
(UE3) leve ls , in m ultip les of the median (MOM), in controls and 
Down’ s syndrome pregnancies. These are p lotted  from the means and 
standard deviations of 390 unaffected and 49 Down’ s syndrome 
pregnancies as given in Table 5-19.
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5 .2 .1 .3 .3  UE3 LEVELS IN OTHER CHROMOSOME ABNORMALITIES
The levels of UE3, in MOM, found in maternal serum from the other 
types of chromosomally abnormal pregnancies are shown on Figure 
5-19 and th e ir  median values in Table 5-20. Differences between 
the d is tr ibu tio ns  of the UE3 levels in the control samples and the 
d if fe re n t  types of chromosome abnormality were assessed by the 
Kolmogorov-Smirnov te s t  (Table 5-20). A s ig n if ic a n t  reduction in 
UE3 levels was found in four trisomy 18 pregnancies ( p<0.0 1 ) ,  a l l  
values being below 0.7 MOM, with a median value of 0.38 MOM. Some 
lowering of UE3 levels  was found in the eight cases of unbalanced 
translocation ( 0 . 05>p>0.01) but there was no s ig n if ic a n t  
difference between the controls and the other types of chromosome 
abnormality.
5 .2 .1 .4  FREE 8 SUBUNIT OF hCG
5 .2 .1 .4 .1  FrB-hCG LEVELS IN UNAFFECTED PREGNANCIES
Fr|3-hCG was assayed as described in Section 4 .1 .6 .1  in 390 control 
samples taken between 15 and 20 weeks of gestation. There were 11 
samples at 15 weeks gestation, 184 at 16 weeks, 136 at 17 weeks, 
39 at 18 weeks, 10 at 19 weeks and 10 at 20 weeks. Maternal serum 
Fr|3-hCG levels declined s l ig h t ly  between 15 and 20 weeks 
gestation. Median values, calculated by l in e a r  in te rp o la tio n , were
6.5 IU/1 at 15 weeks, 6.1 IU/1 at 16 and 17 weeks, 5 .4  IU/1 at 18 
weeks, 4.8 IU/1 at 19 weeks and 4.3 IU/1 at 20 weeks.
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Figure 5 - 1 9
Maternal serum unconjugated e s t r io l  (UE3) leve ls , in m ultip les of 
the median (MOM), in 78 chromosomally abnormal pregnancies 
compared with the levels  in 390 unaffected controls.
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Table 5 - 2 0
Maternal serum unconjugated e s tr io l  (UE3) median values, in 
m ultiples of the median (MOM), and s ignificance tes ting  by the 
Kolmorogov-Smirnov (K-S) te s t  of the d is tr ib u tio n s  of UE3 levels  
fo r  trisomy 18, trisomy 13, unbalanced translocations, balanced 
translocations and sex chromosome abnormalities, against the 
control group.
n UE3
Median
(MOM)
K-S
D
tes t
P
Trisomy 18 4 0.38 0.864 0.005
Trisomy 13 4 0.83 0.380 >0.1
Unbalanced trans. 8 0.66 0.489 0.043
Balanced trans. 4 0.71 0.569 >0.1
Sex chrom. abn. 9 0.77 0.347 >0.1
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5 .2 .1 .4 .2  FrB-hCG LEVELS IN DOWN’ S SYNDROME
The levels of FrB-hCG, in MOM, in maternal serum from 81 cases of 
Down’ s syndrome, p lotted at the appropriate completed week of 
gestation, are shown in Figure 5-20. The numbers and percentages 
of Down’ s syndrome cases and controls with FrB-hCG levels  greater  
than or equal to  selected c u t -o f f  levels  are shown in Table 5-21, 
with, fo r  example 48 out of 81 of the Down’ s syndrome pregnancies 
(60.5%) having FrB-hCG levels  greater than 2.0 MOM, compared with  
63 out of 390 of the controls (16.2%). The median value of the 
Down’ s syndrome cases were found to be s ig n if ic a n t ly  elevated at 
2.30 MOM (95% CL 1.92 to 2.75 MOM) of the controls (p<0.001 by 
t - t e s t  on unpaired va r iab les ) .  A p robab il ity  p lot (Figure 5-21) 
shows that the d is tr ib u t io n  of the FrB-hCG values in the controls  
above 0.3 MOM and in the Down’ s syndrome samples above 0.7 MOM f i t  
log Gaussian d is tr ib u tio n s  (Figure 5-22). The in tersection  point 
of the two curves is 1.60 MOM. Means and standard deviations of 
the controls and Down’ s syndrome FrB-hCG d is tr ib u t io n s  were 
estimated as described in Section 4 .2 .3 .1  and are shown in Table 
5-22.
5 .2 .1 .4 .3  FrB-hCG LEVELS IN OTHER CHROMOSOME ABNORMALITIES
The levels of FrB-hCG, in MOM, in sera from the other 
chromosomally abnormal pregnancies are shown in Figure 5-23. 
Medians fo r the 11 cases of trisomy 18, four cases of trisomy 13, 
10 unbalanced translocations, four balanced translocations and a 
heterogeneous group of nine sex chromosome abnormalities are shown
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Figure 5 - 2 0
Maternal serum free  |3 subunit hCG (Fr3-hCG) leve ls , in m ultip les  
of the median (MOM) in 81 Down’ s syndrome pregnancies compared 
with the levels  in 390 unaffected controls.
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Table 5 - 2 1
Proportion of control, Down’ s syndrome and trisomy 18 samples with  
maternal serum free |3 subunit hCG (Fr|3-hCG) leve ls , in m ultiples  
of the median (MOM), greater than or equal to selected c u t -o f f  
values.
Frl3-hCG Controls Down’ s Trisomy 18
(MOM) (n= 390) (n= 81) (n= 11)
% (n) % (n) % (n)
>3.0 5.6 (22) 34.6 (28) 0 (0)
>2.5 9.5 (37) 44.4 (36) 0 (0)
>2.0 16.2 (63) 60.5 (49) 0 (0)
>1.5 26.7 (104) 72.8 (59) 0 (0)
>1.0 49.7 (194) 82.7 (67) 0 (0)
>0.5 83.8 (327) 100 (81) 18.2 (2)
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Figure 5 - 2 1
P rob ab ility  p lo t of maternal serum free  (3 subunit hCG (Fr|3-hCG), 
in m ultip les of the median (MOM), on a log scale, in selected  
controls, Down’ s syndrome pregnancies and trisomy 18 pregnancies. 
The continuous lines are those defined by log Gaussian 
d is tr ib u tio n s  with means and standard deviations as given in Table 
5-22.
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Figure 5 - 2 2
Log Gaussian d is tr ib u t io n s  of maternal serum free  3 subunit hCG 
(Fr0-hCG) leve ls , in m ultip les  of the median (MOM), in controls, 
Down’ s syndrome pregnancies and trisomy 18 pregnancies. These are 
plo tted  from the means and standard deviations of 390 unaffected, 
81 Down’ s syndrome and 11 Trisomy 18 pregnancies as given in Table 
5-22.
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Table 5 - 2 2
Maternal serum free 13 subunit hCG (Fr|3-hCG) medians, in multiples  
of the median (MOM), and means and standard deviations (SD) of the 
logio d is tr ib u tio n  fo r controls, Down’ s syndrome pregnancies and 
trisomy 18 pregnancies.
n Median
(MOM)
Mean SD
Controls 390 0.98 -0.009 0.311
Down’ s 81 2.30 0.362 0.355
Trisomy 18 11 0.23 -0.638 0.314
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Figure 5 - 2 3
Maternal f ree  |3 subunit hCG (Frl3-hCG) leve ls , in m ultip les of the 
median (MOM), in 119 chromosomally abnormal pregnancies compared 
with the levels  in 390 controls.
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in Table 5-23. Differences between the d is tr ib u tio n s  of Fr0-hCG 
levels  in the controls samples and these various types of 
chromosome abnormality were assessed using the Kolmogorov-Smirnov 
te s t  (Table 5-23). There was no s ig n if ic a n t  d ifference between the 
controls and the trisomy 13 pregnancies, the unbalanced 
translocations, the balanced translocation or the sex chromosome 
abnormalities. The 11 trisomy 18 pregnancies show a s ig n if ic a n t  
decrease in Fr|3-hCG leve ls , with a l l  values being below 0.65 MOM, 
with a median value of 0.23 MOM (p<0.001).
Although the numbers are small, the trisomy 18 Frl3-hCG values
appear to f i t  a log Gaussian d is tr ib u t io n  (See p ro b a b il ity  p lo t,  
Figure 5-21). The log Gaussian d is tr ib u t io n  of Fr3-hCG in the 
trisomy 18 samples, with mean and standard deviation as given in 
Table 5-22, appears to have a greater s h i f t  away from the levels  
in the controls than the Down’ s syndrome samples (Figure 5-22).
The proportions of trisomy 18 samples with levels  greater than or
equal to selected c u t -o f f  levels are shown in Table 5-21, with 
only 2 cases out of 11 (18.2%) having a value greater than or 
equal to 0.5 MOM, compared with 327 out of 390 controls (83.8%) 
and a l l  81 Down’ s syndrome samples (100%).
5 .2 .2  CORRELATION BETWEEN ANALYTES
The levels of corre la t ion  between analytes in controls and Down’ s 
syndrome samples were assessed by ca lcu la ting  the product-moment 
corre la tion  c o e ff ic ie n t  ( r ) ,  using the appropriate m ultip les of  
the median (MOM) or logioMOM, depending on whether the data f i t t e d
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Table 5 - 2 3
Maternal serum free  |3 subunit hCg (Fr|3-hCG) median values, in 
multiples of the medain (MOM), and significance tes t ing  by the 
Kolmogorov-Smirnov (K-S) te s t  of the d is tr ib u tio n s  of FrB-hCG 
levels in trisomy 18, trisomy 13, unbalanced translocations,  
balanced translocations and sex chromosome abnormalities against 
the control group. (D = absolute d iffe rence , p = p ro b a b il i ty ) .
n FrB-hCG
Median
(MOM)
K-S
D
te s t
P
Trisomy 18 11 0.23 0.7483 <0.001
Trisomy 13 4 0.71 0.4279 >0.2
Unbalanced trans. 10 0.61 0.3363 >0.2
Balanced Trans. 4 2.02 0.6769 0.051
Sex chrom abn. 9 0.80 0.2360 >0.2
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a Gaussian or log Gaussian d is tr ib u t io n .  The values of r fo r  
controls and Down’ s syndrome samples fo r  combination of analytes  
and also maternal age are shown in Table 5-24.
Highly s ig n if ic a n t  corre lations ( p<0.01) were found in both the 
Down’ s syndrome and control samples between UE3 and AFP, between 
SPi and hCG, between SPi and FrB-hCG and between hCG and FrB-hCG, 
and, in the control samples only, between SPi and UE3.
Lower levels of corre la tion  (0.05>p>0.01) were found in the 
control samples only between hCG and AFP, between UE3 and hCG and 
between UE3 and FrB-hCG.
No s ig n if ic a n t  corre lation  was found between AFP and FrB-hCG and 
between AFP and SPi nor between any of the analytes and maternal 
age.
5 .2 .3  SUMMARY OF ANALYTE RESULTS
In Down’ s syndrome a l l  f iv e  markers studied, AFP, hCG, SPi, UE3 
and FrB-hCG show a s h i f t  in mean value away from tha t  of the 
control d is tr ib u t io n ,  AFP and UE3 having reduced levels  and hCG, 
SPi and FrB-hCG having increased levels . The comparative s h if ts  of 
the Down’ s syndrome mean away from the control group mean, 
measured in standard deviations, are shown in Table 5-25. The 
re la t iv e  s h i f ts  are hCG > FrB-hCG > AFP > UE3 > SPi.
Trisomy 18 pregnancies show lowered median levels fo r  a l l  f iv e
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Table 5 - 2 4
Correlation co e ff ic ien ts  ( r )  fo r  unaffected and Down’ s syndrome 
pregnancies between alphafetoprotein (AFP), unconjugated e s tr io l  
(UE3), free  3 subunit hCG (FrO-hCG), pregnancy spec if ic  3-1 
glycoprotein (SPi) and maternal age.
CORRELATION COEFFICIENT ( r )  -  UNAFFECTED
-  DOWN’ S
UE3 logSPi logHCG logFr3-HCG Age
logAFP 0.25**
0.44**
UE3
logSPi
logHCG
logFr3-hCG
0.10 0.11* 0.07 0.03
0.23 0.12 0.08 0.14
0.19** -0 .1 3 * -0 .14* 0.01
0.22 0.11 0.06 -0 .2 4
0.29** 0.15** 0.07
0 .35** 0.29* 0.06
0.82** -0 .0 3
0.74** -0 .1 0
-0.01
0.02
**  Highly s ig n if ic a n t  corre la t ion  ( p<0.01)
* S ign ifican t corre la t ion  (0 .0 1 <p<0.05)
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Table 5 - 2 5
Summary, fo r  d i f fe re n t  analytes, of the s h i f t  in mean of the
Down’ s syndrome d is tr ib u t io n  away from that of the control
d is tr ib u t io n .  The s h i f t  fo r  each analyte was derived by d iv id ing  
the d ifference between the mean of the control and Down’ s syndrome
d is tr ib u t io n  by the standard deviation (SD) of the control
d is tr ib u t io n .
Analyte S h if t  in mean of 
Down’ s d is tr ib u t io n  
(SD)
SPi 0.47
UE3 0.72
AFP 0.83
Fr|3-hCG 1.19
hCG 1.34
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analytes studied, although fo r  SPi the reduction is not 
s t a t is t i c a l ly  s ig n if ic a n t .  The median values fo r  trisomy 18 
pregnancies are summarised in Table 5-26. The re la t iv e  lowering is 
hCG < Frl3-hCG < UE3 < AFP < SPi.
Of the other types of chromosome abnormality only the unbalanced 
translocations show some lowering of hCG and UE3 levels  and 
s ig n if ic a n t  lowering of SPi leve ls . These unbalanced 
translocations are however a heterogeneous group.
5 .2 .4  USE OF PREGNANCY MARKERS IN SCREENING FOR CHROMOSOME 
ABNORMALITIES
5 .2 .4 .1  USE OF INTACT hCG IN SCREENING FOR CHROMOSOME 
ABNORMALITIES
There is a small level of co rre la t ion  (Table 5-24) between AFP and 
in ta c t  hCG (0 .0 1 <p<0.05) and the corre la t ion  between e ith e r  
analyte and maternal age is not s ig n if ic a n t ly  d i f fe r e n t  from zero 
(p>0 .05). Therefore, the information which can be derived from 
each variab le  with respect to the id e n t i f ic a t io n  of Down’ s 
syndrome pregnancies is v i r tu a l ly  independent and may be used in 
the calcu lation  of a combined r isk  fac to r .  A r isk  fac to r  fo r  an 
indiv idual pregnancy can be calculated using maternal age and 
e ith e r  hCG alone or hCG and AFP combined. Maternal serum hCG 
levels  are more discrim inating than e ith e r  age or AFP levels  alone 
or in combination fo r  the detection of Down’ s syndrome pregnancies 
(Table 5-27). Since raised hCG levels are found only in Down’ s
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Table 5 - 2 6
Summary of median analyte levels in trisomy 18 pregnancies, in 
multiples of the median (MOM).
Analyte Trisomy 18
median
(MOM)
hCG 0.21
FrB-hCG 0.23
UE3 0.38
AFP 0.68
SPi 0.87
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Table 5 - 2 7
Comparison of fa lse  pos itive  rates fo r  human chorionic  
gonadotrophin (hCG), alphafetoprotein (AFP) and maternal age at  
d i f fe re n t  detection rates.
Detection rate  
(%) fo r  Down’ s 
syndrome
False positive  
rate (%)
Threshold
hCG 60 14 >1.8 MOM
30 2.2 >2.8 MOM
AFP 60 28 ^0.8  MOM
30 9.0 <0.6 MOM
Age 60 37 >28 years
30 6.7 >35 years
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syndrome pregnancies and not in other autosomal trisom ies, any 
screening policy which makes use of these elevated hCG levels  w i l l  
detect only the trisomy 21 cases.
5 .2 .4 .2  USING hCG AND AGE TO SCREEN FOR DOWN’ S SYNDROME
Likelihood ratios were calculated from the overlapping Gaussian 
d is tribu tions  of hCG levels in Down’ s syndrome and unaffected 
pregnancies as described in Section 4 .2 .8 ,  using the means and 
standard deviations given in Table 5-13. A combined r isk  of Down’ s 
syndrome for an individual pregnancy, based on hCG and age was 
calculated by m ultip ly ing the l e f t  hand side of the odds ra t io  of 
having a Down’ s syndrome fetus at m id-trim ester (Table 5-3) by the 
l ike lihood ra t io .  Table 5-28 gives combined risks of Down’ s 
syndrome for individual pregnancies between 15-20 weeks gestation. 
Detection and fa lse  positive rates were estimated in the west of 
Scotland pregnant population as described in Section 4 .2 .9 .  Table 
5-29 shows the e f fe c t  of using d i f fe re n t  m id-trim ester r isk  
thresholds on the detection and fa lse  positive rates, with fo r  
example, a predicted detection rate fo r  Down’ s syndrome of 51% at  
a corresponding 5% fa lse  pos itive  rate  using a m id-trim ester  
c u t-o ff  r isk of 1:310. The var ia t ion  in detection and fa lse  
positive rates between d i f fe re n t  maternal age groups is shown in 
Table 5-30 with, fo r example, in the age group 20-24 years, a 
predicted detection rate fo r  Down’ s syndrome of 29% and a 
corresponding fa ls e  positive  rate of 1.6%, compared with 68% 
detection and a 22% fa lse  positive  rate  in the age group 35-37 
years.
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Table 5 - 2 8
Risk estimates of find ing  a Down’ s syndrome fetus at 
m id-tr im ester, based on maternal age and maternal serum chorionic
gonadotrophin (hCG) at 15-20 weeks gestation (MOM = m ultip les of 
the median).
Mat .
Age
( y r s )
hCG(MOM)
3 . 2  3.1 3 . 0  2 . 9  2 . 8  2 . 7  2 . 6  2 . 5  2 . 4  2 . 3  2 . 2  2 .1  2 . 0
16 1 240 1 270 1 290 1 320 1 350 1 380 1 420 1 460 1 510 1 570 1 630 1 700 1 780
18 1 240 1 260 1 290 1 310 1 340 1 380 1 420 1 460 1 510 1 560 1 620 1 700 1 770
20 1 240 1 260 1 280 1 310 1 340 1 370 1 410 1 450 1 500 1 550 1 610 1 680 1 760
22 1 230 1 250 1 270 1 300 1 330 1 360 1 400 1 440 1 480 1 530 1 590 1 660 1 740
24 1 220 1 240 1 260 1 280 1 310 1 340 1 380 1 410 1 460 1 510 1 560 1 630 1 700
26 1 200 1 220 1 240 1 260 1 280 1 310 1 340 1 380 1 420 1 460 1 510 1 570 1 640
27 1 190 1 210 1 230 1 250 1 280 1 300 1 330 1 370 1 400 1 450 1 500 1 560 1 620
28 1 170 1 190 1 210 1 230 1 250 1 270 1 300 1 330 1 260 1 400 1 450 1 500 1 560
29 1 160 1 170 1 190 1 210 1 220 1 250 1 270 1 300 1 330 1 370 1 410 1 450 1 570
30 1 140 1 150 1 170 1 180 1 200 1 220 1 240 1 270 1 300 1 330 1 360 1 410 1 450
31 1 120 1 130 1 150 1 160 1 180 1 190 1 210 1 240 1 260 1 290 1 320 1 360 1 400
32 1 110 1 120 1 130 1 140 1 150 1 170 1 180 1 200 1 200 1 250 1 270 1 310 1 340
33 1 89 1 100 1 110 1 120 1 130 1 140 1 150 1 170 1 190 1 210 1 230 1 260 1 290
34 1 73 1 80 1 87 1 95 1 100 1 120 1 130 1 140 1 150 1 170 1 190 1 210 1 240
35 1 59 1 65 1 71 1 77 1 85 1 93 1 100 1 110 1 120 1 140 1 150 1 170 1 190
36 1 48 1 52 1 57 1 62 1 68 1 75 1 82 1 91 1 100 1 110 1 120 1 140 1 150
37 1 38 1 41 1 45 1 49 1 54 1 59 1 65 1 72 1 79 1 87 1 97 1 110 1 120
38 1 29 1 32 1 35 1 38 1 42 1 46 1 51 1 56 1 61 1 68 1 76 1 84 1 94
39 1 23 1 25 1 27 1 29 1 32 1 36 1 39 1 43 1 48 1 53 1 59 1 65 1 73
40 1 17 1 19 1 21 1 23 1 25 1 27 1 30 1 33 1 37 1 41 1 45 1 50 1 56
41 1 13 1 14 1 16 1 17 1 19 1 21 1 23 1 25 1 28 1 31 1 34 1 38 1 42
42 1 10 1 11 1 12 1 13 1 14 1 16 1 17 1 19 1 21 1 23 1 26 1 29 1 32
43 1 7 1 8 1 9 1 10 1 11 1 12 1 13 1 14 1 16 1 18 1 20 1 22 1 24
44 1 6 1 6 1 7 1 8 1 8 1 9 1 10 1 11 1 12 1 14 1 15 1 17 1 19
45 1 4 1 5 1 5 1 6 1 6 1 7 1 7 1 8 1 9 1 10 1 11 1 12 1 14
Mat .
k no hCG(MOM)Age
( y r s ) 1 . 9  1 .8  1 . 7  1 .6  1 .5 1 .4  1 .3  1 . 2  1.1 1 0 0 . 8  0 . 6  0 . 4
16 1 880 1 980 1 1100 1 1300 1 1400 1 1600 1 1900 1 2100 1 2500 1 2800 1 3800 1 5200 1 7000
18 1 870 1 970 1 1100 1 1200 1 1400 1 1600 1 1800 1 2100 1 2400 1 2800 1 3800 1 5200 1 6900
20 1 850 1 950 1 1100 1 1200 1 1400 1 1600 1 1800 1 2100 1 2400 1 2700 1 3700 1 5100 1 6800
22 1 830 1 930 1 1000 1 1200 1 1300 1 1500 1 1700 1 2000 1 2300 1 2600 1 3600 1 4900 1 6600
24 1 790 1 880 1 990 1 1100 1 1300 1 1500 1 1700 1 1900 1 2200 1 2500 1 3400 1 4700 1 6200
26 1 720 1 800 1 910 1 1000 1 1200 1 1300 1 1500 1 1700 1 2000 1 2300 1 3100 1 4300 1 5700
27 1 700 1 780 1 880 1 1000 1 1100 1 1300 1 1500 1 1700 1 2000 1 2200 1 3000 1 4200 1 5500
28 1 630 1 700 1 790 1 900 1 1000 1 1200 1 1300 1 1500 1 1800 1 2000 1 2700 1 3700 1 5000
29 1 570 1 640 1 720 1 810 1 930 1 1100 1 1200 1 1400 1 1600 1 1800 1 2500 1 3400 1 4500
30 1 510 1 570 1 640 1 730 1 830 1 940 1 1100 1 1200 1 1400 1 1600 1 2200 1 3000 1 4000
31 1 450 1 500 1 560 1 640 1 720 1 830 1 940 1 1100 1 1200 1 1400 1 1900 1 2700 1 3500
32 1 380 1 430 1 480 1 550 1 620 1 710 1 800 1 930 1 1100 1 1200 1 1700 1 2300 1 3000
33 1 320 1 360 1 410 1 460 1 510 1 600 1 680 1 780 1 900 1 1000 1 1400 1 1900 1 2600
34 1 270 1 300 1 340 1 380 1 430 1 490 1 560 1 640 1 740 1 840 1 1100 1 1600 1 2100
35 1 210 1 240 1 270 1 310 1 350 1 400 1 450 1 520 1 600 1 680 1 930 1 1300 1 1700
36 1 170 1 190 1 220 1 250 1 280 1 320 1 360 1 420 1 480 1 550 1 750 1 1000 1 1400
37 1 140 1 150 1 170 1 190 1 220 1 250 1 290 1 330 1 380 1 430 1 590 1 810 1 1100
38 1 110 1 120 1 130 1 150 1 170 1 200 1 220 1 260 1 300 1 340 1 460 1 540 1 840
39 1 82 1 91 1 100 1 120 1 130 1 150 1 170 1 200 1 230 1 260 1 350 1 490 1 620
40 1 63 1 70 1 80 1 90 1 100 1 120 1 130 1 150 1 180 1 200 1 270 1 380 1 500
41 1 48 1 53 1 60 1 68 1 77 1 88 1 100 1 120 1 130 1 150 1 210 1 280 1 380
42 1 36 1 41 1 46 1 52 1 59 1 68 1 76 1 88 1 100 1 120 1 160 1 220 1 290
43 1 27 1 30 1 35 1 39 1 44 1 51 1 57 1 66 1 76 1 87 1 120 1 160 1 220
44 1 21 1 23 1 27 1 30 1 34 1 39 1 44 1 51 1 59 1 67 1 91 1 130 1 170
45 1 15 1 17 1 19 1 22 1 25 1 29 1 32 1 37 1 43 1 49 1 67 1 92 1 120
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Table 5 - 2 9
Comparison of detection rates fo r Down’ s syndrome 
corresponding fa lse  positive rates at varying m id-trim ester  
thresholds in the west of Scotland pregnant population 
hCG/age screening.
C ut-o ff
r isk
Detection rate  
fo r  Down’ s 
syndrome (%)
False positive  
rate (%)
1:250 45 3.4
1:280 47 4.2
1:300 50 4.7
1:310 51 5.0
1:350 54 5.9
and
risk
using
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Table 5 -30
Detection rates fo r  Down’ s syndrome and corresponding fa lse  
positive rates in d i f fe re n t  maternal age groups using hCG/age and 
a mid-trimester c u t -o f f  r isk  of 1:310.
Age group Detection rate  
( * )
False positive  rate  
(X)
<20 29 1.2
20-24 29 1.6
25-29 35 2.6
30-34 51 6.2
35-37 68 22
38-40 85 54
>40 99 94
Overal1 51 5.0
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5 .2 .4 .3  USING hCG, AFP AND AGE TO SCREEN FOR DOWN’ S SYNDROME
Three possible methods of ca lcu la ting  a combined r isk  fac to r ,  
taking into account maternal age, and serum AFP and hCG levels  
are described below, and the e ffe c ts  on detection rates and
corresponding fa lse  positive rates compared.
5 .2 .4 .3 .1  COMBINING SEPARATE RISKS DERIVED FROM AFP AND hCG 
LEVELS
The risk ( l ike liho od  ra t io )  tha t a spec if ic  hCG or AFP resu lt  is 
associated with a Down’ s syndrome pregnancy can be calculated from 
the overlapping log Gaussian d is tr ibu tio ns  as described in 
Section 4 .2 .8 .  Likelihood ra tios  fo r  hCG were calculated using the 
means and standard deviations fo r  Down’ s syndrome and control 
pregnancies given in Table 5-13 and fo r  AFP those in Table 5-2. A 
combined risk fac to r  fo r  hCG and AFP can be derived simply by
m ultip ly ing together the individual l ike lihood ra t io s ,  but th is  
ignores the small corre la t ion  between the two variab les. Table 
5-31 shows a matrix of like lihood ra tios  calculated by th is  method 
fo r  a range of hCG and AFP leve ls , and an individual woman’ s r isk
can be calculated by incorporating the appropriate population
Down’ s syndrome r isk  from Table 5-3. The overa ll r isk  of having a 
Down’ s syndrome fetus at screening between 15-20 weeks can be 
calculated by m ultip ly ing the l e f t  hand side of the maternal age 
specific  r isk by the combined l ike lihood ra t io .
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Table 5 - 3 1
Combined like lihood ra tios  fo r  Down’ s syndrome fo r  AFP and hCG, 
ignoring the corre la t ion  between variab les.
AFP
(KOH)
0 . 3 0 . 4 0 . 5 0 . 6 0 . 7 0 . 8
hCG(HOH)
0 . 9  1 .0  1.1 1 .2 1 .3 1 .4 1 .5 1 .6 1.7 1.8
0 . 35 1. 06 1.13 1.31 1.50 1.75 2 . 07 2 . 38 2 . 82 3 . 19 3 . 69 4 . 26 4 . 8 2 5.51 6 . 26 7 . 07 8.01
0 . 40 0 . 8 2 0 . 87 1.02 1.16 1. 36 1.60 1 .84 2 . 18 2 . 45 2 . 86 3 . 29 3 . 73 4 . 2 6 4 . 8 4 5 . 47 6 . 20
0 . 45 0 . 6 5 0 . 69 0. 81 0 . 92 1. 08 1. 27 1.46 1.73 1.96 2 . 27 2.61 2 . 96 3 . 38 3 . 84 4 . 3 4 4 . 92
0 . 50 0 . 5 3 0 . 56 0 . 6 5 0 . 7 4 0 . 8 7 1.02 1.18 1.40 1.58 1.83 2.11 2 . 39 2 . 73 3 . 10 3 . 50 3 . 97
0 . 55 0 . 4 3 0 . 46 0 . 5 4 0.61 0 .71 0 . 8 4 0 . 9 7 1.15 1.30 1.50 1.73 1.96 2 . 2 4 2 . 55 2 . 88 3 . 26
0 . 60 0 . 3 6 0.38 0 . 4 5 0.51 0 . 6 0 0 . 7 0 0.81 0 . 9 6 1. 09 1.26 1.45 1.64 1.87 2 . 13 2.41 2 . 73
0 . 65 0.31 0 . 32 0 . 3 8 0 . 4 3 0 . 5 0 0 . 5 9 0 . 6 8 0.81 0 . 9 2 1.06 1.22 1 .39 1.58 1.80 2 . 03 2 . 30
0 . 70 0 . 2 6 0 . 28 0 . 3 2 0 . 37 0 . 4 3 0.51 0 . 5 9 0 . 6 9 0 . 7 9 0.91 1.05 1 .19 1.36 1.54 1.74 1.97
0 . 75 0 . 2 2 0 . 24 0 . 2 8 0 . 3 2 0 . 3 7 0 . 4 4 0 . 5 0 0 . 5 9 0 . 6 7 0 . 78 0 . 90 1.02 1.16 1.32 1.49 1 . 69
0 . 8 0 0 . 2 0 0.21 0 . 2 4 0 . 2 8 0 . 3 2 0 . 3 8 0 . 4 4 0 . 52 0 . 5 9 0 . 68 0 . 78 0 . 8 9 1.01 1.15 1.30 1.47
0 . 8 5 0 . 17 0 . 18 0.21 0 . 2 4 0 . 2 8 0 . 3 3 0 . 3 8 0 . 4 5 0 . 52 0 . 60 0 . 6 9 0 . 78 0 . 8 9 1.01 1.14 1.29
0 . 90 0 . 1 5 0 . 16 0 . 1 9 0.21 0 . 2 5 0 . 2 9 0 . 3 4 0 . 4 0 0 . 45 0 . 53 0. 61 0 . 6 9 0 . 7 8 0 . 89 1.01 1 . 14
0 . 95 0 . 1 3 0 . 1 4 0 . 1 6 0 . 19 0 . 2 2 0 . 2 6 0 . 3 0 0 . 3 5 0 . 4 0 0 . 46 0 . 53 0 . 6 0 0 . 6 9 0 . 7 8 0 . 88 1.00
1.00 0 . 1 2 0 . 13 0 . 1 5 0 . 1 7 0 . 2 0 0 . 2 3 0 . 27 0 . 3 2 0 . 3 6 0. 41 0 . 4 8 0 . 5 4 0 . 6 2 0 . 70 0 . 79 0 . 9 0
1.10 0 . 1 0 0 . 10 0 . 1 2 0 . 13 0 . 1 6 0 . 1 8 0.21 0 . 2 5 0 . 2 9 0 . 3 3 0 . 38 0 . 4 3 0 . 4 9 0 . 5 6 0 . 6 3 0 . 72
1. 20 0 . 0 8 0 . 08 0 . 1 0 0.11 0 . 1 3 0 . 1 5 0 . 17 0.21 0 . 2 3 0 . 27 0.31 0 . 35 0 . 4 0 0 . 4 6 0 . 5 2 0 . 5 9
1. 30 0 . 0 6 0 . 07 0 . 08 0 . 09 0.11 0 . 13 0 . 1 4 0 . 17 0 . 1 9 0 . 22 0 . 26 0 . 2 9 0 . 33 0 . 38 0 . 43 0 . 49
1. 40 0 . 0 5 0 . 06 0 . 07 0 . 08 0 . 0 9 0. 11 0 . 1 2 0 . 1 4 0 . 16 0 . 19 0 . 22 0 . 2 5 0 . 2 8 0 . 3 2 0 . 36 0.41
1. 50 0 . 0 5 0 . 05 0 . 0 6 0 . 0 6 0 . 0 8 0 . 0 9 0 . 1 0 0 . 12 0 . 14 0 . 16 0 . 18 0 . 21 0 . 2 4 0 . 27 0.31 0 . 3 5
1. 60 0 . 0 4 0 . 04 0 . 0 5 0 . 0 6 0 . 0 6 0 . 0 8 0 . 0 9 0 . 10 0 . 12 0 . 14 0 . 16 0 . 1 8 0 . 2 0 0 . 2 3 0 . 26 0 . 29
1. 70 0 . 0 3 0 . 04 0 . 0 4 0 . 0 5 0 . 0 6 0 . 0 7 0 . 0 8 0 . 09 0 . 10 0 . 12 0 . 14 0 . 1 5 0 . 1 8 0 . 2 0 0 . 23 0 . 26
1. 80 0 . 0 3 0 . 03 0 . 04 0 . 0 4 0 . 0 5 0 . 0 6 0 . 0 6 0 . 08 0 . 09 0 . 1 0 0 . 12 0 . 1 3 0 . 15 0 . 17 0 . 19 0 . 22
1.90 0 . 0 3 0 . 03 0 . 0 3 0 . 0 4 0 . 0 4 0 . 0 5 0 . 0 6 0 . 07 0 . 08 0 . 0 9 0 . 1 0 0 . 1 2 0 . 1 3 0 . 15 0 . 17 0 . 1 9
2 . 0 0 0 . 0 2 0 . 02 0 . 0 3 0 . 0 3 0 . 0 4 0 . 0 4 0 . 0 5 0 . 06 0 . 0 7 0 . 08 0 . 0 9 0 . 1 0 0 . 11 0 . 1 3 0 . 15 0 . 1 7
2 . 20 0 . 0 2 0 . 02 0 . 0 2 0 . 0 2 0 . 0 3 0 . 0 3 0 . 0 4 0 . 0 5 0 . 0 5 0 . 06 0 . 0 7 0 . 0 8 0 . 0 9 0 . 1 0 0.11 0 . 1 3
2 . 50 0.01 0.01 0.01 0 . 0 2 0 . 0 2 0 . 0 2 0 . 0 3 0 . 0 3 0 . 04 0 . 0 4 0 . 0 5 0 . 0 5 0 . 0 6 0 . 07 0 . 08 0 . 0 9
3 . 00 0.01 0.01 0.01 0.01 0.01 0 . 02 0 . 0 2 0 . 02 0 . 03 0 . 03 0 . 0 3 0 . 0 4 0 . 0 4 0 . 0 5 0 . 0 6 0 . 06
AFP
(MOH)
1.9 2 . 0 2.1 2 . 2 2 . 3 2 . 4
hCG(KOH) 
2 . 5  2 . 6 2 . 7 2 . 8 2 . 9 3 . 0 3.1 3 . 2 3 . 5 4 . 0
0 . 3 5 8 . 9 5  10.1 11. 2 12. 5 13. 9 15. 4 17 . 0 18. 7 2 0 . 6 22 . 7 24 . 9 2 7 . 2 29 . 7 3 2 . 4 41 . 6 6 1 . 4
0 . 4 0 6 . 92 7 . 79 8 . 66 9 . 68  10.7 11 . 9 13.1 14.5 15. 9 17.5 19. 2 2 1 . 0 2 2 . 9 25 . 0 32.1 4 7 . 4
0 . 4 5 5 . 49 6. 18 6 . 87 7 . 68 8 . 5 2 9 . 4 5  10 .4 11 .5 12. 6 13. 9 15.2 16. 7 18. 2 19. 9 25 . 5 37 . 7
0 . 50 4 . 4 3 4 . 99 5 . 55 6 . 20 6 . 88 7 . 63 8 . 4 0 9 . 27  10. 2 11.2 12. 3 13. 5 14. 7 16.0 20 . 6 30 . 4
0 . 5 5 3 . 65 4.11 4 . 5 6 5 . 10 5 . 66 6. 27 6.91 7.62 8 . 3 9 9 . 23 10.1 11.1 12.1 13.2 16.9 25 . 0
0 . 6 0 3 . 05 3.43 3.81 4 . 26 4 . 7 3 5 . 2 4 5 . 7 7 6 . 37 7.01 7.71 8 . 4 6 9 . 24 10.1 11. 0 14.1 2 0 . 9
0 . 6 5 2 . 57 2 .90 3 . 22 3. 60 4 . 0 0 4 . 43 4 . 8 8 5 . 38 5 . 92 6 . 52 7 . 15 7.81 8 . 5 3 9.31 12.0 17. 7
0 . 7 0 2 . 20 2 . 48 2 . 76 3 . 08 3 . 42 3 . 79 4 . 1 7 4 . 60 5 . 07 5 . 57 6.11 6 . 68 7 .30 7 . 96  10. 2 15.1
0 . 7 5 1 . 89 2. 13 2 . 36 2 . 64 2 . 93 3 . 25 3 . 58 3 . 95 4 . 34 4 . 78 5 . 24 5 . 72 6 . 26 6 . 82 8 . 7 6  13. 0
0 . 8 0 1 . 64 1.85 2 . 06 2 . 30 2 . 56 2 . 83 3 . 12 3 . 44 3 . 78 4 . 1 6 5 . 57 4 . 9 9 5 . 45 5 . 95 7 . 6 4  11. 3
0 . 8 5 1 . 44 1.63 1.81 2 . 02 2 . 2 4 2 . 48 2 . 7 4 3 . 02 3 . 32 3 . 66 4.01 4 . 3 8 4 . 7 9 5 . 22 6.71 9.91
0 . 9 0 1 .27 1.43 1 .59 1.78 1.98 2 . 19 2.41 2 . 93 2 . 66 3 . 22 3 . 53 3 . 86 4 . 22 4 . 60 5.91 8 . 73
0 . 9 5 1.12 1.26 1.40 1.56 1.73 1.92 2.11 2 . 33 2 . 57 2 . 82 3 .10 3 . 38 3 . 70 4 . 0 3 5 .18 7 . 65
1 .00 1 .00 1.13 1.25 1 .40 1.55 1.72 1.90 2 . 09 2 . 30 2 . 53 2 . 78 3 . 04 3 . 32 3 . 62 4 . 65 6 . 87
1 .10 0 . 80 0 . 90 1 .00 1.12 1 .24 1.38 1 . 52 1.67 1.84 2 . 03 2 . 22 2 . 43 2 . 65 2 . 90 3 . 72 5 . 49
1 .20 0 . 6 6 0 . 74 0 . 8 2 0 . 92 1.02 1.13 1.25 1.38 1.51 1.67 1.83 2 . 00 2 . 18 2 . 38 3 . 05 4.51
1 .30 0 . 5 4 0.61 0 . 6 8 0 . 76 0 . 8 4 0 . 93 1.03 1.14 1 . 25 1.38 1.51 1.65 1.80 1.96 2 . 52 3 . 73
1 .40 0 . 46 0 . 52 0 . 5 7 0 . 64 0.71 0 . 79 0 . 8 7 0 . 96 1.05 1.16 1.27 1.39 1.52 1.65 2 . 12 3 . 14
1 .50 0 . 3 9 0 . 43 0 . 4 8 0 . 54 0 . 6 0 0 . 66 0 . 7 3 0.81 0 . 89 0 . 9 8 1.07 1.17 1.28 1.40 1.79 2 . 65
1 .60 0 . 3 3 0 . 37 0.41 0 . 46 0.51 0 . 57 0 . 6 2 0 . 69 0 . 7 6 0 . 8 3 0.91 1 .00 1.09 1.19 1 .53 2 . 26
1 . 70 0 . 2 9 0 . 32 0 . 3 6 0 . 40 0 . 4 4 0 . 49 0 . 5 4 0 . 60 0 . 66 0 . 72 0 . 79 0 . 87 0 . 9 5 1.03 1 .32 1.96
1 . 80 0 . 2 4 0 . 27 0 . 3 0 0 . 34 0 . 3 8 0 . 42 0 . 4 6 0.51 0 . 56 0 . 62 0 . 67 0 . 74 0.81 0 . 88 1.13 1.67
1 .90 0.21 0 . 24 0 . 2 7 0 . 30 0 . 3 3 0 . 37 0.41 0 . 45 0 . 4 9 0 . 54 0 . 60 0 . 65 0.71 0 . 78 1.00 1.47
2 . 00 0 . 1 9 0.21 0 . 2 3 0 . 26 0 . 2 9 0 . 32 0 . 3 5 0 . 39 0 . 43 0 . 47 0 . 52 0 . 56 0 . 6 2 0 . 67 0 . 86 1.27
2 . 20 0 . 1 4 0 . 16 0 . 1 8 0 . 20 0 . 2 2 0 . 25 0 . 2 7 0 . 30 0 . 33 0 . 36 0 . 4 0 0 . 4 3 0 . 47 0 . 52 0 . 66 0 . 98
2 . 50 0 . 10 0.11 0 . 1 3 0 . 14 0 . 1 6 0 . 17 0 . 1 9 0.21 0 . 23 0 . 25 0 . 28 0 . 30 0 . 3 3 0 . 36 0 . 46 0 . 69
3 . 0 0 0 . 07 0 . 08 0 . 0 9 0 . 10 0 .11 0 . 12 0 . 1 4 0 . 15 0 . 1 6 0 . 18 0 . 20 0 . 22 0 . 2 4 0 . 26 0 . 33 0 . 49
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5 .2 .4 .3 .2  THE EFFECT OF CORRELATION ON THE CALCULATION OF A 
COMBINED AFP/hCG RISK FACTOR
Likelihood ra tios  can be calculated fo r  two variables by a 
combined formula which allows fo r the corre la t ion  between the two, 
as described in Section 4 .2 .8 .  Table 5-32 shows a matrix of  
l ike lihood ra tios  calculated by th is  second method fo r  a range of 
hCG and AFP levels . Overall AFP/hCG/age risks can be calculated as 
described in the preceding section.
5 .2 .4 .3 .3  hCG (MOM)/AFP (MOM) RATIOS
Dividing the hCG level ( in  MOM) by the AFP level ( in  MOM) produces 
a ra t io  which fu rth e r  separates the d is tr ib u tio n s  of Down’ s 
syndrome and control samples (Figure 5-24). The median ra t io  of 
the Down’ s syndrome samples was 2.82 compared with a median ra t io  
of 1.01 fo r the control samples (p<0.001 by t - t e s t  on unpaired 
variab les ) .  Figure 5-25 shows a p robab il ity  p lo t of the hCG/AFP 
ra t io s ,  on a log scale, fo r  the Down’ s syndrome samples and the 
controls. The controls form a s tra ig h t l in e ,  showing tha t they f i t  
a log Gaussian d is tr ib u t io n .  The Down’ s samples show a small 
deviation from the s tra ig h t l in e  at the ends of the d is tr ib u t io n ,  
but applying the Kolmogorov-Smirnov te s t  to these values indicates  
that th is  d is tr ib u t io n  does not deviate s ig n if ic a n t ly  from a log 
Gaussian d is tr ib u t io n  (D=0.0947, p>0.2) although the number of
cases used (49) is small. The means and standard deviations of the 
d is tribu tions  of the ra tios  were estimated as described in Section 
4 .2 .3 .1 .  The log mean and standard deviation of the control ra tios
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Table 5 - 3 2
Combined like lihood ra tios  fo r  Down’ s syndrome fo r  AFP and hCG, 
allowing fo r  the corre la t ion  between variab les.
AFP
(MOM) 0-3 0-4 0-5 0-6 0-7 0-8 0-9
hCG (MOM) 
1-0 l-l 12 13 14 1-5 1-6 1-7 1-8
0-35 1-04 I 22 1-46 1-76 2-12 2-54 3-04 3-61 4-27 5-01 5-85 6-80 7-86 9-04 10-4 118
0-40 0-78 0-90 108 1-30 I 56 1-88 2-24 2-66 3-14 3-69 4-30 5-00 5-77 6-64 7-60 8-67
0-45 0-59 0-69 0-82 0-99 1-19 1-43 1 70 202 239 280 3-26 3-79 4-38 503 5-76 6-57
0 50 0-47 0-54 0-64 0-77 0-93 II I 1-33 1 57 1-86 2-17 2-54 2-94 3-40 3-91 4-47 5-10
0-55 0-37 0-43 0-51 0-62 0-74 0-89 1-06 1-25 1-47 1-73 201 2-34 2-70 3-10 3-54 4-04
0-60 0-30 0-35 0-42 0-50 0-60 0-72 0-85 101 1-19 1-40 1 63 1-88 2-17 2-50 2-86 3-25
0-65 0-25 0-29 0-34 0-41 0-49 0-59 0-70 0-83 0-98 1-14 1-33 1-54 1-78 2-04 2-34 2-66
0-70 0-21 0-24 0-28 0-34 0-41 0-49 0-58 0-69 0-81 0-95 1-20 1-28 1-48 169 1-94 2-21
0-75 0-18 0-20 0-24 0-29 0-34 0-41 0-50 0-58 0-68 0-80 0-93 1-07 1-24 1-42 1-62 1-85
0-80 0-15 0-17 0-20 0-24 0-29 0-35 0-41 0-49 0-58 0-67 0-79 0-91 105 1-20 1-37 1-56
0-85 0-13 0-15 0-17 0-21 0-25 0-30 0-35 0-42 0-49 0-58 0-67 0-78 0-89 103 1-17 1-33
0-90 0-11 0-13 0-15 0-18 0-22 0-26 0-31 0-36 0-42 0-50 0-58 0-67 0-77 0-88 1 01 1-15
0-95 0-10 011 0-13 0-16 0-19 0-22 0-27 0-31 0-37 0-43 0-50 0-58 0-67 0-77 0-87 0-99
I 00 0-08 0-10 0-11 0-14 0-16 0-20 0-23 0-27 0-32 0-38 0-44 0-51 0-58 0-67 0-76 0-87
I to 0-07 008 009 0-11 0-13 0-15 0-18 0-21 0-25 0-29 034 0-39 0-45 0-52 0-59 0-67
120 04)5 006 007 008 0-10 0-12 0-14 0-17 0-20 0-23 0-27 0-31 0-36 0-41 0-46 0-53
I 30 004 005 0-06 007 008 0-10 0-11 0-13 0-16 0-18 0-21 0-25 0-28 0-33 0-37 0-42
1-40 004 0-04 0-05 0-06 007 008 0-09 0-11 0-13 0-15 0-17 0-21 0-23 0-27 0-30 0-34
1-50 003 003 0-04 0-05 0-05 007 008 009 0-11 0-12 0-14 0-17 0-19 0-22 0-25 0-28
1-60 0-02 0-03 0-03 004 005 0-05 0-06 0-08 009 0-10 0-12 0-14 0-16 0-18 0-21 0-24
1-70 0-02 002 003 003 0-04 0-05 005 006 007 009 0-10 0-12 0-13 0-15 0-17 0-20
1-80 0-02 0-02 002 0-02 003 0-04 005 005 006 0-07 009 0-10 0-11 0-13 0-15 0-17
1 90 0-02 002 0-02 0-02 0-03 003 004 0-05 005 0-06 0-07 008 0-10 0-11 0-13 014
2-00 001 0-01 002 0-02 0-02 003 0-03 0-04 005 005 0-06 0-07 0-08 0-10 on 0-12
2-20 0-01 OOI OOI 002 0-02 002 0-03 003 004 0-04 0-05 0-06 006 007 008 0-09
250 0OI 0-01 OOI 0-01 0-01 0-02 002 002 002 003 003 0-04 004 005 0-06 0-06
3-00 0-01 0-01 0-01 OOI 0-01 OOI 0-01 OOI 0-01 0-02 0-02 002 0-02 003 0-03 0-04
AFP
(MOM) 19 2-0 2-1 2-2 2-3 2-4 2-5
hCG(MOM) 
2-6 2-7 2-8 2-9 3-0 3-1 3-2 3-5 4-0
035 13-4 15-1 17-2 19-3 21-7 243 27-1 30-1 33-4 37-0 40-9 45-1 496 545 714 108
0-40 9-86 11-2 12-6 14-2 15-9 17-8 19-8 22-0 24-5 27-1 29-9 32-0 36-3 39-8 52-2 79-3
0-45 7-46 8-44 9-52 10-7 12-0 13-4 15-0 16-6 18-5 20-4 22-6 24-9 274 30-0 39-3 59-8
0-30 5-79 6-55 7-38 8-30 9-30 10-4 11-6 12-9 14-3 15-8 175 19-3 21-2 23-2 304 46-2
0-55 4 58 5-18 5-84 6-57 7-36 8-23 9-17 10-2 11-3 12-5 13-8 15-1 16-7 184 24-0 36-4
0-60 3-69 4-18 4-71 5-29 593 6-62 7-38 8 20 9-09 10-1 111 12-2 13-5 148 19-3 29-3
0-65 3-02 3-42 3-85 4-32 4-84 5-41 6-03 6-70 7-43 8-21 9-07 9-99 11-0 12-1 15-8 23-9
0-70 2-50 2-83 3-19 3-58 4-01 4-48 4-99 5-54 6-14 6-79 7-50 8-26 9-08 9-96 13-0 19-7
0-75 2-10 2-37 2-67 300 3-36 3-75 4-17 4-64 5-14 5-68 6-27 6-91 7-59 8-33 10-9 16-5
0-80 1-77 2-00 2-26 2-53 2-84 3-17 3-53 3-92 4-34 4-80 5-30 5-83 6-41 7-03 9-18 13-9
0-85 1-51 1-71 1-93 2-16 2-42 2-70 3-01 3-40 3-70 4-09 4-51 4-97 5-46 5-99 7-82 II 8
0-90 1-30 1-47 1-66 1-86 2 08 2-32 2-58 2-87 3-18 3-51 3-88 4-27 4-69 5-14 6-71 10-2
0-95 1-13 1-27 1-43 1-61 1-80 2-01 2-24 2-48 2-75 3-04 3-35 3-69 406 4-45 5-80 8-77
1-00 0-98 111 1-25 1-40 1-57 1-75 1-95 2-16 2-40 2-65 2-92 3-21 3-53 3-87 5-05 7-63
1-10 0-76 0-86 0-96 1-08 1-21 1-35 1-50 1-67 1-85 204 2-25 2-48 2-72 2-98 3-89 5-87
1-20 0-60 0-68 0-76 0-85 0-95 1-06 1-18 1-31 1-45 1-61 1-77 1-95 2-14 2-34 3-06 4-61
1-30 0-48 0-54 061 0-68 0-76 0-85 0-95 1-05 1-16 128 142 1-56 1-71 1-87 2-44 3-68
1-40 0-39 0-44 0-49 0-55 0-62 0-69 0-77 0-85 0-94 1-04 1-15 1-26 1-39 1-52 1-98 2-98
1-50 0-32 0-36 0-41 0-46 0-51 0-57 0-63 0-70 0-78 0-86 0-94 1-04 1-14 1-25 162 245
I 60 0-27 0-30 0-34 0-38 0-42 0-47 0-52 0-58 0-64 0-71 0-78 0-86 0-95 1-04 1-35 2-03
1-70 0-22 0-25 0-28 0-32 0-36 0-40 0-44 0-49 0-54 0-60 0-66 0-72 0-79 0-87 1-13 1-70
1-80 0-19 0-21 0-24 0-27 0-30 0-34 0-37 0-41 0-46 0-51 0-56 0-61 0-67 0-74 0-90 1-44
1-90 0-16 0-18 0-21 0-23 0-26 0-29 0-32 0-35 0-39 0-43 0-47 0-52 0-57 0-63 0-82 1-23
2-00 0-14 0-16 0-18 0-20 0-22 0-25 0-27 0-30 0-34 0-37 0-41 0-45 0-49 0-54 0-70 105
2-20 0-11 0-12 0-13 0-15 0-17 0-19 0-21 0-23 0-25 0-28 0-31 0-34 0-37 040 0-53 0-79
2-50 0-07 0-08 009 0-10 0-11 0-13 0-14 0-16 0-17 0-19 0-21 0-23 0-25 0-27 0-36 0-54
3-00 0-04 0-05 0-05 0-06 0-06 0-07 0-08 0-09 0-10 0-11 0-12 0-13 0-14 0-16 0-20 0-30
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Figure 5 - 2 4
Ratios of hCG(M0M)/AFP(M0M) in maternal serum in 49 Down’ s 
syndrome pregnancies compared with the levels  in 410 unaffected  
controls.
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Figure 5 - 2 5
P rob ab ility  p lo t of hCG(M0M)/AFP(M0M) ra t io s ,  on a log scale fo r  
Down’ s syndrome and selected control pregnancies. The continuous 
l ines are those defined by log Gaussian d is tr ib u tio n s  with means 
and standard deviations as given in the te x t  (Section 5 .2 .4 .3 .3 ) .
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are 0.0043 and 0.2714 respectively and fo r  the Down’ s syndrome 
ratios 0.4502 and 0.3046 respectively. The log Gaussian 
d is tr ibu tio ns  of the control and Down’ s samples are shown in 
Figure 5-26. The two curves have an intersection  point at a ra t io  
of 1.72. The observed numbers and proportions of Down’ s syndrome 
and unaffected pregnancies with ratios greater than or equal to  
specif ic  values are shown in Table 5-33 ind icating , fo r  example, 
that 57% detection of Down’ s syndrome pregnancies could be 
achieved using hCG/AFP ra tios  at a 5.9% fa lse  pos it ive  ra te .
The hCG/AFP ra t io  can be treated as a new var iab le  and risks  
calculated from the overlapping log Gaussian d is tr ib u tio n s  of 
these ratios fo r  Down’ s syndrome and unaffected pregnancies as 
described in Section 4 .2 .8 .  The combined r isk  of Down’ s syndrome 
fo r  a given age and hCG/AFP ra t io  is estimated by m ultip ly ing the 
l e f t  hand side of the age spec if ic  r isk  by the like lihood ra t io .  
An individual woman’ s r isk  of having a Down’ s syndrome fetus  
between 15-20 weeks gestation, based on the age and serum AFP and 
hCG levels is shown in Table 5-34.
5 . 2 . 4 . 3 . 4  PREDICTED DETECTION RATES
Table 5-35 shows the predicted detection rates in the west of  
Scotland pregnant population at a 5% fa lse  pos itive  rate fo r  each 
of the three methods described above fo r  deriving risks from AFP, 
hCG and maternal age, and also gives the predicted fa ls e  positive  
rates at a 60% detection rate . The detection rates at a 5% fa lse  
positive rate are s im ila r  fo r  the various methods (56-57%)
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Unaffected
Down’s
syndrome
5.0 10.0 20.02.00.5 1.00.2
hCG(MOM)/AFP(MOM) RATIO
Figure 5 - 2 6
Log Gaussian d is tr ib u t io n s  of hCG(M0M)/AFP(M0M) ra t ios  in Down’ s
syndrome pregnancies and unaffected control pregnancies. These are 
plotted  from the means and standard deviations of 49 Down’ s
syndrome and 410 unaffected pregnancies as given in Section
5 .2 .4 .3 .3 .
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Table 5 -33
Detection rates fo r  Down’ s syndrome and corresponding fa lse  
positive rates at selected hCG/AFP ra tios .
hCG/AFP
ra t io
% (n) of Down’ s 
syndrome 
pregnancies 
>the ra t io  
(n=49)
% (n) of control 
pregnancies 
> the ra t io
(n=410)
>5.0 16 (8) 1.0 (4)
>4.5 20 (10) 1.0 (4)
>4.0 22 (11) 1.5 (6)
>3.5 35 (17) 2.0 (8)
>3.0 45 (22) 3.4 (14)
>2.5 57 (28) 5.9 (24)
>2.0 67 (33) 11 (49)
>1.5 80 (39) 25 (102)
>1.0 88 (43) 51 (209)
>0.5 98 (48) 87 (356)
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Table 5 - 3 4
Risk estimates of f ind ing  a Down’ s syndrome fetus  
m id-trim ester, based on maternal age and hCG/AFP ra t io  at 1f 
weeks gestation.
Maternal
age
(years) 54) 4-5 40
Human chorionic gonadotrophin (MOM)/alpha-fetoproiein (MOM) ratio 
3-5 3-2 3 1 3-0 2-9 2-8 2-7 2-6 2-5 2-4 2-3 2-2 2-1
15 1:75 1100 1:140 1:210 1:260 1:290 1:310 1:360 1:370 1:410 1:450 1:500 1:560 1:620 1:690 1:780
16 1:74 1100 1:140 1:200 1:260 1:280 1:310 1:340 1:370 1:410 1:450 1:500 1:560 1:620 1:690 1:780
17 1:74 1too 1:140 1:200 1:260 1:280 1:310 1:340 1:370 1:410 1:450 1:500 1:560 1:620 1:690 1:77018 1:74 1100 1:140 1:200 1:260 1:280 1:310 1:360 1:370 1:410 1:450 1:500 1:550 1:620 1:690 1:770
19 1:73 1100 1:140 1:200 1:260 1080 1:300 1030 1070 1:400 1:440 1:490 1:550 1:610 1:680 1:760
20 1:73 1100 1:140 1:200 1:250 1:280 1:300 1030 1:360 1:400 1:440 1:490 1:540 1:600 1:670 1:75021 1:71 1100 1:140 1:200 1:250 1:270 1:300 1:330 1:360 1:390 1:430 1:480 1:530 1090 1:660 1:740
22 1:70 195 1:130 1:190 1:250 1:270 1090 1:320 1:350 1:390 1:430 1:470 1:520 1080 1:650 1:730
23 1:69 193 1:130 1:190 1:240 1060 1090 1:310 1:340 1:380 1:420 1:460 1:510 1070 1:640 1:710
24 1:66 190 1:130 1:180 1:230 1050 1080 1000 1:330 1:370 1:400 1:450 1:500 1050 1:620 1:690
25 1:64 187 1:120 1:180 1:220 1:240 1:270 1:290 1020 1050 1:390 1:430 1:480 1030 1:590 1:660
26 1:61 183 1:120 1:170 1:210 1030 1050 1080 1000 1:340 1:370 1:410 1:460 1:500 1070 1:640
27 1:59 180 1:110 1:160 1:210 1030 1050 1:270 1:300 1:330 1:360 1:400 1:440 1:490 1:550 1:610
28 1:53 172 1:100 1:150 1:190 tooo 1020 1040 1070 1090 1:320 1:360 1:400 1:440 1:490 1:550
29 1:48 165 1:91 1:130 1:170 1:180 1000 1020 1040 1070 1090 1:320 1060 1:400 1:450 1:500
30 1:43 158 1:82 1:120 1:150 1:160 1:180 1000 1:220 1:240 1:260 1090 1:320 1060 1:400 1:450
31 1:38 151 1:72 1:100 1:130 1:140 1:160 1:170 1:190 1010 1:230 1050 1:280 1010 1:350 1:390
32 1:32 144 1:61 1:89 1:110 1:120 1:130 1:150 1:160 1:180 1:200 1:220 1:240 1070 1:300 1:340
33 1:27 I 37 1:52 1:75 1:95 1:100 1:110 1:120 1:160 1:150 1:170 1:180 1000 1030 1:250 1080
34 1:22 130 1:43 1:62 1:79 1:86 1:94 1:100 1:110 1:120 1:140 1:150 1:170 1:190 1010 1:230
35 1:18 125 1:34 1:50 1:64 1:69 1:76 1:83 1:91 1:100 1:110 1:120 1:140 1:150 1:170 1:190
36 1:15 120 1:28 1:40 1:51 1:56 1:61 1:66 1:73 1:80 1:88 1:100 1:110 1:120 1:140 1:150
37 1:11 116 1:22 1:32 1:40 1:44 1:48 1:52 1:58 1:63 1:70 1:77 1:86 1:100 1:110 1:120
38 Li 12 1:17 1:25 1:31 1:34 1:37 1:41 1:45 1:49 1:54 1:60 1:67 1:74 1:83 1:9339 ” 1 1:13 1:19 1:24 1:26 1:29 1:32 1:35 1:38 1:42 1:47 1:52 108 1:64 1:7240 11:10 1:15 1:19 1:20 102 104 107 109 102 1:36 1:40 1:44 1:49 1:56
41 1:11 1:14 1:15 1:17 1:18 100 1:22 104 107 1:30 1:33 1:37 1:42
42 >1:10 " i 1:11 1:12 1:13 1:14 1:15 1:17 1:19 1:21 103 106 1:29 1:3243 " 11:10 1:11 1:12 1:13 1:14 1:16 1:17 1:19 lOI 10444 | 1:10 1:11 1:12 1:13 1:15 1:16 1:19
45 1:11 1:12 1:14
Maternal
age
(years) 20 1-9 1-8
Human chorionic gonadotrophin (MOM)/alpha-retoprotein (MOM) ratio 
1-7 1-6 1-5 1-4 1 3 1-2 1 1 1-0 0-9 0-8 0-7 0-6 0-5
15 1:880 1:990 1:1100 1:1300 1:1500 1:1800 1:2000 1:2400 10900 1:3400
16 1:880 1:990 1:1100 1:1300 1:1500 1:1700 1:2000 1:2400 10900 1:3400
17 1:880 1:990 1:1100 1:1300 1:1500 1:1700 1:2000 1:2400 10800 1:3400
18 1:870 1:980 1:1100 1:1300 1:1500 1:1700 1:2000 1:2300 10800 1:3400
19 1:860 1:970 1:1100 1:1300 1:1500 1:1700 1:2000 10300 10800 10300
20 1:850 1:960 1:1100 1:1300 1:1500 1:1700 1:2000 10300 10800 10300 <1:4000
21 1:840 1:950 1:1100 1:1200 1:1400 1:1700 1:1900 10300 10700 10300 1:4000
22 1:820 1:930 1:1100 1:1200 1:1400 1:1600 1:1900 10200 10700 1:3200 1:4000
23 1:810 1:910 1:1000 1:1200 1:1400 1:1600 1:1900 10200 10600 1:3100 10900
24 1:790 1:880 1:1000 1:1200 1:1300 1:1500 1:1800 10100 10600 10000 10700
25 1:760 1:850 1:970 1:1100 1:1300 1:1500 1:1700 10000 10500 10900 1:3600
26 1:720 1:810 1:930 1:1100 1:1300 1:1400 1:1700 1:1900 10300 10800 1:3400
27 1:700 1:780 1:900 1:1000 1:1200 1:1400 1:1600 1:1900 10300 10700 10300
28 1:630 1:700 1:810 1:920 1:1100 1:1200 1:1400 1:1700 10000 10400 1:3000 1:3800
29 1:570 1:640 1:730 1:840 1:970 1:1100 1:1300 1:1500 1:1900 10200 10700 10400
30 1:510 1:570 1:650 1:750 1:870 1:1000 1:1200 1:1400 1:1700 IOOOO10400 10000 10800
31 1:450 1:500 1:570 1:660 1:760 1:870 1:1000 1:1200 1:1400 1:1700 10100 10700 1:3400
32 1:380 1:430 1:490 1:560 1:650 1:750 1:880 1:1000 1:1200 1:1500 1:1800 10300 1:2900 10600
33 1:320 1:360 1:410 1:470 1:550 1:630 1:740 1:870 1:1000 1:1200 1:1500 1:1900 10400 10100
34 1:270 1:300 1:340 1:390 1:450 1:520 1:610 1:720 1:860 1:1000 1:1300 1:1600 IOOOO10500 10400
35 1:210 1:260 1:280 1:320 1:370 1:420 1:500 1:580 1:700 1:830 1:1000 1:1300 1:1600 IOOOO10800 10800
36 1:170 1:190 1:220 1:250 1:290 1:340 1:400 1:460 1:560 1:660 1:820 1:1000 1:1300 1:1600 10200 1:3100
37 1:140 1:150 1:170 1:200 1:230 1:270 1:310 1:370 1:440 1:520 1:650 1:800 1:1000 1:1300 1:1800 10400
38 1:110 1:120 1:140 1:160 1:180 1:210 1:240 1080 1:340 1:410 1:500 1:630 1:790 1:1000 1:1400 1:1900
39 1:82 1:92 1:110 1:120 1:140 1:160 1:190 1020 1070 1020 1090 1:490 1:620 1:780 1:1100 1:1500
40 1:63 1:71 1:81 1:93 1:110 1:123 1:150 1:170 1-000 1040 1000 1080 1:480 1:600 1:820 1:1100
41 1:48 1:54 1:61 1:70 1:81 1.-93 1:110 1:130 1:150 1:180 1030 1:280 1060 1:450 1:620 1:900
42 1:36 1:41 1:47 1:54 1:62 1:71 1:84 1:100 1:120 1:140 1:170 1020 1:270 1050 1:470 1:650
43 1:27 1:31 1:35 1:40 1:46 1:53 1:63 1:74 1:89 1:110 1:130 1:160 1010 1060 1050 1:490
44 1:21 1:24 1:27 1:31 106 1:41 1:48 1:57 1:68 101 1:100 1:130 1:160 tooo 1:270 1080
45 1:15 1:17 1:20 1:23 1:26 1:30 1:35 1:42 1:50 1:59 1:73 1:110 1:120 1:150 tooo 1080
at
-2 0
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Table 5 - 3 5
Detection rates fo r  Down’ s syndrome and corresponding fa lse  
positive rates predicted by combining maternal age risks with  
those derived from AFP and hCG levels.
Calculation 5% fa lse positive 60% detection rate
method rate
Detn Cut-off False C ut-o ff
rate risk positive r isk
( * ) rate (%)
(1)
Combined AFP and 57 1:290 6.1 1:340
hCG like lihood
ratios
(ignoring
corre la t ion )
( 2 )
Combined AFP and 56 1:265 6.2 1:320
hCG like lihood  
ra tios  
(including  
corre la tion )
(3)
hCG/AFP ra tios  57 1:235 5.9 1:280
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although a d i f fe re n t  risk threshold is required fo r  each method to  
achieve the 5% follow-up rate . The fa lse  pos it ive  rates and 
corresponding detection rates vary fo r  d i f fe re n t  maternal age 
groups (Table 5-36) although the differences between the methods 
used are small. For example, a detection rate o f 36-39% at a fa lse  
positive rate of 2.2-2.7% in the age group 20-24 years, compares 
with a detection rate of 72-75% at a fa lse  positive  rate of 15-19% 
in the 35-37 years age group.
Using hCG/AFP/age screening increases the overa ll odds of finding  
an affected pregnancy in the high r isk  group (Table 5-37) compared 
with AFP/age screening or maternal age screening (Table 5 -8 ) .  The 
overall odds of finding an affected pregnancy in the high risk  
group ( r is k  >1:235) are 1:60 and are reduced to 1:1,500 in the low 
r isk  group ( r is k  <1:235). The overa ll odds of f ind ing an affected  
pregnancy also vary with d i f fe re n t  maternal ages. For example in 
the age group 25-34 the overa ll odds of find ing an affected  
pregnancy i f  in the high r isk  group are 1:70, but reduced to  
1:1,500 i f  in the low risk group.
5 .2 .4 .4  USING hCG IN SCREENING FOR OTHER CHROMOSOME ABNORMALITIES
In prospective practice the use of elevated hCG results  w i l l  not 
detect trisomies 18 and 13 and the unbalanced translocations, and 
d if fe re n t  selection c r i t e r ia  are required i f  such pregnancies are 
not to be missed. However the increased detection of Down’ s to 57% 
using hCG/AFP/age screening represents 50% of a l l  autosomal 
trisomies present at m id-trimester.
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Table 5 - 3 6
Detection rates fo r  Down’ s syndrome and corresponding fa lse  
posit ive  rates fo r  d i f fe re n t  maternal age groups predicted by 
combining maternal age risks with those derived from AFP and hCG 
leve ls .
Calculation method
(1) (2) (3)
Age Detn False Detn False Detn False
group rate pos. rate pos. rate pos.
(yrs ) rate rate rate
(X) (X) (X) (X) (X) (X)
<20 35 2.0 35 2.2 38 2.4
20-24 36 2.2 37 2.6 39 2.7
25-29 48 2.8 41 3.2 45 3.3
30-34 58 6.1 58 6.3 58 6.3
35-37 75 19 73 17 72 15
38-40 85 44 86 38 83 35
>40 96 81 94 70 93 62
Overal1 57 5.0 56 5.0 57 5.0
Calculation methods:
(1) Combined AFP and hCG like lihood ra t ios  (ignoring  
c o rre la t io n ) .
(2) Combined AFP and hCG like lihood ra t ios  (including  
c o rre la t io n ) .
(3) hCG/AFP ratios
-183-
Table 5 - 3 7
Comparison of overa ll odds of a Down’ s syndrome pregnancy at 
m id-trim ester, using hCG/AFP/age screening with an overa ll fa lse  
positive  rate of 5%.
(a) POPULATION RISKS 
Overal1 
Age >35 years 
Age 25-34 years 
Age 25 years
OVERALL ODDS OF AN AFFECTED 
PREGNANCY
1: 690 
1: 150 
1: 820 
1 :1 20 0
(b) WITH hCG/AFP/AGE RISK >1:235
Overal1 
Age >35 years 
Age 25-34 years 
Age <25 years
60
50
70
85
(c) WITH hCG/AFP/AGE RISK <1:235
Overall 1:1500
Age >35 years 1: 670
Age 25-34 years 1:1500
Age <25 years 1:1900
A second high risk group, to  detect mainly trisomy 18 pregnancies, 
could p o te n t ia l ly  be id e n t if ie d  using low hCG resu lts . For 
example, at a c u t -o f f  of >0.30 MOM, 8 out of 12 (75%) o f the
trisomy 18 pregnancies, 1 out of 8 (13%) of the unbalanced
translocations and 1 out of 9 of the sex chromosome abnormalities  
(Table 5-14) would be detected, but at a cost of adding 2.7% to  
the amniocentesis ra te . A lte rn a t ive ly  ca lcu la ting  the product of  
the serum AFP and hCG results in MOM would allow selection of a 
group of pregnancies below a chosen c u t -o f f .  For example, an AFP X 
hCG fac tor of >0.20 would include 8 out of 12 (75%) trisomy 18 and 
1 out of 8 (13%) of the unbalanced chromosome abnormalities in 
th is  series, but would add 1.2% to the amniocentesis rate .
5 .2 .4 .5  OTHER ANALYTES IN SCREENING FOR DOWN’ S SYNDROME
A summary of the predicted detection rates fo r Down’ s syndrome at  
a 5% fa lse  positive  rate fo r  d i f fe re n t  analytes, e i th e r  singly or 
in combinations of two or three analytes, together with maternal 
age, is shown in Table 5-38. These were calculated as described in 
Section 4 .2 .8  taking into account corre lation  where s ig n if ic a n t .  
AFP is included in a l l  combinations of two or more analytes as i t  
is always l ik e ly  to be incorporated in screening protocols because 
of i ts  usefulness in predicting neural tube defects.
Table 5 -38
Predicted detection rates fo r  Down’ s syndrome at a 5% fa lse  
positive rate fo r  combinations of one, two and three analytes, 
together with maternal age.
Analyte combination Predicted
detection
rate
95% confidence 
in terva l
AFP/age 31 21-41
hCG/age 51 36-66
UE3/age 29 17-43
SPi/age 34 20-48
Fr|3-hCG/age 44 35-59
AFP/hCG/age 57 42-71
AFP/UE3/age 33 20-48
AFP/SPi/age 42 29-58
AFP/FrR-hCG/age 51 43-66
AFP/hCG/UE3/age 53 38-67
AFP/hCG/SPi/age 57 42-71
AFP/hCG/Frl3-hCG/age 55 47-70
AFP/UE3/SPi/age 41 28-57
AFP/UE3/Fr|3-hCG/age 49 35-65
AFP/SPi/FrR-hCG/age 55 40-70
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5 . 2 . 4 . 5 . 1  SPi
Adding SPi to an ex is ting  AFP/age screening programme is less 
e f fe c t iv e  than adding hCG (42% vs. 57% detection ). SPi used in 
addition to AFP and hCG does not increase the detection rate (57% 
vs. 57% detection ).  Adding SPi improves s l ig h t ly  the predicted  
detection rate when used in combination with AFP/UE3/age (41% vs. 
33% detection) or AFP/FrR-hCG/age (55% vs. 51% detection ).
5 .2 .4 .5 .2  UE3
Adding UE3 results to  the r isk  estimation and comparing the 
detection and fa lse  pos itive  results  with those fo r  the 
AFP/hCG/age combination shows a loss of detection fo r  Down’ s 
syndrome (53% vs. 57% detection) at a 5% fa lse  pos itive  ra te . This 
loss of detection when adding UE3 to the AFP/hCG/age combination 
is found at a range of fa ls e  positive  rates, as can be seen in 
Figure 5-27, which shows detection rates fo r  Down’ s syndrome and 
corresponding fa lse  pos itive  rates fo r  age, AFP/age, UE3/AFP/age, 
hCG/AFP/age and UE3/AFP/hCG/age. False positive rates vary fo r  
d if fe re n t  maternal age groups, and from th is  study the addition of 
UE3 to the AFP/hCG/age combination causes a loss of detection  
amongst younger women (Table 5-39).
Adding UE3 also decreases the detection rate s l ig h t ly  when added 
to the AFP/SPi/age combination (41% vs. 42% detection) and also to  
AFP/FrR-hCG/age (49% vs. 51% detection).
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Figure 5 - 2 7
Detection rates fo r  Down’ s syndrome and corresponding fa lse  
pos it ive  rates predicted by combining maternal age risks with 
d i f fe re n t  combinations of AFP, hCG and UE3.
-188-
Table 5 - 3 9
Comparison of the detection rates fo r  Down’ s syndrome and
corresponding fa lse  positive rates fo r  d i f fe re n t  maternal age 
groups predicted by combining maternal age risks with risks  
derived e ith e r  from AFP/hCG or AFP/hCG/UE3.
AFP/hCG/age AFP/hCG/UE3/age
Age Detn False +ve Detn False +ve
group rate rate rate rate
(yrs) (%) (X) W (X)
<20 35 2.2 33 2.4
20-24 37 2.6 33 2.5
25-29 41 3.2 36 3.1
30-34 58 6.3 52 6.4
35-37 73 17 73 16
38-40 86 38 86 37
>40 94 70 98 74
Overal1 56 5.0 53 5.0
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5 .2 .4 .5 .3  FREE 13 hCG
From th is  study adding Frf3-hCG to an existing  AFP screening 
programme is less e f fe c t iv e  than adding in tac t hCG (51% vs. 57% 
detection). Although the median Frf3-hCG level in Down’ s syndrome 
is  higher than the median fo r  in tac t hCG, the greater standard 
deviation, caused by the poorer precision of the FrR-hCG assay, 
increases the fa lse  positive rate .
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PHASE 3
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5.3 ROUTINE APPLICATION OF hCG/AFP/AGE SCREENING
5.3 .1  PROSPECTIVE TRIAL OF hCG/AFP/AGE SCREENING
In the preceding section, retrospective analysis of the
performance of f iv e  serum analytes as markers fo r  Down’ s syndrome
has shown that the most e f fe c t iv e  combination is AFP, in ta c t  hCG
and maternal age. In order to determine the impact of hCG/AFP/ age
screening in routine practice , a blind t r i a l  of th is  type of
screening was carried out between July 1989 and June 1990. A ll
samples sent fo r routine AFP screening from three Glasgow
maternity hospitals (The Queen Mother’ s Hospital, Glasgow Royal
Maternity Hospital and Rutherglen Maternity Hospital) were also
U - , l« i .
analysed for in tact hCG levels as described in Section^The aims 
of the t r i a l  were to determine the detection rates fo r  Down’ s 
syndrome and corresponding fa lse  positive rates at d i f fe re n t  risk  
thresholds, using d if fe re n t  methods of ca lcu lating  r isks, and to  
assess the e f fe c t  of maternal weight and complications of 
pregnancy (twins, threatened abortion, insulin  dependent diabetes)  
on analyte levels . The hCG results were not reported but were
stored as raw data and not used fo r  r isk  ca lcu lation  u n t i l  the
outcomes of the pregnancies were known.
AFP and hCG were analysed in to ta l  of 7830 pregnancies, 
consisting of 7748 singleton pregnancies, 81 sets of twins and one 
set of t r ip le t s .  The d is tr ib u t io n  of the gestations at which the
samples were taken is shown in Figure 5-28 and the age
d is tr ib u tio n  of the women in Figure 5-29. The median age was 26.6 
years and a comparison with the age d is tr ib u t io n  of the west of
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Figure 5 - 2 8
The d is tr ib u t io n  of gestations a t which samples were taken in the 
prospective t r i a l  of hCG/AFP/age screening.
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Figure 5 - 2 9
The d is tr ib u t io n  of maternal ages of women whose samples were in 
the prospective t r i a l  of hCG/AFP/age screening.
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Scotland pregnant population showed that th is  d is tr ib u t io n  was 
representative of the whole pregnant population.
There were 18 autosomal trisomy pregnancies id e n t if ie d  in th is  
group, consisting of 16 Down’ s syndrome (15 in singleton  
pregnancies and 1 in a twin pregnancy) and 2 cases of trisomy 18. 
Table 5-40 compares detection and fa ls e  positive  rates fo r  the 
samples in th is  t r i a l  with those predicted re trospective ly  (see 
Section 5 .2 .4 .3 .4 ) .  Risks were calculated by the hCG(M0M)/AFP(M0M) 
ra t io  method (Section 5 .2 .4 .3 .3 ) .  At any given r isk  threshold the 
detection rate ac tua lly  achieved is close to tha t predicted from 
the retrospective study, but the fa lse  pos itive  rate is higher.
To compare the e f fe c t  of d i f fe re n t  ca lcu la tion  methods on the 
detection rate fo r  Down’ s syndrome, risks were also calculated  
using the formula which includes corre la t ion  (Section 5 .2 .4 .3 .2 ) .  
Table 5-41 gives the detection and fa ls e  positive  rates by th is  
method. Comparing these with the data obtained by the ra t io  method 
(Table 5-40) shows th a t ,  at equivalent detection rates, the fa lse  
positive  rates obtained using the ra t io  method are lower, and are 
generated by lower threshold c u t -o ff  r isks . For example, a 53% 
detection rate at a 6.2% fa lse  positive  rate is  obtained using a 
1:220 c u t -o f f  r isk  by the ra t io  method compared with a 53% 
detection rate at a 6.3% fa lse  positive rate using a 1:260 c u t -o ff  
r isk  by the formula which includes corre la t ion .
The two trisomy 18 pregnancies had hCG levels  of 0.21 MOM and 0.16 
MOM and AFP levels of 0.38 MOM and 1.62 MOM respective ly . This 
second case was also affected by spina b i f id a .
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Table 5 - 4 0
Comparison of detection rates fo r Down’ s syndrome and
corresponding fa lse  pos itive  rates achieved in the prospective 
t r i a l  with those predicted from the retrospective study. Risks
calculated by the hCG(M0M)/AFP(M0M) method.
Prospective Retrospective
(n = 7830) (Controls = 410
Down’ s = 49)
C u t-o ff False Detn rate False Detn rate
risk +ve rate  Down’ s +ve rate Down’ s
(n = 15)
% % (n) % %
1:240 6.7 60 (9) 5.1 57
1:220 6.2 53 (8) 4.5 55
1:200 5.6 53 (8) 4.1 54
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Table 5 - 4 1
Effect of ca lcu la ting  risks in the prospective t r i a l  by 
combined formula including corre la t ion  on the fa ls e  positive  
and detection rate fo r  Down’ s syndrome.
C ut-o ff False +ve Detn rate
risk rate Down’ s
(n=7830) (n=15)
% % (n)
1:280 6.8 60 (9)
1:260 6.3 53 (8)
1:240 5.8 53 (8)
the
rate
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Over time, 12 AFP and hCG results had now been accumulated from 12 
trisomy 18 pregnancies. These were used, together with the AFP and 
hCG results from 7,830 unaffected pregnancies to look at ways of 
u t i l i z in g  these results to screen for trisomy 18. Using the hCG 
results  alone, in MOM, 8 out of 12 (67%) of a ffected pregnancies 
had values <0.25 MOM, compared with 1.1% of unaffected 
pregnancies. Using the product of AFP and hCG ( in  MOM), 8 out of 
12 (67%) of affected pregnancies (67%) had a fac to r  of <0.2,
compared with 1.4% of unaffected pregnancies.
5 .3 .1 .1  EFFECT OF MATERNAL WEIGHT ON hCG AND AFP LEVELS
The median hCG and AFP levels on d if fe re n t  maternal weight bands 
are shown in Table 5-42, along with the median like lihood ra t io  
calculated from hCG/AFP ra tios . Both AFP and hCG levels are 
increased in l ig h te r  women and are reduced in heavier than average 
women. The e f fe c t  is less marked for hCG.
When using the hCG/AFP ra t io  method to ca lcu late r isks , weight 
correction w i l l  make l i t t l e  difference to the 85% of individual 
women with weights ±15 Kg of the median weight, due to the s im ila r  
changes in AFP and hCG cancelling each other out. Assay 
imprecision is l ik e ly  to have a s im ilar  e f fe c t .  However, fo r  women 
with weights outside th is  range, weight correction w i l l  provide a 
more accurate individual r isk . However, o v e ra ll ,  weight correction  
w il l  have l i t t l e  e f fe c t  on the overall screening performance.
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Table 5 -  42
The e f fe c t  of maternal weight on AFP and hCG levels and on the 
l ike lihood ra t io  (LR) derived from these.
Weight
(Kg)
n Median
hCG
Median
AFP
Median LR 
from hCG/AFP 
ra t io
<45 100 1.13 1.25 0.21
45.0-54.9 1479 1.10 1.15 0.28
55.0-64.9 2810 1.03 1.00 0.30
65.0-74.9 1499 0.97 0.92 0.32
75.0-84.9 532 0.90 0.84 0.35
>85.0 301 0.89 0.83 0.39
OVERALL
59.0 6723 0.97 1.00 0.30
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5 .3 .1 .2  THE EFFECT OF TWINS ON hCG LEVELS
The median hCG level in 81 twin pregnancies was 1.85 MOM and the 
median AFP level 1.91 MOM. Twin pregnancies therefore have 
approximately double the levels of hCG and AFP found in singleton  
pregnancies. The one twin pregnancy discordant fo r  Down’ s syndrome 
had an hCG level of 4.63 MOM and an AFP level of 1.94 MOM. At th is  
stage accurate Down’ s syndrome risks cannot be calculated fo r  twin 
pregnancies due to lack of data. The f e a s ib i l i t y  of ca lcu lating  
risks fo r twin pregnancies would require the analysis of a large  
series of a ffected twin pregnancies, both discordant and 
concordant fo r  Down’ s syndrome.
5 .3 .1 .3  THE EFFECT OF THREATENED ABORTION ON hCG LEVELS
In th is  series of 7830 pregnancies, 392 had the 'threatened  
abortion ’ box ticked on the request form, but in the m ajority  of 
cases the in te rva l between the event and drawing of the screening 
blood sample was not known . These samples had a median hCG level 
of 1.03 MOM and a median AFP level of 1.07 MOM. Episodes of  
bleeding, p a r t ic u la r ly  in the few weeks preceding the co llec tion  
of the screening blood sample, may cause a r ise  in AFP levels  due 
to feto-maternal haemorrhage (Wald et a l . ,  1977, Lidbjork et  a l . ,  
1977). In a sub-group o f 28 pregnancies with AFP levels  >2.0 MOM, 
the most l ik e ly  to have had recent threatened abortion, the median 
hCG level was 1.09 MOM and the median AFP level 2.55 MOM. The hCG 
levels  are v i r tu a l ly  unchanged in th is  group of patients . There 
w il l  therefore be a tendency fo r  risks to be underestimated in
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cases of threatened abortion.
5 .3 .1 .4  THE EFFECT OF INSULIN DEPENDENT DIABETES ON hCG AND AFP 
LEVELS
There were 15 cases of insu lin  dependent diabetes (IDDM) in th is  
series , which had a median AFP value of 0.96 MOM and a median hCG 
value of 0.90 MOM. A fu rth e r  41 cases were id e n t if ie d  from routine  
screening between August 1992 and August 1993. The median AFP 
value of the 56 cases was 0.94 MOM and fo r hCG was 0.90 MOM. Two 
of the 56 (3.6%) were in the high r isk  (>1:220) group and three  
of the 56 had (5.4%) AFP values greater than 2.0 MOM. IDDM 
patients do not appear to be e i th e r  over- or under- represented in 
e ith e r  of the high r isk  groups.
5 .3 .2  hCG/AFP/AGE SCREENING IN ROUTINE PROSPECTIVE USE
Following the development of protocols fo r  the use of hCG, AFP and 
maternal age in a population screening programme and the 
demonstration tha t th is  combination resulted in s ig n if ic a n t  
improvement in the s e n s it iv i ty  of detection of Down’ s syndrome 
pregnancies (Section 5 .3 .1 )  the routine maternal serum screening 
programme in the west of Scotland was extended to  include hCG 
analysis in September 1991.
Before implementing th is  change to routine c l in ic a l  practice  
substantial re -w r it in g  of the ex is ting  computerised AFP reporting
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system was required and a new reporting format devised. Consultant 
obstetric ians and antenatal c l in ic  s t a f f  were informed of the 
impending developments by l e t t e r  and revised patien t information  
le a f le ts  and a guide to in te rp re ta t io n  of screening results  
produced.
Maternal serum AFP and hCG results  were measured as described in 
Sections 4 .1 .2 .2  and 4 .1 .3 .1 .  Risks fo r  Down’ s syndrome were
calculated using the hCG(MOM)/AFP(MOM) ra t io  and mid trim ester
maternal age risks of Down’ s syndrome, and a threshold r isk  of 
1:220 was selected. The gestational range fo r  screening was 
extended to 15-21 weeks inclusive.
During the f i r s t  year of operation 30,084 women were screened and 
there were approximately 37,500 b ir th  re la t in g  to th is  period. The 
d is tr ib u t io n  of gestations at which samples were taken is shown in 
Figure 5-30, with 88% of samples taken between 15 and 17 completed 
weeks. The d is tr ib u t io n  of maternal ages is shown in Figure 5-31. 
The median age was 26.4 years and 6.9% of women were aged 35 years 
and over. From cytogenetic records a to ta l  of 50 Down’ s syndrome 
pregnancies were id e n t i f ie d ,  of which 37 were in the screened
population. There were also 10 cases of trisomy 18, of which 7
were in the screened population.
5 .3 .2 .1  SCREENING FOR DOWN’S SYNDROME
A summary of the screening performance is given in Table 5-43. The 
i n i t i a l  6.3% fa lse  pos it ive  rate was reduced to 5.1% a f te r  some
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Figure 5 - 3 0
Ths d is tr ib u t io n  of gestations at which samples were taken in the 
1st year of hCG/AFP/age screening, September 1991 to September 
1992.
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Figure 5 - 3 1
The d is tr ib u t io n  of maternal ages of the women screened in the 1st 
year of hCG/AFP/age screening, September 1991 to September 1992.
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Table 5 - 4 3
Performance of hCG/AFP/age screening fo r  Down’ s syndrome in the 
west of Scotland September 1991 to September 1992.
Total pregnancies screened
*No (%) in high risk group -  i n i t i a l  
- a f t e r  gestation reassessed
Uptake of diagnostic tes ting
No of Down’ s syndrome in screened
population
No (%) in high risk group 
(95% Cl)
No (%) prenatally  diagnosed 
(95% Cl)
Overall odds of being affected i f  
in the high risk group
Overall odds of being affected i f  
in the low risk group
* (C u t-o ff  r isk 1:220)
: 30,084
: 1,904 (6.3%)
: 1,523 (5.1%)
: 70%
37
: 26 (70%)
(53-84%)
: 21 (56%)
(39-72%)
: 1:59
: 1:2600
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gestations had been reassessed. The uptake of diagnostic testing  
was 70%. Of the Down’ s syndrome pregnancies 26 out of 37 (70%)
were in the high r isk  group and 21 of these (56%) were prenata lly  
diagnosed. The overa ll odds of an affected pregnancy i f  in the 
high risk group were 1:59.
The individual risks for each of the 37 Down’ s syndrome 
pregnancies are shown in Table 5-44, c lass if ied  into  high and low 
r is k ,  and, i f  in the high risk group, divided into those women who 
had prenatal diagnosis and those who did not. I t  can be seen that  
neither the actual r isk  nor maternal age were the only factors  
which influenced whether prenatal diagnosis occurred. These same 
risks are shown graphically  in Figure 5-32, compared with the 
population mid tr im ester risk o f Down’ s syndrome and the c u t -o f f  
r isk  of 1:220. The detection rate varies with d i f fe re n t  maternal 
age groups, as is shown in Table 5-45, from 57% in women aged less 
than 25 years to 91% in women aged 35 years and over.
A summary of a l l  of the Down’ s syndrome pregnancies id e n t if ie d  
cytogenetica lly  from the whole pregnant population re la t in g  to  
th is  year of screening with hCG/AFP/age is shown in Table 5-46, 
divided into d i f fe re n t  maternal age groups. I t  can be seen th a t ,  
of the 50 Down’ s syndrome pregnancies, 24 (48%) were prenata lly  
diagnosed, the m ajority of these because of an ind ication  of a 
r isk  of >1:220 from hCG/AFP/age screening and the rest fo r  an 
indication of maternal age of 35 years or greater. In women aged 
35 years or over 11 out of 16 of the Down’ s syndrome pregnancies 
(69%) were p renata lly  diagnosed, and in women aged less than 35 
years 13 out of 34 (38%) were prenata lly  diagnosed.
Table 5 - 4 4
Risks from hCG/AFP/age fo r  Down’ s syndrome pregnancies screened 
September 1991 to September 1992.
 High r isk  group________  Low r isk  group
Prenata lly  Born Born
diagnosed
Age Risk Age Risk Age Risk
20 1 110 23 1:190 21 1 270
21 1 210 33 1:120 21 1 950
23 1 110 34 1: 43 23 1 3100
26 1 160 38 1: 17 25 1 970
30 >1 43 38 1:160 25 1 1100
30 >1 43 27 1 250
30 1 68a 29 1 500
31 1 100b 29 1 500
31 1 170 30 1 3800
32 1 50 31 1 660°
34 >1 22 37 1 650
34 >1 22
34 1 24
36 >1 15
36 1 47
37 1 100
37 1 140
38 >1 10
38 1 60
39 1 52
40 1 44
a Translocation Down’ s 46X Y ,-14 ,+ t(14;21) 
b Mosaic 46XY/47XY+21 
c Mosaic 46XY/47XY+21
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Figure 5 - 3 2
Combined risks of Down’ s syndrome at mid tr im este r ,  from 
hCG/AFP/age, in 37 Down’ s syndrome pregnancies screened between 
September 1991 and September 1992, compared with the a p r i o r i  
maternal age r isk  and the threshold r isk  of 1:200.
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Table 5 - 4 5
Efficacy of screening fo r  Down’ s syndrome using hCG/AFP/age in 
d i f fe re n t  maternal age groups.
Maternal age (years)
<25 25-34 >35
Total Down’ s 7 19 11
No in high r isk 4 12 10
group
% in high risk  group 57% 63% 91%
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Table 5 - 4 6
Summary of a l l  Down’ s syndrome pregnancies in the west of Scotland
fo r  the period screened September 1991 to September 1992.
<25
Maternal
25-34
age
>35 A ll
Screened-HR-PND 3 10 8 21
Screened-HR-Born 1 2 2 5
Screened-LR-Born 3 7 1 11
1st Tri CVS-MA-PND - - 3 3
Not screened-Born 1 5 2 7
Screened elsewhere 
-Born
1 1 - 2
Total 9 25 16 50
% in age group 18% 50% 32%
(Expected %) (23%) (46%) (31%)
HR = High r isk  group (Risk >1:220) 
LR = Low risk  group (Risk <1:220) 
PND = Prenata lly  diagnosed 
CVS = Chorionic v i l lu s  sampling 
MA = Maternal age >35 years
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As a check on the completeness of ascertainment of Down’ s syndrome 
the expected number of Down’ s syndrome pregnancies at b ir th  was 
calculated from the age d is tr ib u t io n  shown in Figure 5-30. From 
th is  45 Down’ s syndrome b irths  would be expected (1 .2 /1000 , 95% Cl 
33-60). However, since there is  a defined spontaneous loss of 
affected pregnancies between the f i r s t  and second tr im ester and 
between the second tr im ester and b ir th  (see Section 1.2) the
number of Down’ s syndrome b irths  ascertained w i l l  be influenced by 
the stage of pregnancy at which they are diagnosed. Of the 50 
Down’ s syndrome pregnancies id e n t if ie d  here, 3 were diagnosed in 
the 1st tr im ester ,  21 in the 2nd tr im ester and 26 at b ir th .  
Allowing fo r  expected fe ta l  loss th is  is equivalent to 45 Down’ s 
syndrome cases at term, identica l to the expected number.
5 . 3 .2 .2  SCREENING FOR TRISOMY 18
The very low hCG results  in trisomy 18 pregnancies provide an 
opportunity to define a second high r isk  group to screen fo r  
affected pregnancies. Using the results  from 12 trisomy 18 
pregnancies, as described in Section 5 .3 .1 ,  a s l id in g  scale of
c u t -o f f  values in MOM fo r  hCG d i f fe re n t  maternal ages was 
calculated to give a r isk  of trisomy 18 which was approximately 
1:100 or greater (Table 5 -47). Using th is  protocol, 87 pregnancies 
(0.3%) were assigned to the high r isk  group fo r  trisomy 18. There 
were 2 trisomy 18 pregnancies id e n t if ie d  in th is  high r isk  group 
from a to ta l  of 7 in the screened population, giving a detection
rate of 29%. Neither of these was prenata lly  diagnosed. There were
Table 5 - 4 7
Cut-o ff  hCG (MOM) fo r  high r isk  group for trisomy 18 at d i f fe re n t  
maternal ages. I f  the resu lt  is less than or equal to the given 
c u t -o f f  then the patient is assigned to the high r isk  group.
Maternal age C u t-o ff  hCG(MOM)
15 0.20
16 0.20
17 0.20
18 0.20
19 0.20
20 0.20
21 0.20
22 0.20
23 0.20
24 0.20
25 0.20
26 0.21
27 0.21
28 0.21
29 0.21
30 0.22
31 0.22
32 0.23
33 0.24
34 0.25
35 0.26
36 0.27
37 0.29
38 0.30
39 0.32
40 0.34
41 0.36
42 0.38
43 0.40
44 0.43
45 0.46
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a to ta l  of 10 trisomy 18 pregnancies id e n t if ie d  cytogenetica lly  
fo r  th is  period and none were prenata lly  diagnosed. One of the 
trisomy 18 pregnancies was id e n t if ie d  a f te r  an in trau te r in e  death 
at 16 weeks gestation and the remaining 9 were id e n t if ie d  at 
b ir th .
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SECTION 6
DISCUSSION
6.1 ANALYTE LEVELS IN MATERNAL SERUM IN DOWN’ S SYNDROME
PREGNANCIES
One of the most important factors a ffec ting  the usefulness of a 
p a rt ic u la r  maternal serum marker as a predictor of Down’ s syndrome 
is the s h i f t  in median value between the unaffected and Down’ s 
syndrome populations. In addition, the spread of the 
d is tr ib u t io n s , as defined by the standard dev iation , and the level 
of corre la t ion  between markers used together w i l l  also a f fe c t  the 
discrim ination between unaffected and Down’ s syndrome pregnancies. 
None of the markers so fa r  studied here o r  elsewhere show complete 
separation of the unaffected and Down’ s syndrome populations.
6 .1 .1  ALPHAFETOPROTEIN
In the present study a median AFP level of 0.72 MOM was found in 
114 Down’ s syndrome pregnancies. This is the single largest series  
of Down’ s syndrome pregnancies investigated fo r  AFP levels . The 
median maternal serum AFP levels  in Down’ s syndrome pregnancies 
in 28 studies, including th is  one, are presented in Table 6-1,  
along with, where stated, the mean and standard deviation of the 
AFP log Gaussian d is tr ib u t io n .  Eliminating three reports where 
samples were also included in another study, a meta-analysis of 25 
studies, comprising 1062 cases o f affected pregnancies, gave an 
overa ll geometric median of 0.75 MOM, with a range from 0.63 to  
1.00 MOM. The median AFP value of 0.72 MOM found in th is  study is  
close to the overa ll geometric median. Only one report, from 
Cowchock and Ruch (1984) found no d ifference between levels  in
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Table 6 -1
Summary of maternal serum alphafetoprotein (AFP) medians, means
and standard deviations (SD) found in Down’ s syndrome pregnancies
in published studies.
n Median Mean SD
AFP (log io ) ( log io )
(MOM)
Merkatz et  al .  (1984) 25 0 . 68a - -
Cuckle et  al .  (1984) 61 0 . 72b - -
S e lle r  (1984) 8 0.80 - -
Guibaud et  al .  (1984) 13 0.76 - -
Tabor et  al .  (1984) 25 0.75° - -
Fuhrmann et  al .  (1984) 43 0.80 - -
Voigtlander & Vogel (1984) 29 0.78 - -
Cowchock & Ruch (1984) 40 1.00 - -
Hershey et  al .  (1985) 28 0.87 - -
Spencer & Carpenter (1985) 27 0.82 - -
Murday & Slack (1985) 45 0.63 - -
Doran et  al .  (1986) 46 0.79 - -
Ashwood et al .  (1987) 26 0.69 -0.212 0.283
Cuckle et  al .  (1987) 68 0.72 -0.1427 0.2052
Tabor et  al .  (1987) 86 0.64 -0.197 0.186
Di Maio et al .  (1987) 18 0.76 - -
Del Junco et  al .  (1989) 22 0.64 - -
Osathanondh et  al .  (1989) 26 0.84 - -
Heyl et  al .  (1990) 18 0.82 -0.112 0.162
Norgaard Pedersen et  a 7.(1990) 42 0.70 -0 .154 0.198
Suchy & Yeager (1990) 16 0.70 - -
Waller et  al .  (1990) 113 0.77 - -
MacDonald et  al .  (1991) 54 0.90 - -
M il le r  et  al .  (1991) 8 0.75 - -
Spencer (1991) 29 0.73d -0 .130 0.208
Ryall et  al .  (1992) 57 0.74 -O.2950 0.464s
Spencer et  al .  (1992b) 90 0.70 -0.1413 0.2013
This study 113 0.72 -0.1427 0.1626
(Zeitune et  a l . , 1991)
Overall weighted geometric
median 1062 0.75
a Estimated from f ig u re  in publication .
b Not included in overa ll analysis as cases also included in 
Cuckle et  al .  (1987). 
c Not included in overa ll analysis as cases also included in 
Tabor et  al .  (1987). 
d Not included in overa ll analysis as cases also included in 
Spencer et  al .  (1992b).
0 Loge -  equivalent to  logio Mean = -0 .1281 , SD = 0.2015.
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Down’ s syndrome and unaffected pregnancies, and the consensus is 
tha t AFP levels in Down’ s syndrome cases are lowered to around 75% 
of that found in unaffected pregnancies.
6 . 1 .2  HUMAN CHORIONIC GONADOTROPHIN
In the present study a median in tac t hCG level of 2.18 MOM was 
found in 49 Down’ s syndrome pregnancies. The maternal serum median 
hCG levels in Down’ s syndrome pregnancies found in 18 studies  
including th is  one are presented in Table 6-2 , along w ith, where 
stated, the mean and standard deviation of the log Gaussian 
d is tr ib u t io n .  Eliminating two reports where samples were also 
included in another study a meta-analysis of 16 studies, 
comprising 634 cases of affected pregnancies, gave an overall 
geometric median of 2.08 MOM, with a range of 1.57 to  2.91 MOM. 
The median value of the present study is of 2.18 MOM is close to  
the overa ll geometric median. The consensus is tha t  in ta c t  hCG 
levels in Down’ s syndrome pregnancies are around double those 
found in unaffected pregnancies, making hCG a powerful predictor  
of Down’ s syndrome.
6 . 1 .3  PREGNANCY-SPECIFIC 0-1 GLYCOPROTEIN
In the present study a median SPi level of 1.17 MOM was found in 
48 Down’ s syndrome pregnancies. The median maternal serum SPi 
level in Down’ s syndrome pregnancies in f iv e  studies, including  
th is  one, are shown in Table 6-3. Meta-analysis of these,
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Table 6 - 2
Summary of maternal serum chorionic gonadotrophin (hCG) medians,
means and standard deviations (SD) found in Down’ s syndrome
pregnancies in published studies.
n Median
hCG
(MOM)
Mean
(log io )
SD
( logio)
Bogart et al .  (1987) 29 1 .61a — _
Arab et  al .  (1988) 77 1 .61b - -
Wald et  al .  (1988b) 77 2.04 0.3096 0.2588
Del Junco et  al .  (1989) 22 2.10 - -
Osathanondh et  al .  (1989) 26 2.59 - -
Petrocik et al .  (1989) 38 2.50 - -
White et al .  (1989) 15 2 - 91b - -
Bartels et  al .  (1990) 43 2.18 - -
Heyl et  al .  (1990) 18 1.89 0.290 0.283
M uller & Bou6 (1990) 50 2.39 - -
Norgaard Pedersen et  a l . (1990) 42 1.57 0.195 0.317
Suchy & Yeager (1990) 16 2.40 - -
MacDonald et  a l .  (1991) 54 1.79 0.25 0.26
Mi 1 le r  et  a 1. (1991) 8 2.11 - -
Spencer (1991) 29 1 .88c 0.2881 0.2257
Ryall et  al .  (1992) 57 2.12 0 . 751d 0.561d
Spencer et  al .  (1992b) 90 2.03 0.3282 0.2825
This study 49 2.18 0.3385 0.3127
(Crossley et  a l . ,1991a)
Overall weighted geometric
median 634 2.08
a Not included in overa ll analysis as cases also included in 
Bartels et  al .  (1990).
b Mean not median.
c Not included in overa ll analysis as cases also included in 
Spencer et  al .  (1992b).
d Loge -  equivalent to  logio Mean = 0.326, sd = 0.244.
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Table 6 - 3
Summary of maternal serum pregnancy-specific 3-1 glycoprotein
(SPi) medians, means and standard deviations (SD) found in Down’ s
syndrome pregnancies in published studies.
n Median
SPi
(MOM)
Mean
(log io )
SD
(log io )
Bartels & Lindemann (1988) 24 2.10 - -
Wald et  al .  (1989) 77 1.20 - -
Knight et  al .  (1989) 24 1.63 - -
Petrocik et  a l .  (1990) 46 1 .98a - -
Bartels et  al .  (1990) 43 1.54 - -
This study 
(Graham et  al .  ,1992)
48 1.17 0.068 0.176
Overall weighted geometric
median 262 1.46
a Estimated from f igure  in publication .
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comprising 262 cases of affected pregnancies, gave an overa ll  
geometric median of 1.46 MOM, with a range o f 1.17 to  2.10 MOM. 
The median SPi level of 1.17 MOM found in th is  study is the lowest 
in the series, but is  in close agreement with tha t found by Wald 
et  al .  (1989), who found a median SPi level of 1.20 MOM in a
series of 77 down’ s syndrome pregnancies.
The i n i t i a l  study of Bartels and Lindemann (1988), based on the 
analysis o f post-amniocentesis maternal serum samples from 24 
Down’ s syndrome pregnancies suggested a much stronger association  
between elevated SPi levels and Down’ s syndrome, with a median
value of 2.1 MOM. However an overa ll median value fo r  unaffected
pregnancies was used, rather than individual medians fo r  d i f fe re n t  
weeks of gestation. Subsequent studies (Wald et  a l . ,  1989, 
Petrocik et  a l . ,  1990, Bartels et  al .  1990, present study) have 
shown that SPi levels  increase with advancing gestation between 
15-20 weeks. Thus, s ig n if ic a n t  e rror may have arisen through the 
use of control samples of e a r l ie r  gestation than those of the
Down’ s syndrome cases.
Some discrepancy is apparent in the SPi levels  found in the Down’ s 
syndrome pregnancies between the various studies. Two studies  
(Bartels & Lindemann, 1988, Petrocik et  a l . ,  1990) found markedly 
elevated leve ls , with a median value at around 2.0 MOM. Two others 
(Knight et  a l . ,  1989, Bartels et  a l . ,  1990) found moderately 
elevated leve ls , with a median SPi value at around 1.5 MOM, and 
the remaining two (Wald et  a l . ,  1989, present study) found only a 
small s h i f t  in SPi levels  in Down’ s syndrome pregnancies, with a 
median value at around 1.2 MOM. These d ifferences are not assay
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dependent, as four studies (Barte ls  et  a l . , 1988, Wald et  a l . ,
1989, Petrocik et a l . ,  1990, Bartels et  a l . ,  1990) a l l  used the 
same commercially ava ilab le  assay method (Enzygnost-SP1, |Behring). 
The present study and tha t by Wald et  al .  (1989) have the most 
representative series of Down’ s syndrome samples and controls as 
they were id e n t if ie d  from maternal serum population screening 
programmes, thus avoiding the selection bias found other studies  
where samples were obtained from pregnancies of advanced maternal 
age or a f te r  prenatal diagnosis of Down’ s syndrome by 
amniocentesis. Also, th is  study and tha t of Wald et  al .  (1989) 
have used much larger numbers of control pregnancies (390 and 385 
respective ly) to assess the normal pregnancy levels  of SP i, 
compared with the other four reports which had between 34 and 117 
control samples.
6 .1 .4  UNCONJUGATEP ESTRIOL
In the present study a median UE3 level of 0.79 MOM was found in 
49 Down’ s syndrome pregnancies. The median maternal serum UE3 
levels  in Down’ s syndrome pregnancies in 12 studies including th is  
one are shown in Table 6-4, along with, where stated, the mean and 
standard deviation of the UE3 d is tr ib u t io n ,  e i th e r  Gaussian or log 
Gaussian. Eliminating one report where samples were also included 
in another study, a meta-analysis of 11 studies, comprising 498 
affected pregnancies, gave a overa ll geometric median of 0.75 MOM, 
with a range of 0.66 to 0.99 MOM. The median UE3 level of 0.79 MOM 
found in th is  study is close to the overa ll geometric median. Only 
one report, Macri et  al .  (1990a), found no d ifference between
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Table 6 - 4
Summary of maternal serum unconjugated e s tr io l  (UE3) medians,
means and standard deviations (SD) found in Down’ s syndrome
pregnancies in published studies.
n Median
UE3
(MOM)
Mean SD
Canick et  al .  (1988) 22 0.79
Wald et  al .  (1988a) 77 0.73 0. 73a 0 . 26a
Del Junco et  al .  (1989) 22 0.70 - -
Osathanondh et  al .  (1989) 26 0.66 - -
Heyl et  al .  (1990) 18 0.77 0. 79a 0 . 33a
Macri et  al .  (1990a) 41 0.99 - -
Norgaard pedersen et  a l . (1990) 42 0.74 - 0 . 129b 0 . 202b
MacDonald et  al .  (1991) 54 0.71 0. 77a 0 . 29a
Spencer (1991) 29 0.73d -0.187 9b 0.2110b
Ryall et  al .  (1992) 57 0.70 -0 .353° 0.411°
Spencer et  al .  (1992b) 90 0.74 -0 .1601b 0.2101b
This study 49 0.79 0 . 79a 0 . 29a
(Crossley et  a l . ,  1993)
Overall weighted geometric
median 498 0.75
a Gaussian d is tr ib u t io n  used 
b Log Gaussian d is tr ib u t io n  used
c Loge -  equivalent to  logio Mean = -0 .153 , SD = 0.178
d Not included in overa ll analysis as cases also included in 
Spencer et  a h  (1992b)
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Down’ s syndrome and unaffected pregnancies, and the consensus is 
that UE3 levels are lowered to around 75% of those found in 
unaffected pregnancies, s im ila r  to AFP.
Some controversy exists as to whether the d is tr ib u t io n  of maternal 
serum UE3 in Down’ s syndrome and unaffected pregnancies f i t s  a 
Gaussian or log Gaussian d is tr ib u t io n .  Four reports (Wald et  a h ,  
1988a, Heyl et  a / . ,  1989, MacDonald et  a 1., 1991, present study) 
f i t  th e ir  data to a Gaussian d is tr ib u t io n ,  while 3 (Norgaard 
Pederson et  a l . ,  1990, Ryall et  a l . ,  1992, Spencer et  a l . ,  1992b) 
use a log Gaussian d is tr ib u t io n .  One group of authors (Wald et  
a l . ,  1988a) have subsequently revised th e ir  data to f i t  a log 
Gaussian d is tr ib u tio n  rather than Gaussian d is tr ib u t io n  (Wald et  
a l . ,  1992). The present study has shown that the d is tr ib u t io n  of  
UE3 in Down’ s syndrome and unaffected pregnancies does not Id e a lly  
f i t  e ith e r  a Gaussian or Log Gaussian d is tr ib u t io n  (Section 
5 .2 .1 .3 .2 ) .
6 . 1 . 5  FREE B HUMAN CHORIONIC GONADOTROPHIN
In the present study a median Fr|3-hCG level of 2.30 MOM was found 
in 81 Down’ s syndrome pregnancies. The median maternal serum 
Fr|3-hCG levels in Down’ s syndrome pregnancies in seven studies, 
including th is  one, are presented in Table 6-5, along with , where 
stated, the mean and standard deviation of the Fr3-hCG log 
Gaussian d is tr ib u t io n . Eliminating two reports where samples were 
also included in another study, a meta-analysis of 5 studies, 
consisting of 332 cases of affected pregnancies, gave an overa ll
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Table 6 - 5
Summary of maternal serum free  |3 human chorionic gonadotrophin
(Fr|3-hCG) medians, means and standard deviations (SD) found in
Down’ s syndrome pregnancies in published studies.
n Median
Fr(3-hCG
(MOM)
Mean
(lo g io )
SD
(log io )
Macri et  a h  (1990b) 29 2 . 31a - -
Spencer (1991) 29 2 .06b 0.3061 0.2744
Spencer & Macri (1992) 23 2 . 15b - -
Ryall et  a h  (1992) 57 2.36 0.860° 0 . 693c
Spencer et  ah  (1992b) 90 2.41 0.3570 0.3316
Wald et  ah  (1993a) 75 2.22 0.3513 0.3461
This study
(Crossley et a h , 1991b)
81 2.30 0.362 0.355
Overall weighted geometric
median 332 2.32
a Estimated from figu re  in publication .
b Not included in overa ll analysis as cases also included in 
Spencer et  a h  (1992b).
c Loge -  equivalent to  log-io Mean = 0.373, SD = 0.301
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geometric median of 2.32 MOM, with a range of 2.22 to 2.41 MOM. 
The median Fr|3-hCG value of 2.30 found in the present study is  
close to the overall geometric median. The consensus is that  
FrB-hCG levels in Down’ s syndrome pregnancies exceed twice the 
level found in unaffected pregnancies, making Fr|3-hCG a powerful 
predictor of Down’ s syndrome.
6 . 1 . 6  OTHER ANALYTES
Free a subunit hCG. There have been f iv e  reported studies of free  
a subunit hCG (Fra-hCG) levels  in Down’ s syndrome pregnancies, 
which are summarised in Table 6-6. Three studies (Bogart et a l . ,  
1987, Bogart et a l . ,  1989, and Kratzer et  a h , 1991), to ta l l in g  33 
cases, found median levels of Fra-hCG >2.0 MOM in Down’ s syndrome 
pregnancies. The study by Ryall et a l .  (1992), with 57 cases of 
Down’ s syndrome, found moderately elevated levels of Fra-hCG in 
Down’ s syndrome with a median level o f 1.39 MOM. The study by 
Spencer (1993), with 36 cases of Down’ s syndrome, found no 
difference in levels between Down’ s syndrome cases and controls.  
There is  also considerable va r ia t io n  in the spread of values 
found, with Bogart et  al .  (1987) and Bogart et  al .  (1989) 
reporting ranges of 1.25 -  3.69 MOM and 0.56 -  2.96 MOM
respective ly . Ryall et  al .  (1992) reported a ±2 SD range of 0.69 -  
2.81 MOM, compared with the considerably smaller ±2 SD range of  
0.93 -  1.04 MOM reported by Spencer (1993). Some doubt must
therefore  ex is t as to whether the assays used in these d i f fe re n t  
studies had the same s p e c if ic i ty ,  and fu rthe r  work is required 
to  assess the extent of Fra-hCG var ia t io n  in Down’ s syndrome
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Table 6 - 6
Summary of maternal serum free  a human chorionic gonadotrophin
(Fra-hCG) medians, means and standard deviations (SD) found in
Down’ s syndrome pregnancies in published studies
n Median
Fra-hCG
(MOM)
Mean
logio
SD
logio
Bogart et  a 1. (1987) 17 2.31
Bogart et al .  (1989) 13 1.82
Kratzer et  a l .  (1991) 3 2.02
Ryall et  al .  (1992) 57 1.39 0.330® 0.351®
Spencer (1993) 36 0.991 0.989 0.028
® Loge -  equivalent to logio Mean = 0.143, SD = 0. 152
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pregnancies.
Progesterone. There have been three reports on maternal serum 
progesterone levels in Down’ s syndrome pregnancies. Moderately 
elevated levels have been reported by Knight e t a l .  (1989) (1.34
MOM in 24 cases) and Kratzer et a l .  (1991) (1.49 MOM in 3 cases). 
Ryall et a l .  (1992) analysed progesterone in 57 cases of Down’ s 
syndrome. The median level of progesterone found was not reported 
but the difference between affected and unaffected cases was not 
s ig n if ic a n t  by t - t e s t  (p>0.05). Knight e t a l  (1989) reported high 
levels  of corre la tion  between progesterone and the other placental 
markers, hCG, SPi and human placental lactogen (hPL).
Human Placental Lactogen. There have been two studies of maternal 
serum hPL levels in Down’ s syndrome pregnancies. Knight e t a l.  
(1989), found elevated levels 1n 24 cases, with a median value of 
1.79 MOM, whereas Ryall et a l .  (1992) found moderately elevated  
levels  in 57 cases, with a median value of 1.19 MOM.
Pregnancy Associated Plasma Protein A. Pregnancy associated plasma 
protein A (PAPP-A) levels in Down’ s syndrome in the second 
tr im ester of pregnancies appear to be v i r tu a l ly  unchanged from the 
levels  found in unaffected pregnancies. Cuckle e t a l .  (1992), in 
18 Down’ s syndrome pregnancies, reported a median level of 0.87 
MOM. Wald and V o lle r  (1992), in 16 Down’ s syndrome cases, found a 
median level of 1.02 MOM, and Knight et a l .  (1993), in 30 cases of 
Down’ s syndrome, found a median level of 1.01 MOM. PAPP-A is  
therefore not a useful predictor of Down’ s syndrome in the second 
tr im ester.
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Cancer Antigen 125. Reports on cancer antigen 125 (CA125) 1n
Down’ s syndrome pregnancies in the second tr im ester are 
c o n fl ic t in g . One study (Hogdall et a h ,  1992), of 15 Down’ s 
syndrome pregnancies and 60 controls, reported elevated levels  but 
did not give a median MOM value. Van Blerk et a l .  (1992), reported 
reduced, but not s ig n if ic a n t ly  d i f fe re n t ,  levels of CA125 in a 
study of 10 Down’ s syndrome pregnancies and 78 controls.
Inh ib in .  Inh ib in , which is involved in the endocrine control of  
gonadotrophin secretion (P e trag lia  e t a l . ,  1989), has been 
reported to be elevated in maternal serum from Down’ s syndrome 
pregnancies (Van L ith  et  a h ,  1992). In a study of 10 Down’ s 
syndrome pregnancies the median inhib in level was 1.9 MOM, a 
s t a t is t ic a l ly  s ig n if ic a n t  d ifference. Thus Inhib in may be a 
p o te n t ia lly  useful marker fo r  Down’ s syndrome, and fu rth e r  studies 
are indicated to investigate i t s  association with the other 
placental markers hCG and FrB-hCG.
Thyroid Auto-antibodies. Thyroid auto-anti bodies were observed by 
Fialkow et a h  (1965) to  be higher in women who had previously had 
a Down’ s syndrome pregnancy. Cuckle et ah  (1988a) followed up 
th is  observation and found higher, but not s t a t is t i c a l ly  
s ig n if ic a n t ly  d i f fe r e n t ,  levels  of thyroid antibodies 1n maternal 
serum samples from pregnancies affected by Down’ s syndrome. The 
authors a t t r ib u te  the lesser e f fe c t  on thyroid antibodies in women 
currently  pregnant with a Down’ s syndrome fetus to the fa c t  tha t  
the immune system is depressed during pregnancy (Sridama et a h ,  
1982), and also tha t  thyroid antibody levels decrease on average
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in women with established thyroid auto-immune disease who become 
pregnant (Amino et a l . ,  1978).
Urea res is tan t neutrophil a lk a l in e  phosphatase. Grozdea et a l .  
(1984) observed a s ig n if ic a n t  increase in urea res is tant  
neutrophil a lka lin e  phosphatase (URNAP) a c t iv i t y  in the mothers of 
Down’ s syndrome children. Cuckle et a l .  (1990a) studied samples 
taken p rio r to termination of pregnancy, from 72 women who had a 
Down’ s syndrome fetus prenata l!y  diagnosed by amniocentesis or 
CVS. Using an a rb ita ry  scoring system, median enzyme a c t iv i t y  in 
the Down’ s syndrome cases was 1.65 MOM of 156 unaffected  
pregnancies, 46 of whom had had an invasive diagnostic procedure 
and 110 of whom had not. Although a p o te n t ia l ly  promising 
discrim inator of Down’ s syndrome the measurement of URNAP has 
several practical problems making i t  unsuitable fo r  use 1n routine  
population screening. The f i r s t  is the necessity fo r  co llec t ing  
blood film s rather than blood samples fo r  analysis. The second is  
tha t th is  technique is fa r  more labour intensive than other assay 
methods used in routine screening, such as RIA or IRMA, with 100 
c e lls  on each s lid e  having to  be scored by microscopic examination 
fo r  the level of s ta in ing in each c e l l .  The th ird  is the 
subjective nature o f the te s t ,  which is shown in th is  study by the
observation that two d i f fe re n t  operators had an average d ifference
in score of 55, while the median scores fo r  unaffected pregnancies 
between 15 and 20 weeks gestation are in the range 70-85. No
information is currently  ava ilab le  on the level of corre la t ion
between URNAP and other pregnancy markers.
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6 . 1 . 7  CORRELATION BETWEEN ANALYTES IN UNAFFECTED AND DOWN’ S
SYNDROME PREGNANCY SAMPLES
S ig n if ic a n t  association between two markers reduces the predictive  
value of the markers as indicators of chromosomally abnormal 
pregnancies when the are used together to derive risks.
The levels  of correlation  reported in various studies between the 
analytes AFP, UE3, hCG and FrB-hCG are summarised in Tables 6-7 to  
6-12. For the AFP/UE3 combination (Table 6-7) corre la t ion  
c o e ff ic ie n ts  ranging from 0.13 to 0.33 have been reported in 
samples from unaffected pregnancies while in Down’ s syndrome
pregnancies corre lation  co e ff ic ien ts  range from 0.08 to 0.478. In 
f iv e  out of seven of these control sample sets, including the 
present study, and in four out of seven o f the Down’ s syndrome 
sample sets, including the present study, the levels of
c o rre la t io n  are s t a t is t ic a l ly  highly s ig n if ic a n t .
Eight studies have reported on the level of co rre la t ion  between 
AFP and hCG (Table 6 -8 ) .  Six of these gave the corre la t ion
c o e ff ic ie n t  fo r Down’ s syndrome sets, ranging from -0 .118  to 0.46. 
Only one of these (Heyl et a l . , 1990) found s ig n if ic a n t
co rre la t io n  (0.01<p<0.05). Of the eight control sets, co rre la t ion  
c o e ff ic ie n ts  ranged from 0.05 to 0.164, and in two studies 
(Spencer et a l . , 1992, Ryall et a l . ,  1992) the level of
co rre la t ion  was highly s ig n if ic a n t  (p<0.01). The present study 
found lower but s t i l l  s ig n if ic a n t  levels of co rre la t ion
(0 .0 1 <p<0.05) in the control samples only.
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Table 6 - 7
Summary of corre lation  co e ff ic ien ts  ( r )  found between AFP and UE3
in Down’ s syndrome and control pregnancies in published studies.
Controls Down’ s syndrome
n r n r
Wald et  al .  (1988a) 385 0 . 13a** 77 0 . 14a
Osathanondh et  al .  (1989) 23 <0.26 26 <0.26
Heyl et  al .  (1990) 85 0 .1 3a 18 0.08a
Norgaard Pedersen et  a 7.(1990) 291 0 . 33b** 42 0 . 36b**
Spencer (1991) 145 0 . 189bd* 29 0.624bd**
Spencer et  al .  (1992b) 2862 0 . 305b** 90 0.374b**
Ryall et al .  (1992) 390 0 . 317c** 57 0.478°**
This study 390 0 . 25a** 49 0 . 4 4 a * *
(Crossley et  a l . ,  1993)
a Correlation co e ff ic ien t  between logAFP-UE3. 
b Correlation co e ff ic ien t  between logAFP-logUE3. 
c Correlation co e ff ic ien t  between logeAFP-logeUE3. 
d Samples also included in Spencer et  a l .  (1992b).
* S ign ifican t corre lation  (0 .01<p<0.05).
** Highly s ig n if ican t  co rre la t ion  (p<0.01).
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Table 6 - 8
Summary of co rre la t io n  coe ff ic ien ts  ( r )  found between logAFP and
loghCG in Down’ s syndrome and control pregnancies in published
studies.
Controls Down’ s syndrome
n r n r
Wald et  a h  (1988b) 385 0.05 77 0.14
Osathanondh et  a h  (1989) 23 <0.26 26 <0.26
Petrocik et  a h  (1989) 125 0.05 - -
Heyl et  ah  (1990) 85 0.16 18 0.46*
Suchy & Yeager (1990) 614 0.033 - -
Spencer (1991) 145 0.280®** 29 -0.119®
Spencer et  a h  (1992b) 2862 0.152** 90 -0 .118
Ryall et  a h  (1992) 390 0 .1 64b** 57 0 . 049b
This study 410 0.11* 49 0.12
(Crossley et  a h ,  1991a)
a Samples also included in Spencer et  ah  (1992b). 
b logeAFP-logehCG
* S ig n if ican t co rre la t ion  (0 .0 1 <p<0.05).
** Highly s ig n if ic a n t  corre la tion  (p<0.01).
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For the AFP/Fr8-hCG combination f iv e  studies have reported on the 
level of co rre la t ion  (Table 6-9) but none found s t a t is t i c a l ly  
s ig n if ic a n t  association.
For the UE3/hCG combination (Table 6-10) reported in six studies, 
corre la tion  co e ff ic ien ts  fo r  the samples from unaffected  
pregnancies ranged from 0.01 to -0.216 and in Down’ s syndrome 
pregnancies from 0.11 to -0 .3267. The level of corre la t ion  fo r  the 
control samples was highly s ig n if ic a n t  (p<0.01) 1n one study and 
approaching significance (0 .0 1 <p<0.05) in two others, including  
th is  study. In the Down’ s syndrome samples two studies show some 
corre la tion  (0.01<p<0.05) and one highly s ig n if ic a n t  co rre la t ion
(p<0.01).
Of the four studies, including th is  one, reporting on corre la t ion  
fo r  the UE3/Fr|3-hCG combination (Table 6-11) only one reported 
highly s ig n if ic a n t  corre la t ion  (p<0.01) 1n the Down’ s syndrome 
pregnancies, whereas three out of four, including the present 
study, reported highly s ig n if ic a n t  corre la tion  (p<0.01) in the 
control samples. Correlation coe ff ic ien ts  ranged from 0.06 to  
-0 .3323 1n the Down’ s syndrome samples and from 0.027 to  -0 .232 in 
the control samples.
For the hCG/FrB-hCG combination (Table 6-12) a l l  four studies, 
including th is  one, reported highly s ig n if ic a n t  levels  of 
corre la tion  (p<0.01) on both control and Down’ s syndrome samples, 
with corre la t ion  co e ff ic ien ts  ranging from 0.682 to 0.82 in the 
control samples and from 0.74 to 0.9376 in the Down’ s syndrome 
samples.
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Table 6 - 9
Summary of corre la tion  coe ff ic ien ts  ( r )  found between logAFP and
logFr|3-hCG in Down’ s syndrome and control pregnancies in published
studies.
Controls Down’ s syndrome 
n r  n r
Macri et  ah  (1990) 450 -0 .05 29 0 .11
Spencer (1991) 145 0 .0884a 29 0 .0205a
Spencer et  a h  (1992b) 2862 0.019 90 0 .184
Ryall et  ah  (1992) 390 0 . 040b 57 -0 .023b
Wald et  ah  (1993a) 367 0.0017 75 0 .1481
This study 390 0.07 81 0 .08
(Crossley et  a h ,  1991b)
a Samples also Included in Spencer et ah  (1992b). 
b logeAFP-logehCG
* S ig n if ican t corre lation  (0.01<p<0.05).
**  Highly s ig n if ic a n t  corre lation  (p<0.01)
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Table 6 - 1 0
Summary of corre la t ion  coe ff ic ien ts  ( r )  found between UE3 and hCG
in Down’ s syndrome and control pregnancies in published studies.
Controls 
n r
Down’ s 
n
syndrome
r
Wald et  a h  (1988b) 385 -0.08® 77 -0.25®*
Osathanondh et  ah  (1989) 23 <0.26 26 <0.26
Heyl et  a h  (1990) 85 0.01® 18 0.46®*
Spencer (1991) 145 - 0 . 1616bd* 29 - 0 . 3267bd
Spencer et  a h  (1992b) 2862 - 0 . 1 19b** 90 - 0 . 293b* !
Ryall et  a h  (1992) 390 - 0 . 216c* 57 - 0 . 220c
This study
(Crossley et  a h ,  1993)
390 -0.13®* 49 0.11®
a Correlation co e ff ic ie n t between loghCG-UE3.
b Correlation c o e ff ic ie n t  between logHCG-logUE3. 
c Correlation c o e ff ic ie n t  between logehCG-logeUE3. 
d Samples also included in Spencer et ah  (1992b).
* S ig n if ican t corre lation  (0.01<p<0.05).
** Highly s ig n if ic a n t  corre lation  (p<0.01).
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Table 6 - 1 1
Summary of co rre la t ion  co e ff ic ien ts  ( r )  found between UE3 and
Fr3-hCG 1n Down’ s syndrome and control pregnancies in published
studies.
Controls Down’ s syndrome
n r n r
Spencer (1991) 145 - 0 . 2132bd** 29 - 0 .0969bd
Spencer et  a h  (1992b) 2862 0 . 027b 90 0 .052b
Ryall et  a h  (1992) 390 -0 .2 3 2 c** 57 - 0 .221°
Wald et  ah  (1993a) 367 - 0 .1 327b** 75 - 0 .3323b**
This study 390 -0 .1 4a ** 49 0 .06a
(Crossley et  a h ,  1991b)
a Correlation c o e ff ic ie n t  between logFr3-hCG-UE3.
b Correlation c o e ff ic ie n t  between logFr3-HCG-logUE3.
c Correlation c o e ff ic ie n t  between logeFr3-hCG-logeUE3.
d Samples also included in Spencer et  al .  (1992b).
* S ig n if ican t corre la t ion  (0 .01<p<0.05).
**  Highly s ig n if ic a n t  co rre la t ion  (p<0.01).
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Table 6 - 1 2
Summary of co rre la t io n  co e ff ic ien ts  ( r )  found between loghCG and
logFr(3-hCG in Down’ s syndrome and control pregnancies in published
studies.
Controls 
n r
Down’
n
s syndrome 
r
Spencer (1991) 145 0 . 8901a** 29 0 . 8924a**
Spencer et  a l .  (1992b) 2862 0.817** 90 0.805**
Ryall et  al .  (1992) 390 0 . 682b** 57 0 . 907b**
Wald et  al .  (1993) 367 0.7382** 75 0.9376**
This study
(Crossley et  a l . ,  1991b)
390 0.82** 49 0 .74**
a Samples also included 1n Spencer et  al .  (1992b). 
b logeFr|3-hCG-logehCG
* S ig n if ic a n t  co rre la t io n  (0.01<p<0.05).
**  Highly s ig n if ic a n t  co rre la t ion  (p<0.01)
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In summary there appears to be a very high level of co rre la t ion  
between hCG and Fr|3-hCG and v i r tu a l ly  none between AFP and 
Fr0-hCG. The majority of reports found s ig n if ic a n t  corre la t ion  
between AFP and UE3, and s ignificant co rre la t ion  was reported in 
some between UE3 and hCG and UE3 and Fr|3-hCG, and in a few between 
AFP and hCG.
In te rp re ta t ion  of correlation coe ff ic ien ts  fo r  s ig n if ic a n t  
corre la tion  is dependent on sample size. Correlation  co e ff ic ien ts  
which are s ig n if ican t in a large sample set may not be so in a 
small sample set. The calculated value of the corre la t ion  
c o e ff ic ie n t  ( r )  is affected by the standard deviation of the 
analyte values and variations in standard deviation between 
studies may a l te r  the level of correlation found.
6,2  ANALYTE LEVELS IN MATERNAL SERUH FROM TRISOMY 18 PREGNANCIES
The median levels of the analytes AFP, hCG, SP1, UE3 and Fr|3-hCG 
from published studies are shown in Table 6-13. Much less data is  
ava ilab le  from trisomy 18 pregnancies than from Down’ s syndrome, 
mainly due to the much lower incidence of trisomy 18.
The overall weighted geometric median fo r  AFP in trisomy 18 
pregnancies was 0.64 MOM from 164 pregnancies from 13 d i f fe re n t  
reports, including th is  one. The value of 0.68 MOM found in th is  
study was close to the overall value.
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Table 6 - 1 3
Summary of analyte medians found in trisom y 18 pregnancies in
published studies.
n
AFP
MOM
hCG
MOM
Median
SPi
MOM
UE3
MOM
FrB-hCG
MOM
Merkatz et  ah  
(1984)
13 0 . 65a - - - -
Hershey et  a h  
(1985)
3 0. 77a
" "
«*•
Doran et  ah  
(1986)
10 0.64
" " "
Llndenbaum et  ah  
(1987)
38 0. 60b
Bogart et  a h  
(1987)
3 0.73 0.13
“ " '
Bartels  & Lindemann 
(1988)
4 1.47®
Bogart et  ah  
(1989)
2 «*• 0.13
Norgaard Pedersen 
et  a h  (1990)
7 0.49
"
0.38
'
Canlck et  a h  
(1990a)
10 0 . 57b 0.27 0.49
Bartels  et  a h  
(1990)
12
"
0.14 1.25®
Darnule et  a h  
(1990)
12 0 . 75b 0.30
"
0.65
"
M il le r  et  a h  
(1991)
9 0.49 0.36
' "
Bogart et  a h  
(1991)
2 0.48
B l i tz e r  et  a h  
(1991)
13 0.79 0.27 0.41
Staples et  a h  12 
(1991)
(continued on next page)
0.68 0.34 0.55 0.31
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Table 6 - 1 3  (contd)
n
AFP
MOM
hCG
MOM
Median
SPi
MOM
UE3
MOM
Frl3-hCG
MOM
Barkai et  a 1. 
(1993)
15 0.66 0.23 - 0.40 -
This study 
(Zeitune et  a L ,
19
1991)
0. 68b —
This study 
(Crossley et  a 1.,
12
1991a)
— 0.21 •
This study 
(Crossley et  a l . ,
11
1991b) " '
0.23
This study 9 
(Graham et  a l . , 1992)
0.87
This study 
(Crossley et  a l . ,
4
1993)
0.38
Overall weighted
geometric median 0.64 0.25 1.13 0.47 0.27
(n) (164) (102) (25) (73) (23)
a Estimated from figu re  in publication .
b States tha t excludes open neural tube defects and an ter io r  
abdominal wall defects
-240 -
For hCG the overall weighted geometric median was 0.25 MOM in 102 
pregnancies from 11 d i f fe re n t  reports, including th is  one. The 
value of 0.21 MOM found in th is  study was close to the overa ll  
value. For Frl3-hCG the overa ll geometric median was s im ila r  , a t  
0.27 MOM, in 23 cases from two d i f fe re n t  reports, including th is  
one.
In contrast the other placental marker, SP1, with the same s i te  of 
synthesis as in ta c t  hCG and Frp-hCG, does not seem to show any 
a lte ra t io n  in value in trisomy 18 pregnancies. From three reports, 
including the present study, an overa ll geometric median of 1.13 
MOM was found in 25 pregnancies. The three reports had f a i r l y  
d i f fe r in g  median MOM values fo r  SP1 in trisomy 18 pregnancies, 
with a range of 0.87 to  1.47 MOM. These same authors (B arte ls  & 
Lindemann, 1988, Bartels et  ah  , 1990, present study) also
reported d i f fe r in g  median values in Down’ s syndrome pregnancies.
Levels of UE3 were found to be lowered 1n trisomy 18, with an 
overa ll geometric median of 0.47 MOM in 73 pregnancies from seven 
d i f fe re n t  reports, including th is  one. The value o f 0.43 MOM found 
in th is  study is close to the overa ll median.
Thus in tact hCG and Fr3-hCG are the most powerful predictors of  
trisomy 18, followed by UE3 and then AFP.
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6.3 PREDICTED DETECTION RATES FOR DOWN’ S SYNDROME FROM
RETROSPECTIVE STUDIES. USING BIOCHEMICAL MARKERS
Single analytes in combination with maternal  age.
Table 6-14 compares predicted detection rates fo r  Down’ s syndrome 
using risks derived from one analyte combined with maternal age 
r isks. Using AFP/age the present study predicted a 37% detection  
rate fo r  Down’ s syndrome at a corresponding 6.6% fa lse  positive  
rate (Section 5 .1 .2 .4 ) .  Predicted detection rates fo r  Down’ s 
syndrome, and corresponding fa lse  positive  rates from other 
published studies are shown in Table 6-14. Because of the varying 
fa lse  positive rates quoted i t  is d i f f i c u l t  to compare these 
exactly , but overa ll the average detection rate is  36% at a 
corresponding fa lse  pos it ive  rate of 7.0%.
Considering UE3/age, the present study predicted a detection rate  
fo r  Down’ s syndrome of 29% at a 5% fa ls e  positive rate . This is  
compared with other published studies in Table 6-14. Again i t  is  
d i f f i c u l t  to  compare these due to the large d ifferences in fa lse  
positive  rate , but overa ll the average detection rate is  37% at a 
corresponding fa lse  pos it ive  rate of 8.0%
The hCG/age combination in the present study gave a better  
predicted detection rate  fo r  Down’ s syndrome than e ith e r  AFP/age 
or UE3/age, with a predicted detection rate fo r  Down’ s syndrome of 
51% at a corresponding 5% fa ls e  positive  rate . This is  compared 
with other published studies in Table 6-14. Again there is a wide 
range of  fa lse  positive  rates, but the three studies (Wald et  a l . , 
1988b, Spencer et a l . ,  1992b, present study) which quoted fa lse
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Table 6 - 1 4
Predicted detection rates fo r Down’ s syndrome and corresponding 
fa ls e  positive rates in whole pregnant populations, fo r  single  
analytes in combination with maternal age, from published studies.
False
positive
rate
Detn
rate
Calculation
method
AFP/age
Tabor et  al .  (1987) 9.4 53 BT
Cuckle et  al .  (1987) 5.4 36 LR
MacDonald et  al .  (1991) 6.5 32 LR
Ryall et al .  (1992) 7.2 25 RM
Spencer et  al .  (1992b) 6.6 31 LR
Present study 
(Zeitune et  al .  ,1991)
6.6 37 LR
UE3/age
Wald et al .  (1988a) 5.2 41 LR
MacDonald et  al .  (1992) 17.0 48 LR
Ryall et  al .  (1992) 7.2 31 RM
Spencer et  al .  (1992b) 5.4 38 LR
Present study 
(Crossley et  a l . ,  1993)
5.0 29 LR
hCG/aqe
Wald et  al .  (1988b) 5.0 49 LR
MacDonald et  al .  (1991) 8.0 46 LR
Ryall et al .  (1992) 9,8 35 RM
Spencer et  al .  (1992) 4.9 45 LR
Present study 
(Crossley et  a l . , 1991)
5.0 51 LR
FrB-hCG/aqe
Macri et al .  (1990b) 5.0 57 DA
Ryall et  al .  (1992) 8.4 41 RM
Spencer et  al .  (1992b) 5.0 54 LR
Wald et al .  (1993a) 5.0 56 LR
Present study 
( Crossley et  a l . ,  1991b)
5.0 44 LR
Calculation methods: LR = Likelihood ra t io  RM = Regression model 
BT = Bayes theorem DA = Discriminant analysis
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positive rates at or close to 5% had s im ila r  predicted detection  
rates fo r  Down’ s syndrome, with a range of 45-51%.
Considering the Frl3-hCG/age combination, the present study gave a 
predicted detection rate fo r  Down’ s syndrome of 44%, at a fa lse  
positive rate of 5%. Table 6-14 compares th is  with other published 
studies. Four of the f iv e  studies (Macri et  a h ,  1990, Spencer et  
a h ,  1992b, Wald et  a h ,  1993a, present study) stated detection  
rates fo r Down’ s syndrome at a 5% fa lse  positive ra te , and these 
had a range from 44-57%.
Thus in tact hCG and Fr3-hCG are be tte r  predictors of Down’ s 
syndrome than AFP and UE3 when used in combination with maternal 
age.
Double analytes in combination with maternal  age.
Table 6-15 compares predicted detection rates fo r  Down’ s syndrome, 
and corresponding fa ls e  pos itive  rates, using combinations of two 
analytes, a l l  including AFP, together with maternal age. From the 
present study hCG gave the highest predicted detection rate  for  
Down’ s syndrome, when used in combination with AFP and age, and 
UE3 the lowest. The predicted detection rates, at a 5% fa lse  
positive rate are 57% fo r  AFP/hCG/age, 51% fo r  AFP/Fr0-hCG/age and 
33% for AFP/UE3/age. Other studies s im ila r ly  found lower detection  
rates fo r Down’ s syndrome using UE3 instead of e i th e r  in ta c t  or 
free  3 hCG (Wald et  a h ,  1988b, 1993, Norgaard-Pedersen et  a h ,
1990, Spencer et a h ,  1992b). Spencer et  ah  (1992b) and Wald et  
ah  (1993), who both compared the predicted performance of in tact  
versus free 3 hCG, found improved performance in the predicted
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Table 6 - 1 5
Predicted detection rates fo r  Down’ s syndrome and corresponding 
fa lse  positive rates in whole pregnant populations, fo r  pairs of 
analytes in combination with maternal age, from published studies.
False
positive
rate
Detn
rate
Calculation
method
AFP/hCG/aqe
Wald et ah  (1988b) 5.0 55 LR
Norgaard-Pedersen et  a 7.(1991) 7.8 55 DA
MacDonald et  ah  (1991) 6.2 48 LR
Ryall et ah  (1992) 6.4 38 RM
Spencer et ah  (1992b) 4.9 51 LR
Present study 
(Crossley et a h , 1991a)
5.0 57 LR
AFP/UE3/age
Wald et ah  (1988a) 5.2 45 LR
MacDonald et a l .  (1991) 14.1 43 LR
Ryall et  a h  (1992) 8.9 47 RM
Spencer et a l .  (1992b) 5.6 35 LR
Present study 
(Crossley et  a l . ,  1993)
5.0 33 LR
AFP/Frl3-hCG/aqe
Macri et  a h  (1990) 5.0 72 LR
Spencer et a h  (1992b) 5.1 60 LR
Wald et  ah  (1993a) 5.0 58 LR
Present study 
(Crossley et  a h , 1991b)
5.0 51 LR
Calculation methods: LR = Likelihood ra t io
RM = Regression model 
DA = Discriminant analysis
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detection rate fo r  Down’ s syndrome using Fr|3-hCG. This is in 
contrast to the findings of the present study. The poorer 
performance of FrB-hCG in the present study may be a t tr ib u ted  to 
the poor precision of the assay used in th is  study (Section 
4 .1 .4 .2 ) ,  which increased the spread of values and hence the 
standard deviation of the FrB-hCG values in unaffected and Down’ s 
syndrome pregnancies (Table 5-22).
Tr ip le  analytes in combination with maternal  age.
Table 6-16 summarises published studies which gave predicted  
detection rates and corresponding fa lse  positive  rates fo r  
combinations of three analytes, e i th e r  AFP/UE3/hCG/age or 
AFP/UE3/Frl3-hCG/age. The present study found reduced predicted  
detection rates fo r  Down’ s syndrome, at a 5% fa lse  pos itive  rate ,  
when UE3 was added to e i th e r  AFP/hCG/age or AFP/Fr|3-hCG/age. A 
detection rate of 53% was predicted with AFP/UE3/hCG/age and 57% 
with AFP/hCG/age. For the AFP/UE3/Fr3-hCG/age combination the 
predicted detection rate was 49% compared with 51% with 
AFP/FrB-hCG/age. Spencer et  al .  (1992b) noted a s im ila r  e f fe c t  
with and without the use of UE3. A detection rate of 51% obtained 
using AFP/hCG/age could be matched when UE3 was added only at the 
expense of increasing the fa lse  positive  rate from 4.9% to  5.3%. 
Other studies (Wald et  a l . , 1988b, Norgaard-Pedersen et  a l . ,  1990) 
have found an improvement in the predicted detection rate fo r  
Down’ s syndrome when UE3 is used in addition to AFP/hCG/age. The 
improved detection rates reported by others (MacDonald et  a l . ,  
1991, Ryall et  a l . ,  1992) by the addition of UE3 have been 
para lle led  by an increase in the fa lse  positive  ra te . Of the two 
studies which compared the addition of UE3 to the AFP/FrB-hCG/age
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Table 6 - 1 6
Predicted detection rates fo r  Down’ s syndrome and corresponding 
fa lse  positive rates in whole pregnant populations, fo r
combinations of three analytes in combination with maternal age, 
from published studies.
False
positive
rate
Detn
rate
Calculation
method
AFP/UE3/hCG/age
Wald et  ah  (1988b) 5.0 61 LR
Norgaard-Pedersen et  a 7.(1990) 7.3 58 DA
Macdonald et ah  (1991) 7.7 60 LR
Ryall et  ah  (1992) 7.9 43 RM
Spencer et ah  (1992b) 5.3 51 LR
This study 
(Crossley et a h , 1993)
5.0 53 LR
AFP/UE3/Frl3-hCG/age
Spencer et ah  (1992b) 5.1 60 LR
Wald et  ah  (1993a) 5.0 62 LR
This study 5.0 49 LR
Calculation methods: LR = Likelihood ra t io
RM = Regression model 
DA = Discriminant analysis
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combination, Wald et  ah  (1993a) found a small improvement in the 
predicted detection rate fo r  Down’ s syndrome with the addition of  
UE3, but Spencer et ah  (1992b) found no improvement.
6 .3.1 IS UE3 USEFUL IN SCREENING FOR DOWN’ S SYNDROME?
This present study f a i l s  to show any improvement in the predicted  
detection rate for Down’ s syndrome by the addition of UE3 to that  
obtainable e ith e r  by the AFP/hCG/age combination or the 
AFP/Fr|3-hCG/age combination. This is a t tr ib u ta b le  to the high 
level of corre lation  found between UE3 and AFP which causes a 
decrease in the like lihood ra t ios  derived from the Down’ s syndrome 
d is tr ib u t io n  in th is  series (Table 6 -17 ).  The contribution to  
overa ll r isk  estimates by additional markers is dependent on 
several parameters: the s h i f t  in the mean value of the affected
pregnancies, the spread of the d is tr ib u tio n s  of values in affected  
and unaffected pregnancies and on the level of corre la t ion  between 
any analytes used together. S ig n if ican t associations between 
markers, as found fo r UE3 and AFP, w i l l  reduce th e i r  pred ic tive  
value when used in combination.
The study by Wald et  ah  (1988a) showed a more modest association
between AFP and UE3 than that reported here (0.13 vs 0.25 in the
controls and 0.14 vs 0.44 in the Down’ s pregnancies). These 
authors used a modified Amersham AMERLEX RIA (designated IM2) 
o r ig in a l ly  optimised fo r  use in the th ird  tr im ester. Levels of 
corre la tion  s im ilar  to those found by Wald et  ah  (1988a) have
been reported by Heyl et  ah  (1990) who also used the modified IM2
Table 6 - 1 7
Median l ike lihood ra tios  (LR), calculated from AFP/hCG results  and 
from AFP/hCG/UE3 results  fo r  49 Down’ s syndrome pregnancies and 
390 controls.
Median LR
Analytes Down’ s syndrome Controls
AFP/hCG 2.81 0.31
AFP/hCG/UE3 2.42 0.32
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assay, while Norgaard-Pedersen et ah  (1990), using a d i f fe re n t  
immunoassay method, found higher levels of corre la t ion  between AFP 
and UE3 (Controls: r=0.33, Down’ s: r=0 .36). Fisher et  a h  (1989)
also noted that AFP and UE3 are not independent in Down’ s syndrome 
pregnancies but give no information on the UE3 assay method used. 
The optimised second tr im ester RIA k i t  (Amersham, designated IM4) 
used in the present study was also used by Spencer et  a h  (1992b) 
who found levels of co rre la t ion  (Controls: r=0.31, Down’ s: r=0.37) 
s im ila r  to those reported here. This suggests tha t corre la t ion  
coe ff ic ien ts  may be assay dependent.
Reynolds and John (1992) compared the performance of the Amersham 
th ird  trim ester assay (IM 2), modified as described by Canick et  
a h  (1988), with that of the optimised second tr im ester k i t  (IM 4),  
as used in the present study and found s ig n if ic a n t  d ifferences in 
results . The modified IM2 assay method uses standards with 
assigned values lower than th e i r  true concentration due to  the use 
of a 'ze ro ’ standard which contains measurable amounts of UE3. 
This assay method should thus give lower values 1n comparison to  
the optimised second tr im ester assay method (IM4) which requires  
no such modification and employs a charcoal stripped zero standard 
containing no UE3 (personal communication, Dr C Davies, Kodak 
diagnostics, C a rd if f ) .  However consistently higher values were 
found. These higher values may be ind icative  of the presence of  
s ig n if ic a n t  c ro ss -rea c tiv ity  with other steroids in maternal serum 
(possibly este tro l and the conjugated forms of e s t r io l ) .  The same 
study also noted s ig n if ic a n t ly  d i f fe re n t  d is tr ib u tio n s  of UE3 
values between the two d i f fe re n t  assay methods, with an increased 
spread of MOMs obtained with the optimised second tr im ester assay.
The UE3 d is tr ib u tio n  parameters established using the modified IM2 
assay cannot be used with the replacement IM4 assay. The low level 
of corre lation  and t ig h te r  d is tr ibu tio ns  may explain the enhanced 
performance predicted by Wald et  ah  (1988b) with the addition of  
UE3 to The AFP/hCG/age combination.
Wald et ah  (1992a) have predicted an increase in detection of 
Down’ s syndrome, at a 5% fa ls e  positive rate , from 58% to 67% 
using AFP/hCG/UE3/age when ultrasound is used fo r  dating  
pregnancies rather than LMP. For AFP/hCG/age the increase was from 
54% to 58% using ultrasound estimation of gestation. Of these 
three analytes, UE3 shows the largest rate of change in median
value with gestation between 15 and 20 weeks and hCG the smallest. 
In te rp re ta t io n  of UE3 results  is therefore most affected by 
inaccuracies in estimates of gestation. In the present study,
based on a large screening population in the west of Scotland, 
around 80% of pregnancies have an ultrasound estimate of gestation  
ava ilab le  at the time of sampling. Since i t  is un like ly  tha t in 
any screening programme a l l  pregnancies w i l l  have ultrasound 
estimates of gestation, the projected gains in detection claimed 
fo r  UE3 by Wald et  a l  (1992a) are un like ly  to  be realised in 
practice. Rather a h ierarchical system which makes use of the 
gestational information ava ilab le  at the time of sampling has to  
be employed in practice.
Considering the four biochemical markers AFP, UE3, hCG and Fr|3-hCG
in d iv id u a lly ,  hCG and Fr8-hCG are better predictors of Down’ s
syndrome pregnancies than AFP and UE3 (Table 6 -14 ).  However, AFP 
has an important additional role in the detection o f pregnancies
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at r isk  fo r  open neural tube defects, and is thus the f i r s t  choice 
analyte in any second trim ester multiparameter prenatal screening 
programme, and should be combined with hCG or Fr|3-hCG.
The benefits of adding UE3 to AFP/hCG/age or AFP/Fr3-hCG/age 
screening fo r  Down’ s syndrome therefore appear equivocal and 
careful consideration should be given to  the advantages and 
disadvantages of using a th ird  analyte o f marginal pred ictive  
value in population screening programmes. For each additional  
marker assayed, the co e ff ic ien t  of va r ia t ion  of the f in a l  r isk  
estimate increases (Holding 1991b, Spencer and Carpenter 1991). 
Reynolds (1992) estimated that the CV of the overa ll r is k  was 
around 22% when two parameter screening (AFP+hCG) was used and 
increased to around 40% when three parameter screening 
(AFP+hCG+UE3) was used. This 1s borne out by results  in the UK 
External Q uality  Assessment Scheme fo r Down’ s syndrome screening, 
where the average between-lab variation  in r isk  estimation over 
six months in 1993 (May-October) fo r  laboratories using 
AFP/hCG/UE3 (13 centres, CV 53%) is greater than fo r  those using 
AFP/hCG (30 centres, CV 34%). The cumulative e f fe c t  of ana ly tica l  
imprecision may u lt im ate ly  lead to loss of detection in routine  
c l in ic a l  practice .
Prospective analysis of AFP, hCG and UE3 in a large series of 
unselected pregnancies is required to determine the practica l  
value of UE3 as a th ird  analyte for prenatal screening fo r  Down’ s 
syndrome.
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6 . 3 .2  INTACT VERSUS FREE 0 hCG IN SCREENING FOR DOWN’ S SYNDROME
Recent studies have suggested tha t Fr3-hCG may be a superior 
marker to in tac t  hCG in Down’ s syndrome screening (Macri e t  ah  , 
1990, Spencer, 1991, Spencer et  a h , 1992b). Others have predicted  
a small increase in detection rate fo r  Down’ s syndrome (Wald et  
a h , 1993a), while others have fa i le d  to demonstrate any
improvement when using Fr3-hCG (present study, Stone et  a h , 
1993). The summaries of predicted detection rates fo r  Down’ s 
syndrome from published studies using in ta c t  hCG/age and 
Fr3-hCG/age (Table 6-14, Section 6 .3 ) suggest that neither marker 
is s ig n if ic a n t ly  be tte r  than the other. However, meta-analyses of 
medians show that the median MOM fo r  Fr3-hCG (2.32 MOM, Table 6-5) 
is higher than that fo r  in ta c t  hCG (2.08 MOM, Table 6 -2 ) .  However 
quoted standard deviations tend to be s l ig h t ly  higher in Down’ s 
syndrome pregnancies using FrD-hCG than fo r  in ta c t  hCG, with a 
range of 0 .23-0 .32  using in ta c t  hCG (Table 6 -2) compared with 
0.27-0 .36  using Fr3-hCG (Table 6 -5 ) .  This increased standard 
deviation may cancel out the e f fe c t  of the higher median value 
found with Fr3-hCG. However one advantage of using Fr8-hCG is  
th a t ,  unlike in tac t  hCG, i t  is pred ictive  of Down’ s syndrome at 
a l l  gestations from 7-20 weeks (Spencer et  a h ,  1992a, Aitken et  
a h ,  1993). Prospective analysis of hCG and Fr8-hCG in a large 
series of unselected pregnancies is required to determine which of 
these two analytes is the bette r  detector of Down’ s syndrome in 
c l in ic a l  practice in the second tr im ester of pregnancy.
One question which has been raised as to  the usefulness of Fr3-hCG 
in routine use is the s t a b i l i t y  of the in tac t  hCG molecule. Since
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only 0.5% of to ta l  hCG is present as the free  3 subunit (Osturk et  
a h ,  1988) only a small amount of in ta c t  hCG would need to  
dissociate into a and 3 subunits to have a s ig n if ic a n t  e f fe c t  on 
the levels  of Fr3-hCG. Knight and Cole (1991) suggested that  
Fr3-hCG might be a r t i f i c i a l l y  elevated in poorly stored samples of 
maternal serum. Stevenson et al .  (1993) found tha t  levels  of 
Fr3-hCG increased by 14% in 24 hours in whole blood at room 
temperature, with the r ise  reaching 43% a f te r  four days. Spencer 
et  al .  (1993) found a slower rate of change, with Fr3-hCG levels  
in whole blood increasing by 2.8% per day at room temperature, and 
levels 10% higher a f te r  87 hours. Thus increased Fr3-hCG levels
are l ik e ly  to be found in blood samples collected from a wide
geographical area, which can take several days to a rr iv e  at the 
laboratory. When sample co llection  and processing time cannot be 
c a re fu l ly  con tro lled , a possible a lte rn a t iv e  would be to co llec t  
samples as dried whole blood f i l t e r  paper spots, which have been 
shown by Spencer et  al .  (1993) to have no increase in Fr3-hCG
levels over 9 days when stored at e ith er  room temperature or 37°C.
Blood spots have been successfully employed in prenatal screening 
fo r  Down’ s syndrome (Verloes et al ,  1992).
In both in ta c t  and free  3 subunit molecules peptide bonds can be 
missing between 3 subunit residues 44 and 45 or between residues 
47 and 48, causing 'n icked’ molecules (Sakakibara et  a h ,  1990). 
There is  a greater extent of 'n ick ing ’ in the free  3 subunit than 
in in ta c t  hCG (Pursieux et  a h ,  1990). Not a l l  Fr3-hCG antibodies  
recognise the 'n icked ’ form (Kardana and Cole, 1992) and fu rthe r  
work is required to establish whether the use of antibodies such 
as FBT11 which measure to ta l  free 3 subunit concentration (both
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the 'n icked’ and 'unnicked’ forms) (Kardana and Cole, 1992) give 
improved s e n s it iv i ty  of detection of Down’ s syndrome pregnancies.
6 .3 .4  DIFFERING WAYS OF CALCULATING RISKS FROM ANALYTES
The most common method of calculating risks from analyte levels  in 
the studies discussed in section 6.3 is to use like lihood ra t io s ,  
which are calculated from the overlapping Gaussian or log Gaussian 
d is tr ib u t io n s  (Cuckle et  a h ,  1987, Wald et  a h ,  1988a, Wald et  
a h ,  1988b, Reynolds and Penney, 1989), and th is  method has been 
used in the present study. However some other authors have used 
d if fe r in g  s t a t is t ic a l  methods to calculate risks from analyte  
levels  e .g . discriminant analysis (Norgaard-Pedersen et  a h ,  1990, 
Macri et  a h ,  1990) and a regression model (Ryall et  a h ,  1992).
This Study
This study has compared some of the possible methods of exp lo it ing  
the p red ic tive  value of AFP and hCG fo r  use in screening fo r  
Down’ s syndrome. Wald et  ah  (1988a, 1988b) f i r s t  suggested a
multi parameter l ike lihood ra t io  method fo r  combining risks from 
several variables which has the added refinement of allowing fo r  
any corre la t ion  between variables. However when th is  approach was 
used in the present study to calculate risks from AFP and hCG 
v i r tu a l ly  no d ifference in detection rates was obtained 
irrespective  of whether corre lation  was included or not (Table
5 -35 ),  with a predicted detection rate fo r  Down’ s syndrome of 
56-57% at a 5% fa lse  pos itive  rate.
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Arab et  al .  (1988) and White et  al .  (1989) each proposed the use 
of simple ra t io  methods fo r  combining AFP and hCG results to  
provide a combined r isk  fac to r ,  although th is  approach has been 
c r i t ic iz e d  elsewhere (Cuckle et  a l . ,  1989a). Using these hCG/AFP
ra t ios  alone (Table 5 -33 ),  without adding maternal age r isks, 57% 
of Down’ s syndrome pregnancies had an hCG(MOM)/AFP(MOM) ra t io  
>2.5, compared with 5.9% of unaffected pregnancies, very s im ila r  
to  the resu lts  of Arab et  al .  (1988). However these results  are 
somewhat at variance with those of Cuckle et  al .  (1989a) although 
the parameters of the AFP and hCG d is tr ib u tio n s  (means, standard 
deviations, co rre la t ion  co e ff ic ie n ts )  o f the la t t e r  series and 
those presented here (Tables 5-2, 5-13, 5-24) are s im ila r .  The
hCG/AFP ra t io  method can be extended by combining age risks with  
the risks derived from the hCG/AFP ra t io s .  This has the e f fe c t  of 
decreasing the fa ls e  positive rate o v e ra ll ,  of increasing the 
detection rate  amongst older mothers and of reducing the fa lse
pos it ive  rate  in women under 30 years. A 57% detection rate fo r
Down’ s syndrome, at a 5% fa lse  positive ra te , using hCG/AFP ra tios  
combined with maternal age r isks, was predicted from retrospective  
studies (Table 5 -35 ) .  In routine c l in ic a l  practice , in 30,084
pregnancies, a detection rate fo r  Down’ s syndrome of 70% at a 5.1%
fa lse  pos it ive  rate was achieved using th is  method to calculate
risks.
The s im i la r i t y  in detection rates between calcu lating  risks using 
the separate d is tr ib u t io n s  of AFP and hCG, e i th e r  with or without 
corre la t ion  (Table 5 -35 ) ,  is  to  be expected, since the level of
corre la t ion  found between AFP and hCG in th is  study is low. The
performance o f hCG/AFP ra tios  combined with maternal age risks is
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surpris ing, since th is  approach th e o re t ic a l ly  does not give 
appropriate weight w ithin the calculation to hCG as a be tte r  
predictor of Down’ s syndrome than AFP. However the log Gaussian 
d is tr ib u t io n s  of the Down’ s syndrome pregnancies and controls are 
fu r th e r  separated in the hCG/AFP ra tios  (by 1.64 standard 
deviations (SD) of the controls) compared with AFP (by 0.83 SD of  
the controls) or hCG (by 1.34 SD of the contro ls ). The hCG levels  
in the Down’ s syndrome pregnancies are contributing more than the 
AFP levels  to th is  increased separation of the d is tr ib u t io n s , and 
therefore  the new var iab le , the hCG/AFP ra t io ,  is weighted
according to the respective a b i l i t i e s  of hCG and AFP to  detect 
Down’ s syndrome. Spencer et  al .  (1992b) have found no difference  
in predicted detection rate fo r  Down’ s syndrome using e ith e r  
m u lt iv a r ia te  analysis or hCG/AFP ra tios  and age, with a 50%
detection rate at a 5% fa lse  positive rate in both cases. However 
they did not f ind  th is  fo r  Fr|3-hCG, where the use of the ra t io  
method led to a small loss of detection.
Discriminant  Analysis.
The predicted detection rates fo r  Down’ s syndrome obtained by 
Norgaard-Pedersen et  al .  (1990), using discriminant analysis, are 
lower at a higher fa ls e  pos itive  rate fo r  both AFP/hCG/age and 
AFP/UE3/hCG/age than those obtained by others e .g . present study, 
Wald et  al .  (1988b) (see Tables 6-15 and 6 -16 ).  However the
authors a t t r ib u te  th is  lower detection rate to th e i r  lower hCG 
median in Down’ s syndrome pregnancies (1.57 MOM), compared with  
that found in other published studies (see Table 6 -2 ) .  Macri et  
al .  (1990b) used discriminant analysis to calcu late  r isks. Their  
calculated predicted detection rates fo r  Down’ s syndrome, both
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using Fr|3-hCG/age (Table 6-14) or AFP/Fr|3-hCG/age (Table 6-15) are 
the highest when compared with others using the same combination 
of analytes.
Regress ion.
Ryall et  al .  (1992) used a regression model to ca lcu late  risks fo r  
combinations of one to f iv e  d i f fe re n t  analytes from AFP, in tac t  
hCG, Fra-hCG, Fr|3-hCG, UE3 and hPL, together with maternal age. 
Detection rates from the regression model are lower than those 
found in the present study and in other studies (see Tables 6-14,
6-15, 6 -16 ).  From th e i r  results  they concluded th a t  the best
detection rate fo r  Down’ s syndrome might be obtained using f iv e  
analytes, AFP, Fra-hCG, FrB-hCG, UE3, and hPL, together with  
maternal age, and predicted a 64% detection rate at a 
corresponding fa lse  positive  rate of 6.8%. To improve the 
detection rate fu r th e r ,  probit analysis was carried out to weight 
the results of the biochemical variab les. This improved the 
predicted detection rate fo r  Down’ s syndrome, using the f iv e  
analytes above, to 76% with a corresponding 3.9% fa ls e  positive  
rate . The e f fe c t  of applying th is  weighting, derived from probit  
analysis, to other combinations of analytes was not stated, and i t  
is  therefore d i f f i c u l t  to  compare the e f fe c t  of th is  with other 
methods of ca lcu lating  risks.
The p a r t ic u la r  ca lcu lation  method used to derive risks fo r  a l l  
combinations of analytes from published studies is indicated in 
Tables 6-14, 6-15 and 6-16.
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Use o f  MOMs.
Some authors have cast doubt on the use o f MOMs fo r  ca lcu lating  
risks (Macri et  a 1., 1990c, Parvin et  a l . ,  1991, Bishop et  a l . ,
1993). Macri et  a h  (1990) discussed various factors  which may 
a f fe c t  calculated MOM values, such as true population differences  
between centres, assay precision d ifferences and differences in 
the lower l im its  of accuracy between assay methods. Parvin et  al .  
(1991), using AFP as a model, demonstrate th a t  assay method 
differences can a f fe c t  the d is tr ib u t io n  of MOMs and that the 
impact is greater on the lower t a i l  of the d is tr ib u t io n  than on 
the upper t a i l ,  due to the log Gaussian d is tr ib u t io n  of AFP. 
D isp arit ies  in r isk  estimates are less l ik e ly  to arise  i f  
laboratories use d is tr ib u t io n  parameters fo r  each analyte fo r  the 
affected and unaffected populations tha t are based on the local 
assay method. Laboratories should check the d is tr ib u t io n s  of MOM 
in th e ir  own pregnant population before applying published r isk  
tables or ca lcu la tion  packages.
Bishop et  al .  (1993) demonstrate tha t there are differences in 
percentiles above and below d i f fe re n t  threshold MOMs at d i f fe re n t  
gestations in a model population. The d ifferences appeared less 
marked when applied to  a data base of 5,423 actual patient AFP 
results between 15-19 weeks. The authors question the v a l id i t y  of 
combining data in MOM from d i f fe re n t  gestational ages to calculate  
r isks. However they do not suggest an e a s ily  applied a l te rn a t iv e  
and the differences found in an actual pa tien t data set are small.
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6 .4  FACTORS AFFECTING THE INTERPRETATION OF SERUM MARKER RESULTS
6 .4 .1  GESTATION
In te rp re ta t io n  of screening results  is c r i t i c a l l y  dependent on an 
accurate knowledge of the gestation at the time of sampling. The 
gestation used a ffec ts  the conversion of concentration units fo r  
the various serum markers into MOM from which like lihood ratios  
are derived. In cases where gestation is over-estimated hCG and 
Fr!3-hCG results w i l l  be higher than expected and AFP and UE3
results  lower. This is  because at 12-14 weeks gestation hCG and
FrB-hCG results are higher and AFP and UE3 results  lower than at
15-20 weeks. Underestimated gestation w i l l  therefore cause risks  
to  be underestimated.
In the retrospective studies on serum markers presented here
complete information on gestation e ith e r  by certa in  dates (LMP) or
by ultrasound estimation was not ava ilab le  fo r  a l l  samples. Around 
80% of pregnancies had an ultrasound estimate of gestation
ava ilab le  at the time of sampling, and a s l ig h t ly  smaller 
proportion had information both from LMP and ultrasound 
estimation, which in many cases was discordant. Therefore a 
h ierarch ical system to select the most appropriate gestation was 
devised. Estimates of gestation were based mainly on the time 
since the f i r s t  day of the las t menstrual period (LMP), modified 
by ultrasound as suggested by Rossavik and Fishburne (1989). 
Ultrasound estimation of gestation was used only when the date of 
the LMP was not ava ilab le  or there was a discrepancy of two weeks 
or greater between the gestation estimated from the LMP and that
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from ultrasound examination. The gestations used therefore re f le c t  
the qua lity  of information l ik e ly  to be ava ilab le  in routine  
practice and avoids dependence on a single dating method which is 
un like ly  to be ava ilab le  fo r  a l l  samples.
The above system of determining gestation has been used 
successfully in routine prospective screening with an additional  
modification to take into  account of whether LMP information was 
c la s s if ie d  as 'c e r ta in ’ or 'uncerta in ’ . Where LMP information was 
uncertain, an ultrasound estimate of gestation, 1f ava ilab le ,  was 
used in preference. Computer software is  read ily  ava ilab le  to  
recalculate Down’ s syndrome risks fo r  patients who have an 
ultrasound scan to review gestation a f te r  the te s t  results  have 
been sent back to the re fe rr in g  hospital. However i t  should be 
noted that the policy of reviewing gestation by ultrasound a f te r  
the report of a positive screening resu lt ,  which has the e f fe c t  of 
removing a proportion of women from the high r isk  group may 
u ltim ate ly  lead to loss of detection of Down’ s syndrome 
pregnancies. I t  is less frequent fo r women who are assigned to  the 
low risk group to have reviewed the gestation on which th e ir  
orig ina l r isk  ca lcu lation  was based.
Wald et al .  (1992a), in a study o f over 2,000 women having routine  
screening, predicted tha t use of ultrasound estimates of 
gestation, rather than those based on LMP, would increase the 
detection rate fo r  Down’ s syndrome, at a 5% fa ls e  pos it ive  rate  
fo r  AFP/hCG/age from 54% to 58%, and fo r  AFP/hCG/UE3/age from 58% 
to  67%. Holding (1991a) estimated that i f  so le ly  LMP information  
was ava ilab le  at the time of screening, around 15% o f women would
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need to have a recalculation o f r isk . Both Holding (1991a) and 
Gardosi and Mongelli (1993) have proposed tha t results  from 
screening programmes be reported fo r  the range of gestations  
within the screening period.
6 .4 .2  TWINS
In the present study maternal serum AFP and hCG levels  in 81 twin 
pregnancies were, on average, approximately double those found 1n 
singleton pregnancies, with a median hCG level of 1.85 MOM and a 
median AFP level of 1.91 MOM. In one twin pregnancy discordant fo r  
Down’ s syndrome an hCG level of 4.63 MOM and an AFP level of 1.94 
MOM were found.
Sim ilar results in unaffected twin pregnancies have been reported 
by others. Alpert et  ah  (1990), in 51 twin pregnancies, found 
AFP, hCG and UE3 medians o f 1.58 MOM, 1.80 MOM and 1.44 MOM 
respectively. Canick et  a l  (1990b), in 35 twin pregnancies, found 
levels of 2.32 MOM, 1.93 MOM and 1.67 MOM respectively and Wald et  
ah  (1991), in 200 twin pregnancies, 2.13 MOM, 1.84 MOM and 1.67 
MOM respectively. Neibiolo et  a h  (1991) found median hCG levels  
of 2.26 MOM in twin pregnancies. The UE3 levels  in twin 
pregnancies are lower than those found fo r  AFP or hCG.
There is l i t t l e  ava ilab le  data on serum marker levels  in twin 
pregnancies concordant or discordant fo r  Down’ s syndrome. Wald et  
ah  (1991) have proposed a screening policy fo r  twins, using 
median values for twins to  ca lcu late MOMs and from these
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calculating  Down’ s syndrome risks using the parameters of affected  
and unaffected singleton pregnancies. This would be expected to  
y ie ld  a s im ilar  fa lse  pos itive  rate fo r  Down’ s syndrome to that  
fo r  singleton pregnancies but the detection rate would be expected 
to  be lower because of the presence o f an unaffected co-twin. 
Information on marker levels  in twin pregnancies in which one or 
both twins have Down’ s syndrome needs to be co llected , perhaps by 
means of a multicentre study, before the l ik e ly  p red ic tive  value 
of th is  approach can be properly assessed and before th is  type of 
screening is implemented.
Screening fo r Down’ s syndrome in twin pregnancies presents a 
c l in ic a l  dilemma. Invasive diagnostic procedures 1n twin 
pregnancies are more d i f f i c u l t  and in cases where a Down’ s 
syndrome fetus is diagnosed the presence of an unaffected co-twin 
raises the problem of the coincidental termination of a normal 
fetus or the medical complication of se lective  f e t ic id e .  Therefore 
reporting Down’ s syndrome risks in twin pregnancies may not be 
read ily  accepted by obs te tr ic ian  or pa t ien t .
6 . 4 . 3  THREATENED ABORTION
Pregnant women experiencing vaginal bleeding have elevated levels  
of maternal serum AFP more often than the general pregnant 
population (Wald et  a h , 1977, Lidbjork et  a l . , 1977). This is
thought to re f le c t  feto-maternal haemorrhage in these cases, with 
the elevated AFP levels o rig ina ting  from fe ta l  blood, in which the 
AFP concentration is around 50,000 times higher than in the
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maternal c ircu la tion  at 17 weeks gestation (Wald and Cuckle, 
1984).
The present study has found unchanged levels of maternal serum hCG 
in cases of threatened abortion, even in those cases with elevated  
AFP. Levels of hCG in the fe ta l  c irc u la t io n  are lower than those
found in the maternal c ircu la t io n  (V a itu k a l t is ,  1977), by a fac to r
of between 100 and 1000 times (Gordon and Chard, 1979), and
feto-maternal haemorrhage is therefore un like ly  to influence  
maternal serum hCG levels .
Episodes of bleeding, p a r t ic u la r ly  i f  recently proceeding the 
co llec t ion  of the screening blood sample, may cause a r ise  in 
maternal serum AFP levels , and there w i l l  therefore be a tendency 
fo r  risks to be underestimated in case of threatened abortion. 
Since hCG levels are un like ly  to be affected i t  is possible in 
these cases to calculate a r isk  of Down’ s syndrome using hCG/age 
only, with around a 6% loss of predicted detection fo r  Down’ s
syndrome.
6 .4 .4  INSULIN DEPENDENT DIABETES MELLITUS
The present study found s l ig h t  lowering of both AFP and hCG levels  
in maternal serum, to 0.94 MOM and 0.90 MOM respective ly , in 56 
pregnancies in woman affected by IDDM. The s im ila r  lowering of 
both AFP and hCG w il l  almost cancel each other out when 
calculating  Down’ s syndrome r isks, and in th is  study (Section 
5 .3 .1 .4 )  the d iabetic pregnancies where neither over- nor
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under-represented in the high r isk  groups fo r  Down’ s syndrome or 
neural tube defects.
S im ilar levels of AFP and hCG in 24 IDDM patients were found by 
Canick et  al .  (1990), with levels of 0.97 MOM and 0.87 MOM 
respectively. UE3 levels were 0.87 MOM. Wald et  al .  (1992c), in 
samples taken from 92 d iabetic  pregnancies between 1975 and 1983, 
found s im ilar  levels of hCG to the present study and that of 
Canick et al .  (1990), with a median level of 0.95 MOM. The UE3 
level in the d iabetic  pregnancies was 0.92 MOM. However the AFP 
levels were lower than those found in the present study and by 
Canick et  al .  (1990) with a median value of 0.77 MOM, but less 
reduced than those previously reported from the same centre (0.60  
MOM, Wald et  a l . ,  1979). Reece et a l  (1987) found s im ila r  AFP
levels to those found in the present study in 39 IDDM patients ,  
who had a median AFP levels  of 0.91 MOM (0.96 MOM when weight 
corrected). The level of AFP found by Baumgarten et  al .  (1988), in 
46 IDDM patients was 0.8 MOM.
There appears to be a d ifference in AFP levels in IDDM patients  
from recent samples, such as 1n th is  study, from those found by 
Wald et al .  (1992c) in samples taken more than a decade ago. This 
difference may re f le c t  improving control of IDDM in pregnancy. 
Several studies have used high levels of glycosylated haemoglobin 
as a marker fo r  poor control of IDDM. Reece et  al .  (1987) found an 
inverse corre lation  between glycosylated haemoglobin and AFP in 
161 IDDM patients, fo r  samples taken w ithin six weeks o f each 
other. However Powrie et  al .  (1987), in 27 IDDM patients , did not 
f ind  th is  e f fe c t .  Baumgarten and Robinson (1988), in 46 IDDM
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patients , confirmed the findings of Reece et al .  (1987) with the 
patients with the highest levels of glycosylated haemoglobin 
having the lowest levels of AFP. Martin et  al .  (1990) found that  
the 25% of the 93 pregnancies in th e ir  study who had levels  of 
glycosylated haemoglobin greater than 4 SDs above the normal mean 
had a lower AFP level (0.68 MOM) when compared with the remaining 
75%, who had a mean AFP level of 0.84 MOM.
Caution should therefore be applied when using correction factors  
fo r  AFP results in IDDM patients . Published correction data based 
on patient samples taken more than a decade ago (e .g . Wald et  al .  
1979, 1992c) would appear to be inappropriate to currently
pregnant diabetic patients and th e ir  use might lead to loss of 
detection of Down’ s syndrome pregnancies.
6 . 4 . 5  MATERNAL WEIGHT
The present study has found that women of greater than average
maternal weight tend to  have lower than average serum
concentrations of AFP and hCG, while l ig h te r  than average women 
have increased concentrations. The e f fe c t  of maternal weight on 
AFP levels had been previously noted ((Haddow et  a l . ,  1981, Wald
et a l . ,  1981, Crandall et  a l . ,  1983), and various formulae
proposed for correcting AFP values fo r  maternal weight (Wald et
a l . , 1981, Johnston and Lingley, 1984, Palomaki et  a l . ,  1985).
Drugan et  al .  (1989b) have pointed out tha t obese women have a 
greater re la t iv e  increase in body fa t ,  and hence a smaller actual 
plasma volume re la t iv e  to weight than women of average weight.
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Because of th is  formulae for weight correction may cause an 
overcompensation fo r  weight in women over 90 Kg. When screening 
using AFP/age, correction for maternal weight w i l l  a f fe c t  the 
risks calculated fo r  individual women, but w i l l  have minimal 
impact on overall screening performance.
Other studies have shown the same trends fo r  AFP, hCG and UE3 
(Palomaki et a l . , 1990, Wald et a l . ,  1992a, Bartels et  a l . ,  1993). 
When AFP and hCG are used together, e i th e r  with or without UE3, 
maternal weight has less e f fe c t  on the ca lcu la tion  of risks fo r  
individual women, and correcting fo r maternal weight w i l l  have 
v i r tu a l ly  no e f fe c t  on overall screening performance in terms of  
detection rate fo r  Down’ s syndrome and corresponding fa lse  
positive  rate (present study, Palomaki et  a h ,  1990, Wald et  a h ,  
1992a).
6 .4 .6  RACE
The median levels of AFP, hCG and UE3 found in black women, 
expressed as multiples of the median of the levels  in Caucasian 
women, from published studies, are shown 1n Table 6-18. Levels of  
AFP found are 10-13% higher in black women. For hCG a range of  
levels  was found in black women, with an average 12% increase over 
the hCG level found in Caucasian women. However, two studies found 
no change in levels in black women (Petrocik et  a h ,  1989, Canick 
et  a h ,  1990) while three others found levels  which were between 
19-27% higher (Muller and Bou6, 1990, Simpson et  a h ,  1990, Kulch 
et a h ,  1993). One study (Bogart et  a h ,  1991) found a higher
-267-
Table 6 - 1 8
Levels of AFP, hCG and UE3 found in black women, expressed as 
multiples of the median fo r  Caucasian women, from published 
studies
Weight
Corr.
n AFP
(MOM)
hCG
(MOM)
UE3
(MOM)
Crandall et al .  
(1983)
Yes 288 1.10 - -
Macri et al .  
(1987)
No 1,954 1.13 - -
Petrocik et al .  
(1989)
No 50 - 1.00 -
Canick et al .  
(1990)
No 235 1.12 1.03 0.95
M uller & Bou6 
(1990)
No 214 - 1.27 -
Simpson et al .  
(1990)
No 300 - 1.21 0.95
Bogart et al . No 310 - 1.00 -
(1991) Yes — 1.10 —
Kulch et al .  
(1993)
Yes 134 - 1.19 1.05
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levels  in black women only when the results were weight corrected. 
Black women tend, on average, to be heavier than Caucasian women 
(Crandall et  a l . , 1983, Bogart et  a l . ,  1991). UE3 levels  appear 
unchanged in black women.
Crandall et  al .  (1983) found no difference in AFP levels  between 
e ith e r  Hispanic or Oriental women and Caucasian women. Bogart et  
al .  (1991) found weight corrected hCG levels 16% higher in a small 
series of Oriental women, but no s ta t is t ic a l  d ifference in levels  
between Hispanic and Caucasian women.
For screening populations with s ig n if ican t numbers of black women 
or other ethnic groups risks should be calculated a f te r  correction  
of AFP and hCG resu lts , by using medians appropriate to  the 
p a rt ic u la r  ethnic group.
6 .4 .7  MATERNAL SMOKING
I t  has been demonstrated by Palomaki et  al .  (1993) and Bartels et  
a l .  (1993) tha t in pregnant women who smoke, levels  of hCG were 
reduced to  around 80% of the levels in non-smoking women. Levels 
of AFP and UE3 were v i r tu a l ly  unchanged between smokers and 
non-smokers. Recent unpublished results from th is  laboratory would 
confirm th is ,  with a hCG median of 0.80 MOM in 617 smokers, 
compared with 1.13 in 1514 non-smokers. For AFP the median levels  
were 1.04 MOM in the smokers and 0.98 MOM in the non-smokers. The 
smokers were s ig n if ic a n t ly  l ig h te r  (d ifference in medians: 1.7 Kg) 
and younger (d ifference in medians: 4 years). The lower hCG
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resu lts  w i l l  cause smokers to be under-represented in the high 
r is k  group for Down’ s syndrome compared with non-smoking women of  
the same age and the use of d i f fe re n t  hCG median values fo r  
smokers and non-smokers could be considered. There is however no 
information currently  ava ilab le  on whether levels of hCG are 
s im ila r ly  lowered in smoking women carrying a Down’ s syndrome 
fe tus.
Some published studies have found a d e f i c i t  of smokers among women 
who had pregnancies associated with Down’ s syndrome (Hook and 
Cross, 1985, 1988, Christianson and Torfs, 1988). Cuckle et al
(1990b) found a lower, but not s t a t is t i c a l ly  s ig n if ic a n t ly  
d i f fe r e n t ,  proportion o f smokers amongst women who had a pregnancy 
associated with Down’ s syndrome, compared with age matched 
controls. Data on Down’ s syndrome rates in smokers and non-smokers 
need to be interpreted with caution, since pregnant women who 
smoke tend to be younger than those who do not, and therefore  on a 
population basis the Down’ s syndrome incidence w i l l  tend to be 
lower in smokers, purely on the basis of age. Further studies, 
c a re fu l ly  controlled fo r  age are required to determine whether 
smoking does have a protective  e f fe c t  against a Down’ s syndrome 
b ir th .
6 . 4 . 8  REPEAT TESTING
Because of regression to the mean, a second sample w i l l  tend to  
have pregnancy marker results which are closer to  the average 
value than those fo r  the f i r s t  sample (Haddow et  a h , 1986). Cases
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affected by Down’ s syndrome are as l ik e ly  as unaffected
pregnancies to be moved from the high r isk  group to the low r isk  
group by the results from a second sample. Repeat tes t ing  (except 
in cases where the gestational has shown tha t  the f i r s t  sample has 
been taken too ea r ly )  is  inappropriate and w i l l  lead to loss of 
detection o f affected cases. Lustig et  al .  (1988), in the
C a li fo rn ia  AFP screening programme fo r  Down’ s syndrome, reported 
f iv e  out of 23 cases of Down’ s syndrome which had not been
detected, due to repeat tes t ing  reassigning them from the high to
the low r is k  group.
Cuckle et  al .  (1989b), although considering repeat tes t in g  an 
u n ju s t if ie d  policy, compiled a nomogram to combine AFP results  
from the f i r s t  and second sample to give a Down’ s syndrome risk  
combined from both. To combine results of m ultip le  markers from 
f i r s t  and second samples in th is  way would be considerably more 
complex.
In the west of Scotland prenatal screening programme, repeat 
tes t in g  of women who are assigned to the high r isk  group fo r  
Down’ s syndrome is discouraged. However where a repeat sample is  
received, and the results  of the second assign the patien t to  the 
low r isk  group, an additional comment is  added to the report,  
s ta ting  th a t  th is  does not inva lida te  the Down’ s syndrome r isk  
from the f i r s t  sample.
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6.5 SCREENING FOR DOWN’ S SYNDROME IN ROUTINE CLINICAL PRACTICE
Screening protocols fo r  the detection of chromosomally abnormal 
pregnancies, developed from retrospective studies of pregnancy 
markers in stored maternal serum samples, are increasingly being 
applied in c l in ic a l  practice . There is wide va r ia t io n  in the
combinations o f markers used and in the age d is tr ib u tio n s  of the 
populations in which they are applied, and th is  is re f lec ted  in 
the va r ia t io n s  in detection and fa lse  positive rates reported in
many studies. Care is therefore required when comparing the
performance o f d i f fe re n t  screening programmes.
6.5.1 AFP/AGE SCREENING IN PROSPECTIVE USE
Data derived from the investigation of AFP levels  in pregnancies 
with autosomal trisomy in the present study (Section 5 .1 )  were 
used to modify the ex is ting  maternal serum AFP screening programme 
fo r  NTD operating in the west of Scotland since 1976, to  provide 
risks of an autosomal trisomy in individual pregnancies.
Over a 3 i  year period approximately 100,000 pregnancies were
screened using th is  protocol and a detection rate fo r  Down’ s 
syndrome of 41% was obtained, with a fa lse  pos itive  rate  of 6.1%. 
The detection rate fo r  a l l  autosomal trisomies was 43% (Tables 
5-9 , 5 -10 ) .  However some older women were offered amniocentesis or 
chorionic v i l lu s  sampling so le ly  on the basis of age >35 years 
e ith e r  preceding or instead of a maternal serum screening te s t  and 
the autosomal trisomy pregnancies diagnosed in th is  way are shown
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in Table 5-11.
Some d i f f i c u l t i e s  emerged in the app lication of th is  type of 
screening. In te rp re ta t io n  of numerical risks proved problematical 
fo r  both patients and medical s t a f f  who were more fa m il ia r  with  
the simpler concept of a maternal age threshold. The rate of 
diagnostic tes ting  was s ig n if ic a n t ly  higher in older women than in 
younger women with the same calculated r isk  although in both cases 
the calculated risks are exactly the same and the age factor  
already incorporated. Although uptake of diagnostic testing  
overa ll was 42% and therefore the potentia l detection rate fo r  
autosomal trisomies of 43% was reduced to an actual prenatal 
diagnosis rate of 25% (Table 5 -10 ),  th is  f igu re  represents a 
substantial increase in detection over the o r ig in a l system based 
sole ly  on maternal age. Thus although AFP is a re la t iv e ly  weak 
marker fo r  Down’ s syndrome, when combined with maternal age and 
applied in whole population screening i t  provides a s ig n if ic a n t ly  
better  method of u t i l i z in g  prenatal diagnostic resources.
Data from other published prospective studies are summarised in 
Table 6-19. A ll of these other studies (DiMaio et  a h , 1987,
Lustig et  a l . , 1988, New England Collaborative Study, 1989) had
incomplete ascertainment of Down’ s syndrome cases, with the number 
of cases in the women assigned to the high r isk  group being 
estimated from the age d is tr ib u t io n  of the screened population. 
Also these studies d iffe red  from the west of Scotland study 
described above in tha t a l l  three were confined to women who were 
a l l  or mainly under 35 years of age. However comparison of a l l  
four studies, including th is  one, shows an approximately l in e a r
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Table 6 - 1 9
Comparison of detection rates fo r  Down’ s syndrome and 
corresponding fa lse  positive  rates achieved using AFP/age 
screening in routine practice .
No.women 
screened
False
positive
rate
Detn
rate
Palomaki (1986) 51,141 2 . 1ac 2iacd
Di Maio e t  a7, ( 1987) 34,354 4 . 2bd 33bd
Lustig et  a h  (1988) 174,784 2. 3a 21ad
New England co llabora tive  
study (1989)
77,273 2. 7a 25ad
Present study 100,481 6.1 41
a Women aged <35 years only. 
b Mainly women aged <35 years.
c Cases also included in New England co llaborative  study (1989).
d Total number of Down’ s syndrome pregnancies in screened 
population estimated.
-274-
increase in detection with increasing fa lse  pos itive  ra te . A ll  
demonstrate tha t  is possible to extend screening fo r  Down’ s
syndrome to women younger than 35 years by using AFP/age rather
than maternal age alone. Down’ s syndrome cases are detected in 
these younger women which would not otherwise have been prenata lly  
diagnosed i f  age had been the only c r i te r io n  on which to select  
women fo r  diagnostic tes t ing .
6 .5 .2  MULTIMARKER/AGE SCREENING IN PROSPECTIVE USE
Analysis o f hCG was added to the existing west of Scotland AFP 
screening programme in September 1991. Up to September 1992 30,084 
pregnancies were screened (See Section 5 .3 .2 )  and 70% of Down’ s
syndrome pregnancies in these women assigned to the high risk
group. The uptake of diagnostic testing by women in the high risk  
group increased to 70%, in women of a l l  ages, resu lting  in 56% of  
the Down’ s syndrome pregnancies in the screened population being 
prenata lly  diagnosed. Addition of hCG analysis to the ex is ting  
screening programme has resulted in a marked increase in the 
prenatal diagnosis rate  fo r  Down’ syndrome.
Data from published prospective studies using two analytes  
together with maternal age are summarised in Table 6-20 and fo r  
three analytes and maternal age in Table 6-21. The three studies 
using double analytes (Herrou et  a h , 1992, Spencer and Carpenter, 
1993, present study), with a to ta l  of over 48,000 pregnancies, 
have a higher detection rate than three of the four studies using 
t r i p l e  analytes, (Wald et  a h , 1992, Haddow et  a h ,  1992, P h i l l ip s
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Table 6 - 2 0
Comparison of data from published prospective Down’ s syndrome 
screening studies using two markers in addition to maternal age. 
DS = Down’ s syndrome, HRG = High risk group.
Herrou 
et  al .  
(1992)
Spencer & 
Carpenter 
(1993)
Present
study
Analytes used UE3/hCG AFP/Fr3- hCG AFP/hCG
No.women screened 10,000a 8,179 30,084
% >35 years 
% >37 years 0%
10.6%
4.9%
6.9%
3.0%
I n i t a l  fa ls e  +ve rate  
Final fa ls e  +ve rate 4.7%
6.9%
5.2%
6.3%
5.1%
No. o f women in HRG 466 426 1,523
No.DS 1n screened 
population
10 16 37
No. DS detected 6 11 26
Detection rate  
(95% Cl)
60%
(26-88)
69%
(41-89)
70%
(53-84)
Uptake of diagnostic  
tes t in g
88% 89% 70%
DS rate/1000 1.0 2.0 1.2
Overall odds of DS i f  
in HRG
1:47 1:39 1:59
a A ll  women aged <38 years.
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Table 6 - 2 1
Comparison of data from published prospective Down’ s syndrome 
screening studies using three markers in addition to maternal age. 
DS = Down’ s syndrome, HRG = High risk group.
Wald 
et  al .  
(1992b)
Haddow 
et al .  
(1992)
Phi 11ips 
et  al .  
(1992)
Cheng 
et  al .  
(1993)
Analytes used AFP/hCG/
UE3
AFP/hCG/
UE3
AFP/hCG/
UE3
AFP/hCG/
UE3
No.women screened 12,603 25,207 9 , 530a 7,718
% >35 years 
% >37 years 4.8%
4.9% 0% 10.7%
I n i t a l  fa ls e  +ve rate  
Final fa ls e  +ve rate
5.7% 
4.1%
6.6%
3.8%
7.2%
3.2%
8.0%
6.0%
No. of women in HRG 514 962 307 461
No.DS in screened 
population
25 36 7 22
No. DS detected 12 21 4 20
Detection rate  
(95% Cl)
48%
(28-69)
58%
(41-74)
57%
(18-90)
90%
(71-99)
Uptake of diagnostic  
tes t ing
75% 79% 70% 69%
DS rate/1000 2.0 1.4 0.7 2.9
Overall odds o f DS i f  
in HRG
1:43 1:46 1:77 1:23
a Women aged <35 years only.
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et  a l . , 1992).
However, each of the double marker plus maternal age studies used 
d if fe re n t  combinations of analytes. Herrou et  al .  (1992), in 
western France, used a combination of hCG/UE3/age in women aged 
less than 38 years. The detection rate fo r  Down’ s syndrome was 60% 
at a 4.7% fa ls e  pos itive  ra te , but would have been expected to be 
higher i f  women of a l l  ages had been screened. Spencer and 
Carpenter (1993), in Romford, Essex, used a combination of
AFP/Fr|3-hCG/age applied to  the whole pregnant population 
regardless of age, and achieved a detection rate fo r  Down’ s 
syndrome of 69% at a fa lse  positive  rate of 5.2%. The present 
study, in the west of Scotland, in a whole pregnant population, 
had a detection rate fo r  Down’ s syndrome of 70% at a 5.1% fa lse  
positive rate . In routine use in the second tr im este r ,  comparing 
the west of Scotland data with tha t of Spencer and Carpenter 
(1993), there appears l i t t l e  d ifference in detection of Down’ s 
syndrome when e ith e r  in tac t or free  8 subunit hCG is used in
combination with AFP and age. Herrou et  al .  (1992) used UE3
instead of AFP and achieved approximately the same rate of 
detection fo r  Down’ s syndrome, suggesting that UE3 is an e f fe c t iv e  
substitute  fo r  AFP. However AFP is also used fo r  screening fo r  
neural tube defects and th is  would be lost i f  UE3 were used 
instead.
Four prospective studies using the three markers, AFP, UE3 and hCG 
have been published (Wald et  a l . ,  1992b, Haddow et  a l . ,  1992,
P h il l ip s  et  a l . ,  1992, Cheng et  a l . ,  1993). These achieved 
detection rates fo r  Down’ s syndrome ranging from 48-91% at fa lse
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positive rates of between 3.2-6.0%. The most representative  
population with regard to age d is tr ib u tio n  was tha t screened by 
Wald et  al .  (1992b) in which 4.8% of women were aged 37 years and 
over. A detection rate for Down’ s syndrome of 48% was obtained at  
a fa lse  positive rate of 4.1%. Haddow et  al .  (1992), in New 
England, USA reported a detection rate fo r  Down’ s syndrome of 58% 
at a fa lse  positive rate of 3.8% in a screened population where 
only 4.9% of women were aged 35 years and over. P h i l l ip s  et  al .  
(1992), in Tennessee, screened only women aged less than 35 years 
and achieved a detection rate for Down’ s syndrome of 58% at a 3.2% 
fa lse  positive rate. The detection rate (and corresponding fa lse  
positive rate) in these last two studies would have been expected 
to be higher i f  a l l  older pregnant women had also been screened. 
The fourth study (Cheng et  a l . ,  1993), in S ea tt le ,  reported a
detection rate for Down’ s syndrome of 91% at a fa ls e  pos itive  rate  
of 6.0%. The screened population in th is  study appears atypical as 
the incidence of Down’ s syndrome is much higher (2 .9 /1000) than 
would be expected in a typ ical pregnant population, and also when 
compared with the other studies in Tables 6-20 and 6-21. This may 
be a ttr ibu ted  to the skewed age d is tr ib u t io n , with only 19.8% of  
women aged less than 25 years, compared with 39% in the west of  
Scotland pregnant population, and 35.9% aged 30-34 years compared 
with 23.8% in the west of Scotland.
These studies, including the data presented here in section 5 .3 .2 ,  
demonstrate that the use of multiple markers in combination with  
maternal age to screen fo r Down’ s syndrome in the second tr im ester  
is an e f fe c t iv e  strategy in c l in ic a l  practice. However there is no 
evidence to suggest that any of the d i f fe re n t  marker combinations
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used (AFP/hCG, AFP/Fr|3-hCG, UE3/hCG or AFP/hCG/UE3) o ffe rs  
s ig n if ic a n t ly  better or worse detection and fa ls e  pos it ive  rates 
than any of the others. Meaningful comparisons of detection  
performance are however only possible in large populations of  
comparable age d is tributions and at standardised fa ls e  positive  
rates.
6.6 BIOCHEMICAL SCREENING FOR TRISOMY 18
6.6 .1  AFP SCREENING FOR TRISOMY 18
The present study predicted th a t ,  using AFP/age screening and a 
c u t-o ff  r isk of 1:280, 37% of autosomal trisomy pregnancies, which 
w il l  include trisomy 18 pregnancies, would be assigned to  the high 
r isk  group. This has been borne out in routine practice . In 
100,481 pregnancies screened 7 of 13 (54%) trisomy 18 pregnancies 
were detected by screening (Table 5-10). No other Investigators  
appear to have attempted to optimise the detection of autosomal 
trisomies other than Down’ s syndrome in AFP/age screening 
programmes by using appropriately modified age risks and AFP 
d is tr ib u tio n  data as described in th is  study in Section 5.1 .  
Drugan et  al .  (1989a), reviewed the results  of cytogenetic  
analyses performed on 1154 pregnancies when the ind ication  was low 
maternal serum AFP, and found 6 Down’ s syndrome pregnancies, 1 
trisomy 18 pregnancy, and 6 other chromosome abnormalities. They 
concluded that risks quoted by screening programmes should include 
other chromosome abnormalities.
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Reviewing other published prospective series o f AFP/age screening 
shows that programmes set up to detect Down’ s syndrome also detect 
a proportion of trisomy 18, and other chromosome abnormalities. 
Di Maio et al .  (1987) found three trisomy 18 and one trisomy 13 
pregnancies in addition to nine Down’ s syndrome pregnancies within  
a high risk group of 1451. Lustig et  al .  (1998), in the 1940 women 
who opted fo r  amniocentesis out of 2552 women 1n the high r isk  
group, found four trisomy 18 and one trisomy 13 pregnancies in 
addition to 17 Down’ s syndrome pregnancies. The New England 
Collaborative Study (1989) found four trisomy 18 pregnancies in 
addition to 18 Down’ s syndrome pregnancies in the 1593 women 1n 
the high risk group who opted for amniocentesis.
6 .6 .2  MULTIMARKER SCREENING FOR TRISOMY 18
The highly s ig n if ican t reduction in maternal serum hCG levels
found in trisomy 18 pregnancies (Section 5 .2 .1 .1 .3 )  o ffe rs  a 
fu r th e r  opportunity to detect trisomy 18 pregnancies through 
selection of a second high risk group.
Using the protocol based on the analysis of AFP and hCG in 12
trisomy 18 and 7830 unaffected pregnancies in th is  study, a 
detection rate of 67% was predicted fo r  additional fa ls e  positive  
rate of jus t  over 1%. However routine screening in 30,084 women 
detected only two out of seven (29%, 95% Cl 4-71%) of trisomy 18
pregnancies within the high risk group of 0.3%. With th is  small 
number of trisomy 18 pregnancies the confidence in te rva l is wide 
and greater numbers are required to properly assess the l ik e ly
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success of th is  screening policy. Once AFP and hCG results  have 
been accumulated from a s u f f ic ie n t ly  large number of trisomy 18 
pregnancies (e .g . greater than 25) i t  should be possible to assign 
to women an exact risk of trisomy 18, using like lihood ratios  
derived from the d is tr ibu tio n  data.
Other authors have, from retrospective studies, described varying 
protocols fo r  screening fo r trisomy 18. Canick et  al .  (1990a), 
using results of 10 cases of trisomy 18, proposed tha t a simple 
c u t-o ff  system, taking samples which had AFP results  <0.75 MOM, 
UE3 results <0.60 MOM and hCG results <0.55 MOM, would detect 60% 
of trisomy 18 pregnancies, with a corresponding fa ls e  positive  
rate of 0.4%.
M i l le r  et  al .  (1991) reported that four o f nine (44%) trisomy 18 
pregnancies had hCG levels less than 0.25 MOM, and tha t less than 
1% of unaffected pregnancies had values below th is  leve l.
Staples et  al .  (1991), using a s im ila r  approach to tha t which they 
have proposed fo r Down’ s syndrome screening (Ryall e t  a l . ,  1992), 
devised a regression equation, using results  from 12 cases of 
trisomy 18 pregnancies and 390 controls. They predicted a 58.3% 
detection rate for trisomy 18, with a corresponding fa ls e  positive  
rate of 0.3%, using a combination of f iv e  analytes, Fr3-hCG, UE3, 
es trad io l ,  Fra-hCG,and hPL. Using only Fr|3-hCG and UE3 gave a 
s im ila r  predicted detection rate of 57.9%, a t  the same fa lse  
positive rate.
Barkai at  al .  (1993) combined data from th e i r  own series of 15
trisomy 18 pregnancies with that from other published studies, and 
by meta-analysis derived the parameters fo r  log Gaussian
d is tr ib u tio n s  fo r  AFP, UE3 and hCG. Using these together with
maternal age risks fo r  trisomy 18 (taken to be one tenth of those 
fo r  Down’ s syndrome compiled by Cuckle et  al .  (1987 )) ,  they 
estimate that 67% of trisomy 18 pregnancies might be detected, 
with a fa lse  positive  rate of 0.3%.
Palomaki et  al .  (1992) applied prospectively the protocol that  
they had previously proposed (Canick et  a l . ,  1990a) to 19,491
women screened. Of these 92 women (0.5%) were assigned to  the high 
r isk  group and six cases of trisomy 18 were id e n t i f ie d .  However
the number of trisomy 18 pregnancies in the whole screened
population was not ava ilab le , but was estimated from the age 
d is tr ib u t io n  to be seven, giving an estimated detection rate of  
85%.
Thus, screening fo r  trisomy 18 using a va r ie ty  of d i f fe re n t  
protocols appears to be a practica l proposition, with an 
acceptably small percentage of women a d d it io n a lly  being id e n t if ie d  
at high r is k .  The best markers appear to  be e i th e r  in ta c t  hCG or 
Fr|3-hCG and UE3.
6.7 IMPACT OF BIOCHEMICAL SCREENING FOR DOWN’ S SYNDROME IN THE 
WEST OF SCOTLAND
In the west of Scotland the introduction of biochemical screening 
methods has led to increasing prenatal detection of Down’ s
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syndrome. Figure 6-1a compares the fa lse  pos itive  rates in the 
screened population obtained using maternal age alone, AFP/age 
screening and hCG/AFP/age screening. The corresponding uptake of 
diagnostic testing  is also shown. Figure 6—1b shows the 
corresponding detection rates and prenatal diagnosis rates fo r  the 
d if fe re n t  screening methods. I t  can be seen tha t the fa lse  
positive rate and uptake of diagnostic tes ting  were s im ila r  fo r  
age screening and AFP/age screening, but the detection rate  
increased by over 30% and the prenatal diagnosis rate  almost 
doubled to 23% with the introduction of AFP/age screening. With 
the addition of hCG analysis the fa lse  positive  rate f e l l  by over 
15% from 6.1% to 5.1%, but an increased number of women (3.6% vs 
2.6%) had diagnostic tes t in g . The detection rate increased fu rther  
to 70% with 56% of affected cases in the screened population being 
prenata lly  diagnosed. AFP/hCG/age screening has more than doubled 
the detection rate fo r  Down’ s syndrome over tha t  achievable with  
maternal age alone, and, because of the increased uptake of 
diagnostic testing  by women in the high r isk  group, has given a 
fourfo ld  increase in the number actually  p renata lly  diagnosed.
The impact of various screening measures applied in the west of 
Scotland on the b ir th  incidence of Down’ s syndrome is presented in 
Figure 6 .2 . This takes into  account women who proceeded d ire c t ly  
to diagnostic testing  without p art ic ipa ting  in screening, the 
incomplete uptake of diagnostic testing by women at increased r isk  
and also the proportion of women who decline prenatal screening 
(20%). In 1986, when age was used to select women fo r  diagnostic  
tes t ing , 13% of Down’ s syndrome pregnancies were detected 
prenata lly . For 1987-1990, when AFP/age screening was routine and
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Figure 6 -  1
Screening in the west of Scotland using age (1 9 8 6 ),age/AFP (July  
1987-Dec 1990), age/AFP/hCG (Sept 1991-Sept 1992).
(a) False positive  rates and corresponding uptake of diagnostic  
testing .
(b) Detection rates fo r  Down’ s syndrome and corresponding prenatal 
dignosis rates.
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Figure 6 - 2
Proportions of Down’ s syndrome pregnancies prenata lly  diagnosed in 
the west of Scotland in 1986 (age screening), July 1987 -  Dec 1990 
(AFP/age screening) and Sept 1991 -  Sept 1992 (hCG/AFP/age
screening).
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some additional cases were detected using maternal age c r i t e r i a ,  
detection increased to 31%. The introduction of hCG analysis in 
1991 resulted in a further increase in prenatal detection of  
Down’ s syndrome, to 48% of a l l  affected pregnancies, a to ta l  which 
includes some cases diagnosed prior to screening by CVS in the 
f i r s t  trim ester. Thus almost four times as many Down’ s syndrome 
pregnancies are now prenatally diagnosed with hCG/AFP/age 
screening compared with that achieved by maternal age. AFP/hCG/age 
screening has also improved the prenatal diagnosis rate  in women 
aged 35 years and over, from 42% in 1986 to 69% in September 1991 
-  September 1992 through increased compliance o f diagnostic  
testing .
The displacement of maternal age screening by multimarker 
biochemical screening has extended testing  to the whole pregnant 
population, irrespective of age, and id e n t i f ie s  a proportion of 
younger women as being at increased r isk . Many women aged >35
years are now given a reduced risk and are spared the necessity
fo r  diagnostic testing , with i ts  known r isk  o f miscarriage.
I t  is known that considerable anxiety may be generated by a 
positive screening result (Abuelo et  a h ,  1991, Keenan et  a h ,  
1991), and much e f fo r t  is required to convey to women the 
rationale  of screening before they decide to  be screened. 
Counselling should include an explanation of the type of 
abnormalities being screened fo r ,  the meaning of being screen 
positive or screen negative and the possible need fo r  follow-up
tests . To help towards th is  end the west of Scotland screening
programme has produced a le a f le t  explaining the te s t  to  patients ,
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and also a booklet fo r ante-natal c l in ic  s t a f f  which gives more 
information about the test and further d e ta i l  about such things as 
detection rates for Down’ s syndrome in d i f fe re n t  age groups and 
explanations of typ ical report comments.
The options following a positive diagnostic results  should also be 
explained and counselling should be ava ilab le  fo r  women who choose 
to terminate or choose to continue an affected pregnancy. 
Continued lia ison between laboratories providing a screening 
service and the obstetric  units is required so th a t  developments 
and improvements to screening protocol may be incorporated into  
routine practice without adverse a f fe c t .
6 . 8  FUTURE PROSPECTS
The current timing of prenatal screening fo r  Down’ s syndrome is  
dictated by the need to carry out screening fo r  neural tube 
defects at around 16-18 weeks gestation when maximum s e n s it iv i ty  
is achieved. Neural tube defect pregnancies do not have elevated  
levels of maternal serum AFP in the f i r s t  tr im ester  of pregnancy 
(UK Collaborative Study, 1977, Aitken et  a l . ,  1993). However there  
is  mounting evidence that maternal serum screening fo r  Down’ s 
syndrome may be possible in the f i r s t  tr im ester ,  which would bring 
the benefit of e a r l ie r  detection and termination of pregnancy. 
Retrospective studies have identif ied  several markers which show 
varia t ion  in Down’ s syndrome pregnancies a t th is  stage of 
gestation, although the pattern of var ia t ion  is  d i f fe re n t  fo r  some 
markers between the f i r s t  and second trim esters .
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In f i r s t  tr im ester Down’ s syndrome pregnancies levels  are reduced 
fo r  AFP (Brambrati et  a l . ,  1986, Barkai et  a l . ,  1987, Brock et  
a l . ,  1990, Wenger et  a l . ,  1990, Van L i th . ,  1991), UE3 (Cuckle et  
a l . ,  1988, Brock et  a l . ,  1990, Crandall et  a l . ,  1991, Aitken et
a l . ,  1993) PAPP-A (Brambrati et  a l . ,  1993, Wald et  a l . ,  1993b,
Muller et  a l . ,  1993) and SPi (Brock et  a l . ,  1990, Macintosh et  
a h ,  1993). Fr|3-hCG levels are markedly elevated (Macri et  a h ,
1993, Aitken et  a h ,  1993) while in tact hCG levels have been shown
to  be e ith e r  l i t t l e  a lte red  (Cuckle et  a h ,  1988, Bogart et  a h ,  
1990., Johnston et  a h ,  1991, Van L ith , 1992, Aitken et  a h ,  1993) 
or moderately elevated (Brock et  a h ,  1990, Kratzer et  a l  1991). 
FrB-hCG and PAPP-A appear to  be the most useful markers fo r  Down’ s 
syndrome, but Fr|3-hCG has the advantage th a t ,  unlike PAPP-A, i t  is 
a good predictor of Down’ s syndrome at a l l  gestations between 7 
and 20 weeks.
L i t t l e  is currently  known about the control of production of these 
various placental and fe ta l  markers and how th is  might be a ltered  
in Down’ s syndrome and other chromosomally abnormal pregnancies. 
None of the fe to -p lacenta l markers AFP, a or 8 subunit of hCG, SPi 
or PAPP-A, has the coding gene located on chromosome 21. In second 
tr im ester Down’ s syndrome pregnancies hCG and Fr|3-hCG levels  are 
considerably elevated, SPi is  s l ig h t ly  elevated and PAPP-A levels  
unchanged. In the f i r s t  tr im ester a d i f fe re n t  pattern is  seen, 
with elevated levels  of FrB-hCG, hCG levels  which are l i t t l e  
changed and reduced levels of SPi and PAPP-A.
I t  was o r ig in a l ly  suggested by Wald et  ah  (1988b) tha t the change 
in maternal serum marker levels  in Down’ s syndrome pregnancies
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might be due to immaturity of the fe to -p lacenta l u n it ,  leading to 
the pattern of AFP, hCG and UE3 levels more typ ica l of those 
existing 2-3 weeks e a r l ie r  in gestation. However the accumulation 
of more data on other pregnancy markers in both the f i r s t  and 
second trimesters has confounded th is  simple explanation. For 
example the higher levels of SPi found in second tr im ester Down’ s 
syndrome pregnancies do not re f le c t  the pattern o f a few weeks 
e a r l ie r  in gestation.
An understanding of the control of production and secretion of 
pregnancy markers by the feto -p lacenta l un it  into the maternal 
circu la tion  may contribute to improved design and performance of 
prenatal screening protocols.
6.9 CONCLUSIONS
Prenatal screening by biochemical methods described in 
retrospective studies and applied in routine c l in ic a l  practice in 
a large unselected population have demonstrated tha t around 
two-thirds of Down’ s syndrome pregnancies can be detected in the 
second trim ester. In addition to more than doubling the detection  
rate achievable using maternal age alone, the app lication  of 
biochemical screening has been shown to be much more e f fe c t iv e  in 
practice, with increased u t i l iz a t io n  of diagnostic tes t ing  by 
women of a l l  ages including women aged 35 years and over. This has 
resulted in a measurable decline in the b ir th  incidence of Down’ s 
syndrome in the west of Scotland.
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However, such screening is neither p e rfec t ly  sensitive  nor 
spec if ic  and the report of a positive screening resu lt  may 
generate s ig n if ic a n t  anxiety in the patien t. In addition the 
improvement in s e n s it iv i ty  has led to an increase in the number of 
women who undergo therapeutic termination of a ffected pregnancies 
at advanced gestations. Implementation of biochemical screening 
had thus created an increased counselling workload.
Prospects fo r  improved s e n s it iv i ty  rest upon the discovery of new 
placental or fe ta l  markers with greater p red ic tive  power than 
those curren tly  in use. Improvements in s p e c if ic i ty  would reduce 
the size of the fa lse  pos itive  group and thus reduce the burden of 
anxiety in the screened population and the number of women 
requiring counselling. E a r l ie r  detection of a ffected pregnancies 
by extension of screening to the f i r s t  tr im ester  and the 
consequent reduction in the trauma associated with la te  
termination would be of major benefit to the pa t ien t .
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